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Atherosclerotic cardiovascular disease still represents the leading cause of death in
Western countries. A wealth of scientiﬁc evidence demonstrates that increased blood
cholesterol levels have a major impact on the outbreak and progression of athero-
sclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, in-
cluding statins and ezetimibe, have proved effective in improving clinical outcomes.
This document focuses on the clinical management of hypercholesterolaemia and
has been conceived by 16 Italian medical associations with the support of the Italian
National Institute of Health. The authors discuss in detail the role of hypercholester-
olaemia in the genesis of atherosclerotic cardiovascular disease. In addition, the im-
plications for high cholesterol levels in the deﬁnition of the individual cardiovascular
risk proﬁle have been carefully analysed, while all available therapeutic options for
blood cholesterol reduction and cardiovascular risk mitigation have been explored.
Finally, this document outlines the diagnostic and therapeutic pathways for the clini-
cal management of patients with hypercholesterolaemia.
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Hypercholesterolaemia and cardiovascular
risk
The fundamentals of prevention
Despite the progressive reduction in cardiovascular mortal-
ity observed in the industrialized world, the conditions re-
sulting from atherosclerosis and thrombosis (especially
ischaemic cardiomyopathy, ischaemic stroke, and periph-
eral arterial disease) are still extremely common and
among the principal causes of early death and permanent
disability in the European population.1 These diseases have
multifactorial causes, some of which can be modified by
lifestyle intervention, such as lack of exercise, smoking,
and unhealthy diet. Other diseases, such as dyslipidaemias,
arterial hypertension, and diabetes, can be modified by
pharmacological treatment. Lipid metabolism disorders
may be related to other diseases (secondary forms) or ge-
netic abnormalities (familial forms) or may be due to the
interaction between predisposing and environmental fac-
tors. These may modify the levels and the function of
plasma lipoproteins, whichmay in turn facilitate the devel-
opment of cardiovascular diseases when combined with
other risk factors. The plasmatic cholesterol and triglycer-
ides (TG) bind different apoproteins to form lipoproteins
that are classified as: HDL with antiatherogenic properties;
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LDL, which transport the majority of plasma cholesterol
and are atherogenic; and chylomicrons and VLDL, which
are rich in TGs and not atherogenic but may cause pancrea-
titis when present in high concentrations.
Both genetic and anatomopathological observational
and interventional studies have shown that dyslipidaemias
and hypercholesterolaemia, in particular, play a crucial
role in the development of cardiovascular disease. Large-
scale epidemiological studies conducted in the latter half
of the last century, such as the Multiple Risk Factor
Intervention Trial (MRFIT)2 and the Framingham Study,3
which was characterized by an extremely long observa-
tional period, unequivocally demonstrated a strong and lin-
ear relationship between cholesterolaemia, mortality, and
incidence of cardiovascular diseases, especially ischaemic
cardiomyopathy, a relationship that decreases in relative
terms with age.4 The strong relationship was observed in
both subjects with and without a prior history of cardiovas-
cular disease. In addition, there is also a relationship be-
tween LDL cholesterol (C-LDL) and cardiovascular risk.2
Indeed, high levels of C-LDL are one of the most important
modifiable cardiovascular risk factors.5
Dyslipidaemias prevention and treatment must be con-
sidered an essential part of individual interventions aimed
at reducing the burden of cardiovascular disease. These in-
terventions should primarily address subjects who are at
the highest risk and who will benefit the most from them.
Therefore, identifying the subjects at highest cardiovascu-
lar risk represents the starting point for the implementa-
tion of measures aimed at reducing risk factors through the
modification of unhealthy lifestyles and the introduction of
pharmacological intervention.
Between 2008 and 2012, a survey was conducted on the
adult general population, known as the Osservatorio
Epidemiologico Cardiovascolare/Health Examination
Survey (OEC/HES), as part of the National Health Institute
(ISS), Associazione Nazionale Medici Cardiology Ospedalieri
(ANMCO), and Heart Care Foundation (HCF) partnership
agreement. This survey, which involved a representative
sample of 23 municipalities, at least one for each region of
Italy, examined 7912 adults aged 35 to 74 years, plus a
subsample of 802 elderly people (aged 75–79 years) and an-
other of 397 young people (aged 25–34 years). In the adult
sample, the prevalence of hypercholesterolaemia (defined
as240mg/dL or lower when being treated with lipid-low-
ering drugs), measured on serum after 12h fasting in the
same laboratory, was approximately 34% [confidence inter-
val (CI) 33–36] in men and 36% (CI 35–38) in women, with a
39% increase in men and 33% increase in women when com-
pared with the previous survey conducted in 1998–2002 (in
the 1998–2002 survey, the prevalence was 21%, CI 20–22, in
men and 25%, CI 23–26, in women). Low-density lipoprotein
cholesterolaemia was calculated by applying Friedewald’s
formula, excluding subjects with triglyceridaemia
>400mg/dL. Twenty-six per cent of men and 27% of
women had a value 155mg/dL. Of those with dyslipidae-
mia, approximately 40% did not know they had this disor-
der, and more than 35% were aware that they had the
disorder but did not follow any diet or specific therapy.6,7
Those on lipid-lowering therapy had dietary habits very
similar to those of the general population (11.8% of
saturated fats and 328mg/day of dietary cholesterol con-
sumption) and in excess of the guidelines of the European
Society of Cardiology and the European Atherosclerosis
Society (ESC/EAS),8 which recommend that saturated fats
consumption should not exceed 7% and dietary cholesterol
should not exceed 300mg.
Recent longitudinal studies conducted in the USA [MRFIT,
Coronary Artery Risk Development in (Young) Adults
(CARDIA), and Chicago Heart Association Detection Project
in Industry (CHA)] showed that, in the general population,
those with a favourable risk profile (arterial pressure
<120/80mmHg, total cholesterol (TC) <200mg/dL with-
out specific therapy, body mass index <25kg/m2, non-
smokers, and no diabetes) are those who present the low-
est cardiovascular and all-cause mortality, have the best
quality of life in old age, and cost less in terms of health
care.2,9–12 This led to a new direction in cardiovascular pre-
vention aimed not merely at identifying and guiding those
with a high cardiovascular risk but also at keeping risk low
during the course of life by means of healthy lifestyle
choices.13 The lower risk of a major cardiovascular event
(myocardial infarction or stroke) in people with a favour-
able risk profile was also shown after 10 years of follow-up
in the cohorts of the CUORE project.14,15
Patients who have already had an acute coronary syn-
drome (ACS) or a stroke are at higher risk of future events
and automatically qualify as deserving of a thorough as-
sessment and intensive treatment for all their risk factors,
including high C-LDL level. Conventionally, the term used
to indicate the intervention undertaken to reduce the risk
of future events in these patients is secondary prevention,
whereas the term primary prevention refers to the same in-
tervention undertaken for subjects with no prior history of
cardiovascular events. However, those individuals with a
combination of many risk factors may have unexpectedly
high cardiovascular risk, which may be similar to, or even
higher than, the risk of those subjects who have had a pre-
vious cardiovascular event. All the current guidelines on
the prevention of cardiovascular disease in clinical practice
recommend global risk factors assessment.5,8,16 Indeed, in
most individuals, atherosclerosis and thrombosis are the
product of an interaction among different risk factors.
Based on observational studies, several global risk assess-
ment algorithms are available, including the American
Framingham Study,3 the European Systematic Coronary
Risk Evaluation (SCORE) for the regions of Europe at high
and low risk, and the Italian risk charts of the CUORE proj-
ect, all of which include cholesterolaemia as a risk factor.
The purpose of the risk charts is to facilitate the estimation
of the probability of a fatal/non-fatal major cardiovascular
event (myocardial infarction, ACS, and stroke) in appar-
ently healthy individuals without signs and symptoms of
disease. The European SCORE system, in particular, esti-
mates the risk at 10 years of a first fatal atherosclerotic
event (acute myocardial infarction, acute coronary syn-
drome, stroke, peripheral arterial disease, and sudden
death). On the basis of this risk, subjects are classified as
low, medium, high, or very high risk (Table 1).5 In Italy, the
ISS performed a comparison between the CUORE project
charts, which were previously used in Italy, and the
European SCORE charts and found the CUORE charts to
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yield similar results to the corresponding charts of the
SCORE project (Table 2).17,18 The SCORE charts, despite
following European guidelines, are not advantageous in
terms of ease of use for global risk calculation when com-
pared with the CUORE algorithm; furthermore, it is impor-
tant to remember that one general criterion in the choice
of the instrument used to estimate the risk is that it must
have been developed in the population in which it will ef-
fectively be used.
Otherwise European guidelines suggest using algorithms
based on local data, where available.
Total risk assessment using risk charts, regardless of the
type, do not have to be utilized in patients with familial
hypercholesterolaemia (FH), a condition caused by LDL re-
ceptor (LDLR) mutation, because the levels of C-LDL
>240mg/dL or of TC >320mg/dL place these patients, by
definition, in a condition of high risk. Similarly, patients
with several other clinical conditions are considered, ac-
cording to the ESC guidelines, to be at high and very high
risk and therefore do not satisfy the criteria for SCORE
chart application (Table 1).
The lipid target value in the management of
cardiovascular risk
In the OEC/HES survey, the prevalence of high risk (5%
SCORE and20% CUORE) was seen to be 8.5%in men aged 35–
69 years and 1.1% in women. Of note, it should be taken into
account that subjects on treatment with cholesterol-lowering
medication appear to be at lower risk as neither the SCORE
nor the CUORE algorithm considers the concomitant treat-
ment with specific therapy for dyslipidaemia. In the same sur-
vey, 53% men and 83% women appear to be at low risk,
with the remaining part of the population atmedium risk.
Regarding the C-LDL targets, it is important to remember
that the prevalence of non-optimal C-LDL ( 115mg/dL) in
the same general OEC/HES population examined in 2008–
2012 was greater than 65% and more than 25% had high C-
LDL values ( 155mg/dL). A frequency this high in the
general population indicates that inadequate action is ad-
dressed to high-risk subjects. More incisive community life-
style intervention is required, which is aimed at improving
eating habits, moderating alcohol consumption, reducing
smoking (which still involves over 20% of the adult popula-
tion), and increasing physical activity (40% of adult women
and 32% of males do not practice daily physical activity).
Lifestyle changes, which, as recommended in all guide-
lines, should always accompany pharmacological therapy,
are often considered by the subject/patient as deprivation
rather than a way to return to a more favourable risk pro-
file (lower risk) and keep fit, because the benefits are not
obvious in the short-term though they are important for
the long-term prevention of all chronic degenerative
diseases.
International guidelines indicate C-LDL reduction as one
of the most important interventions in terms of reducing
the risk of premature cardiovascular events. High TC and
C-LDL plasmatic levels can be reduced by lifestyle changes
or with pharmacological therapy. Unfortunately, lifestyle
changes alone have not proved sufficient to significantly
reduce these levels and many of the drugs developed in the
past were not effective and safe enough. By inhibiting 3-
hydroxy-3-methylglutaryl coenzyme A reductase, statins
Table 2 Risk level correspondence between SCORE and
CUORE risk charts.
SCORE CUORE
<1 <5
1 5–10
2 10–14
3–4 15–20
5–9 20–30
 10 >30
Readapted from Donfrancesco et al.18
Table 1 LDL cholesterol target according to risk conditions
Risk Conditions Target C-LDL
Low Rating according to the SCORE risk charts <1%. <115mg/dL
Medium Rating according to the SCORE risk charts  1% and <5%. <115mg/dL
High Patients with familial dyslipidaemia or severe hypertension. Patients with diabetes, without other
cardiovascular risk factors or organ damage. Patients with moderate chronic kidney disease (GFR
30–59mL/min/1.73 m2).
<100mg/dL
Rating according to the SCORE risk charts 5% and <10%.
Very high Patients with documented cardiovascular disease (per coronary angiogram, stress echocardiogra-
phy, radionuclide imaging, and ultrasound evidence of carotid plaques), prior myocardial infarc-
tion, prior ACS, prior coronary revascularization intervention (with CABG or PCI) or peripheral
revascularization, prior ischaemic stroke and peripheral arterial disease, diabetics with one or
more cardiovascular risk factors, and/or organ damage markers (e.g. microalbuminuria) and
with severe kidney disease (GFR <30mL/min/1.73 m2).
<70mg/dL
Rating according to the SCORE risk charts >10%.
CABG, coronary artery bypass grafting; C-LDL, LDL cholesterol; GFR, glomerular ﬁltration rate; PCI, percutaneous coronary intervention; ACS,
acute coronary syndrome.
Readapted from Perk et al.5
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have been shown to significantly reduce C-LDL in the ab-
sence of significant adverse events or, in any case, with a
completely favourable risk–benefit ratio and therefore rep-
resent a milestone in cardiovascular prevention. There is
validated evidence that these agents reduce the risk of
myocardial infarction and stroke, in both primary and sec-
ondary prevention intervention. As far back as the 1990s, it
was shown19,20 that statin therapy reduces mortality and
the recurrence of ischaemic events. The efficacy of an in-
tensive therapy (with C-LDL <70mg/dL as target) in
ischaemic cardiomyopathy was subsequently proved.21,22
The benefits of treatment with statins has been confirmed
in real-world population registries23 and subsequent meta-
analysis of numerous randomized controlled trials (RCTs),
including over 170 000 patients in the Cholesterol
Treatment Trialists’ Collaboration.24,25 It has been ob-
served that a 1mmol/L (approximately 38mg/dL) reduc-
tion in C-LDL is associated with a 20–25% decrease in the
relative risk of new major cardiovascular events (cardio-
vascular mortality and non-fatal infarction). It is likely that
this treatment has made a significant contribution to the
considerable reduction in the age-standardized cardiovas-
cular mortality rates observed in recent years (from 62/
100000male inhabitants in 1980 to 19 in 2008 and from 13/
100000 female inhabitants to 4 in 2008), without affecting
the high total mortality for cardiovascular causes in the
population.1
Unlike relative risk, whose reduction is the same for
each starting condition, the absolute benefit of treatment
is, however, greater the higher the patients’ basic absolute
risk and C-LDL levels. On the basis of this evidence, the
most recent European guidelines, as indicated previously,
clearly indicate that there are different cardiovascular risk
categories and that each one must be matched with a cer-
tain C-LDL target, which should be lower the higher the
risk. The targets for the treatment of dyslipidaemia are
based, above all, on the results of clinical studies aimed at
reducing lipids, in the majority of which the C-LDL levels
are used as indicators of response to therapy; C-LDL, there-
fore, remains the main target of the strategies for dyslipi-
daemiamanagement.
By extrapolating the available data, the absolute reduc-
tion in C-LDL below 70mg/dL or a relative reduction of at
least 50% provide the best benefits in terms of reduction in
cardiovascular disease; therefore, for patients with a very
high cardiovascular risk, the target is<70mg/dL or a more
than 50% reduction in baseline C-LDL.5,8 In subjects with
high or moderate risk, a C-LDL target of <100 and 115mg/
dL, respectively, should be taken into consideration. In
asymptomatic individuals, the first step consists of assess-
ing cardiovascular risk and identifying any modifiable ele-
ments. The assessment should be repeated at 5-year
intervals if the absolute cardiovascular risk is low and there
are no significant variations in the recommended values of
the main risk factors.8 Clinicians should obviously use their
judgement to avoid premature or unnecessary implemen-
tation of lipid-lowering therapy. Indeed, lifestyle interven-
tion can have an important long-term impact on health,
whereas the long-term effects of pharmacological therapy
must be weighed against potential side effects and poly-
morbidity, a condition that, of course, increases with age.
On both sides of the Atlantic, controversy has recently
developed between the high-dose/high-efficacy statin-
based strategy and the target-based strategy. Indeed, the
very recent US guidelines criticized the benefit of reaching
specific C-LDL targets and have even disputed the appro-
priateness of their use in clinical practice, proposing in-
stead an appropriate intensity of treatment with statins
over all other cholesterol-lowering agents in order to re-
duce cardiovascular risk in those subjects who are most
likely to benefit, such as those with coronary disease.16 In
these patients, the guidelines suggest high-intensity statins
(approximately 50% reduction in C-LDL) if <75 years and
moderate-intensity statins (30–50% reduction in C-LDL) in
those over 75 years of age.16 This strategy has been vehe-
mently disputed.26 Indeed, treatment compliance is signif-
icantly greater in patients with a strategy addressing a
specific target than with the ‘fire-and-forget’ approach
that is recommended in the USA. In addition, the benefit of
obtaining C-LDL levels that are well below 70mg/dL, even
with agents other than statins, was demonstrated by the
Improved Reduction of Outcomes: Vytorin Efficacy
International Trial (IMPROVE-IT)27 study, which assessed
the effect of ezetimibe in combination with simvastatin
compared with simvastatin monotherapy in patients with
stable ischaemic cardiomyopathy with the levels of C-LDL
that were low at the outset. The results of the IMPROVE-IT
study would therefore appear to support the opinion of
European experts.
The role of lifestyle in the approach to patients
with dyslipidaemia
The reduction in age-standardized cardiovascularmortality
rates observed in all industrialized countries in recent de-
cades is to a great extent related to lifestyle changes that
must proceed and accompany any pharmacological ap-
proach to dyslipidaemia control.28 The study conducted by
Palmieri et al.29 examined the relativeweight of the reduc-
tion in risk factors comparedwith acute-phase intervention
in explaining the reduction in mortality rates between
1980 and 2000 in Italy. The reduction in mortality for
ischaemic cardiomyopathy between 1980 and 2000 was
due to the effects derived from treatments and risk factor
reduction. Approximately 23660 (55%) fewer deaths from
ischaemic cardiomyopathy were attributable to changes in
the risk factors in the population (range: 20260–28455). In
particular, the reduction in TC (0.35mmol/L) prevented
or delayed 10045 deaths (23%) from coronary causes. The
reduction, albeit limited, of 10% in sedentary lifestyle pre-
vented or delayed approximately 2490 deaths. On the con-
trary, the 0.1% increase in the prevalence of diabetes
caused approximately 945 additional deaths, whereas the
increase, albeit limited, in obesity (increase in body mass
index) is thought to have caused approximately 245 addi-
tional deaths.
Diet and cholesterol
There is a recognized relationship between dietary choles-
terol and cardiovascular mortality.8,30,31 More specifically,
of the various diet-related factors, saturated fatty acids
have the greatest impact on C-LDL. It is calculated that for
every 1% increase in saturated fatty acid intake, there is a
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0.8–1.6mg/dL increase in C-LDL.32 Industrial-processed
partially hydrogenated fatty acids represent the greatest
source of trans-unsaturated fats in the diet, accounting for
between 2% and 5% of the daily dietary intake in Western
countries. Their effect on C-LDL values is similar to that of
saturated fatty acids.33
It has been calculated that if 1% of the dietary intake of
saturated fatty acids was substituted by monounsaturated
fatty acids, polyunsaturated fatty acids (PUFAs) n-6, and
carbohydrates, C-LDL values could drop by 1.6, 2.0 and
1.2mg/dL, respectively.32
Polyunsaturated fatty acids n-3 do not have any direct
cholesterol-lowering effect, and indeed, their TG-reducing
effect could lead to a slight increase in C-LDL, when calcu-
lated using Friedewald’s formula. The protective cardio-
vascular effect of a diet rich in fish, which contains these
substances, is exercised by means of other mechanisms.
The GISSI-Prevenzione (Italian Group for Myocardial
Infarction Survival) study,34 which studied, among other
things, the effects of an extra 1 g of PUFA n-3 per day, in
fact showed a significant reduction in sudden death for ar-
rhythmia in over 11000 patients who had had myocardial
infarction.
Carbohydrates also have no impact on C-LDL and there-
fore replacing saturated fats with carbohydrates consti-
tutes an advantageous option.28 A diet rich in fibre,
legumes, fruits, vegetables, and wholegrain cereals has a
direct cholesterol-lowering effect and should, therefore,
be encouraged so that by replacing saturated fatty acids it
is possible to optimize the effects of diet on C-LDL and the
potentially unfavourable effects of carbohydrates on the
other lipoproteins areminimized.35
The evidence derived from RCTs on the benefit of diet in
terms of a reduction in cardiovascular risk and of the type
of diet to be adopted, primarily concerns the Dietary
Approaches to Stop Hypertension (DASH) diet and the
Mediterranean diet.36–39 Both have shown efficacy in re-
ducing cardiovascular risk,30 and the Mediterranean diet,
in particular, has been shown to reduce cardiovascular risk
in both primary and secondary prevention.
The Mediterranean diet as described by Ancel Keys and
Margaret Keys40 in their book published in 1975 indicated
the Mediterranean diet of those years as being ‘. . .a large
bowl of pasta and beans, a lot of bread, without any added
spreadable fat, large amounts of fresh vegetables, a mod-
est portion of meat or fish twice a week, wine. . .; and fresh
fruit only for dessert. . . For the prevention of coronary
heart disease, it would be difficult to find something better
than the daily diet of the population of Naples in the early
1950s’. During the same years, Fidanza et al.41 reported a
7% saturated fat consumption in their survey of eating hab-
its in Nicotera. This average consumption of saturated fats
in the populations with the longest life expectancy is also
qualitatively indicated in the DASH study diet.42
The fact that European guidelines recommend a con-
sumption not exceeding 10% should not bemisleading: Italy
is considered a country at low coronary risk, thanks to the
benefits of our diet, and the Italian diet model suggests
(and recommends) consumption closer to Mediterranean
cultural characteristics than those recorded in the rest of
Europe. Unfortunately, the recent OEC/HES survey showed
that the average fat consumption levels in the adult popu-
lation have changed since the 1960s, more specifically, sat-
urated fat consumption now accounts for 12% of all
calories, mean cholesterol consumption is >350mg/day
(compared with a recommended intake of less than
300mg) and the consumption of fibre is low (less than 20g/
day comparedwith a recommended intake of 30–45 g).43
One interesting recently published editorial44 considers
the ‘weak points’ of the Mediterranean diet (high con-
sumption of added salt for the preservation and prepara-
tion of food, high consumption of extra virgin olive oil and
wine, both of which have a high calorie content and the use
of refined cereals). Indeed, in Italy, the prevalence of obe-
sity and overweightness among adults exceeds 70% of the
population43 and moderate use must be made of high-
calorie foods that are rich in saturated fatty acid and cho-
lesterol and have a high salt content.
The guidance provided by the ESC/EAS guidelines on diet
are summarized in Table 3.
Exercise and cholesterol
A correct lifestyle must combine the positive effects of
diet with those of exercise, which is able to improve the
cardiovascular risk profile by reducing lipid, glycaemia,
and blood pressure values.45–47
Regular exercise increases HDL cholesterol (C-HDL) and
reduces TG, with consequent improvements in C-LDL and
TC levels, albeit to a lesser extent. Moderate exercise
causes a 4–43% increase in C-HDL levels. Athletes who prac-
tice endurance sports have 40–50% higher HDL levels and
20% lower TG levels than a corresponding sedentary popu-
lation. The mechanism by which exercise determines these
effects would appear to be associated with an increase in
lipoproteinase and a reduction in hepatic lipase, which
leads to TG catabolism and an increase in C-HDL. In addi-
tion, even without any change in C-LDL, an increase in the
size of LDL particles has been observed, with an obvious re-
duction in small, dense LDL particles, which are notoriously
more atherogenic.
The improvement in C-HDL does not appear to be related
to the type of exercise, rather there is a dose–response
Table 3 The recommendations of the ESC/EAS diet
guidelines8
Reduce saturated fatty acids to less than 10% of the entire
calorie intake by replacing them with polyunsaturated
fatty acids.
Transunsaturated fatty acids: eliminate or minimize con-
sumption of those of industrial origin and restrict to less
than 1% those of a natural origin.
Salt <5 g.
30–45 g of ﬁbre a day
200 g of fruit per day
200 g of vegetables a day
Fish at least twice a week
Reduce alcohol consumption: do not exceed two glasses of
wine a day for men and one glass for women.
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relationship: moderate exercise, performed at a heart rate
of between 40% and 60% of maximum heart rate, for 30–
40min, 5 times a week, or better still every day, has the ef-
fects on the lipid profile indicated above. Exercise has bene-
fits in both men and women, albeit to a lesser extent in the
latter, especially in the postmenopausal period. Other mech-
anisms, such as an improvement in endothelial function, re-
duced oxygen consumption, and inflammatory profile
modulation contribute to a protective action, even in pa-
tients with a positive history of prior cardiovascular events.
Therefore, regular exercise has a protective role with re-
gard to cardiovascular diseases, in both primary and sec-
ondary prevention, and is one of the types of lifestyle
intervention with the greatest impact on the cardiovascu-
lar risk profile (Table 4).
Other interventions
Certainly efficacious, but to a relatively lesser extent, is
the effect of weight loss: loss of approximately 10kg redu-
ces C-LDL by approximately 8mg/dL. Greater benefit is
achieved with weight loss obtained by means of a low-fat
diet.47,48
Moderate alcohol consumption (no more than 20–30 g/dL
in men and 10–20mg/dL in women), in subjects who do not
have hypertriglyceridaemia, may be acceptable.
Smoking can affect the lipid profile by causing the oxida-
tion of small and dense LDL particles, which are more ath-
erogenic. In addition to having a series of beneficial effects
on cardiovascular risk, stopping smoking is one of the mea-
sures recommended in order to improve lifestyle.8
Lipid-lowering therapy individualized according
to cardiovascular risk: the indications of the
Regulatory Authority in Italy
Although they are not guidelines, the notes produced by the
Italian Medicines Agency (AIFA) listing the reimbursement
criteria for certain medications must be known and consid-
ered for expenditure management. AIFA note number 13,
which regulates anti-dyslipidaemia drug reimbursement,
has been considered one of the most complex regulations,
because it considers many clinical situations and has been
subject to numerous changes throughout the years.
Indeed, cardiovascular risk has been calculated in di-
verse ways throughout the years with the Framingham
charts being the first point of reference, followed by the
CUORE project charts, and lastly the European SCORE
charts. The use of anti-dyslipidaemia drugs, and statins, in
particular, pertains to patients, in both primary and sec-
ondary prevention interventions, who have a moderate,
high, or very high cardiovascular risk and often present
with organ damage or other cardiovascular conditions such
as diabetesmellitus, kidney disease, or genetic disease.
Therapeutic target and drug choice
To decide how to treat a patient with hypercholesterolae-
mia, physicians must ask certain questions (Figure 1):
• What are the patient’s clinical conditions?
• What is the patient’s overall cardiovascular risk?
• What is his/her C-LDL target?
• Which drugs can be used to achieve it?
In light of these questions, physicians should be familiar
with the patient’s personal and family history; consider
gender, age, weight, smoking habits, body mass index; and
blood pressure; and know glycaemia, total cholesterolae-
mia and cholesterol fractions, triglyceridaemia values, cre-
atininaemia, and creatinine clearance. Physicians must
assess the presence of organ damage as microalbuminuria,
left ventricular hypertrophy, and atheromatous plaques.
Thereafter, the presence of one or more of the following
conditionsmust be identified:
(1) secondary cardiovascular prevention;
(2) diabetes mellitus;
(3) Stage III or IV chronic kidney disease [glomerular fil-
tration rate (GFR) <60mL/min];
(4) familial dyslipidaemia; and
(5) primary cardiovascular prevention with moderate
or high cardiovascular risk.
If the patient simultaneously presents more than one of
the above conditions, treatment must be chosen according
to the condition for which the overall cardiovascular risk is
greater.
Table 4 Recommendations for physical exercise
Exercise improves the lipid proﬁle.
Encourage all adults to do moderate exercise which achieves
a heart rate of between 40% and 60% of maximum heart
rate for 30–40min 5 times a week.
Encourage sedentary patients to start exercising.
Physical exercise is also strongly recommended in patients
with a history of cardiovascular events, angina, infarction,
percutaneous or surgical revascularisation procedures, and
heart failure. The intensity of the exercise and the way in
which it is practised should be adjusted to suit the individ-
ual characteristics of the patient and deﬁned after cardio-
logical assessment or an adequate period of cardiovascular
rehabilitation.
Four Logical steps:
1. What are the paent’s clinical condions?
1. What is the paent’s absolute 
cardiovascular risk?
2. What is the lipid target?
3. Which essenal, chronic drugs fully 
reimbursed by the NHS can be used to 
achieve it?
Figure 1 Algorithms for National Health Service prescription of statins
in compliance with AIFA note number 13.
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Patients receiving secondary cardiovascular
prevention interventions
Clinical documentation should be collected regarding pre-
viously diagnosed atherosclerotic disease (stable chronic
angina, prior myocardial infarction with or without ST-
segment elevation, and unstable angina), coronary revas-
cularization procedures (coronary artery bypass grafting
and angioplasty), ischaemic stroke, and peripheral athero-
sclerotic arterial disease (Figure 2).
Patients with diabetes mellitus
The presence of diabetes mellitus represents a condition of
high cardiovascular risk, which nevertheless differs accord-
ing to the presence or absence of other cardiovascular risk
factors, organ damage, or the presence of other diseases.
These variables can help determine the LDL target to
achieve (Figure 3).
This topic is dealt with in greater depth in the
‘Peculiarities of diabetic dyslipidaemia’ section.
Patients with chronic kidney disease
The prevalence of this condition is far greater than com-
monly thought. As shown by the Health Search data, an av-
erage of 10% of all patients of a general practitioner (GP)
have a GFR <60mL/min, and therefore with a kidney dis-
ease Stage III or higher, according to the National Kidney
Foundation Disease Outcomes Quality Initiative guidelines.
If the subpopulation of diabetic and hypertensive subjects
over 65 years of age is considered separately, the percent-
age of subjects with kidney disease reaches 33–35%. These
Very high overall cardiovascular risk
Lipid target: LDL-cholesterol < 70 mg/dL (or reducon in LDL-cholesterol ≥ 50%): high-intensity (i.e. 
potent and at high doses) stan needed
AIFA note no. 13
Atorvastan
Simvastan
Fluvastan
Lovastan
Pravastan
Target not reached or evidence of severe side eﬀects in the ﬁrst 6 months of treatment with other 
stans?
Rosuvastan
(in paents in whom there was evidence of serious side eﬀects)
Stan and Ezemibe
(in extemporaneous or pre-formulated association)
Figure 2 Patients receiving secondary cardiovascular prevention interventions.
Target not reached: 
Rosuvastatin or
Ezetimibe and statin
(in extemporaneous or pre-formulated 
associaon)
Patients with diabetes mellitus
Diabetes with organ damage and/or  with 
other cardiovascular risk factors (smoking, 
hypertension)
High overall cardiovascular risk Very high overall cardiovascular risk
Lipid target: 
LDL- cholesterol <100 mg/dL
Lipid target as in secondary prevenon: 
LDL-cholesterol <70  mg/dL or LDL-cholesterol reducon ≥50% 
AIFA note no. 13:
Atorvastan
Simvastan
Fluvastan
Lovastan
Pravastan
Diabetes without organ damage and without 
other cardiovascular risk factors (smoking, 
hypertension)
Stans not tolerated
Ezetimibe 10 mg/day
Target not reached: 
Ezetimibe and statin
(in extemporaneous or pre-formulated
associaon)
Rosuvastatin
(only in paents in whom there is evidence of serious side 
eﬀects during treatment with other stans)
Figure 3 Patients with diabetes mellitus.
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subjects have a high cardiovascular risk, which must be ap-
propriately treated.
The Document Panel believes that, in conflict with the
recommendations of AIFA note number 13, the possibility
of the statin intervention, even in the early stages of
chronic kidney disease, should be assessed in order to ob-
tain effective cardiovascular prevention even if the treat-
ment does not slow progression of the kidney disease
(Figure 4).
Patients with familial dyslipidaemia
Familial dyslipidaemias are genetic conditions
characterized by high plasma lipid fraction levels and an
often early occurrence of cardiovascular events. Because
of the severe complications that patients with familial dys-
lipidaemia can have, the presence of familial dyslipidaemia
must be identified and adequately treated.
Monogenic familial hypercholesterolaemia has a preva-
lence between 1:200 and 1:500. In the absence of a molec-
ular analysis, which is not always easy to perform, the
monogenic familial hypercholesterolaemia can be strongly
suspected by the presence of C-LDL >190mg/dL and a
first-degree relative with these biochemical alterations as
well as by a family history of coronary heart disease (CHD)
at a young age (<55 years in men and<65 years for
women). A finding of tendon xanthomas constitutes further
confirmation.
Familial combined hyperlipidaemia (FCHL) has a preva-
lence of 1–2:100; therefore, each physician should expect
to have a number of subjects with FCHL among his/her pa-
tients. It is characterized by phenotypical variability that
often presents with an alteration in the laboratory tests as
prevalent hypertriglyceridaemia (Frederickson type IV) or
prevalent hypercholesterolaemia (Frederickson type IIB).
Once again, in the absence of a genetic diagnosis, suspi-
cion is strong when C-LDL >160mg/dL and/or TG
>200mg/dL with vertical transmission of the same lipid
disorders and in the presence of atherosclerotic disease in
the family history (Figure 5).
Interventions for primary cardiovascular prevention
In a patient with hypercholesterolaemia without prior
events or known atherosclerotic conditions, who is not dia-
betic and whose kidney function is normal, without any
suspicion of familial dyslipidaemia or secondary hypercho-
lesterolaemia, the cardiovascular risk is moderate or high
if associated with other risk factors or organ and should be
assessed (in agreement with note number 13) with the
European SCORE rating system. After an initial phase of
non-pharmacological measures such as an intense lifestyle
intervention lasting for at least 3months, if C-LDL values
>139mg/dL for subjects at medium risk and >100mg/dL
for subjects at high risk, appropriate pharmacological ther-
apymust be started.
General principles of therapy with statins
Statins are not all the same. Figure 6 shows a diagram with
the comparative assessment of the C-LDL reduction rate
for each statin.49
In order to reduce cardiovascular risk, there is a class ef-
fect of all statins, related to C-LDL the reduction. Most of
the clinically detectable effects of long-term statin use on
either cardiovascular or general mortality and morbidity
are related to the reduction in C-LDL.
Statins differ in pharmacokinetic characteristics (ab-
sorption, plasma protein binding, metabolism, and solubil-
ity) and in their interaction with other medications, which
must be known in order to individualize therapy. Usually,
by doubling the dose of a statin, there is a further 4–7% re-
duction in C-LDL, whereas by combining the statin with
10mg of ezetimibe, it is possible to obtain a further reduc-
tion (at least 15%), with a better possibility of achieving
the set target.
Simvastatin + ezetimibe
AIFA circular no. 13 recommends         1° choice: 
for C-LDL ≥130 mg/dL
≥
: 
Patients with chronic kidney disease
Stage V (creanine 
clearance <15 ml/min)
High overall cardiovascular risk
Very high overall cardiovascular risk
Lipid target: 
LDL- cholesterol <100 mg/dL
Stage  III (creanine 
clearance 30–59 ml/min)
Stans not tolerated
Ezetimibe 10 mg/die
Is it possible to reach the target 
with the maximum dosage of 
stans?
Statins + ezetimibe
Lipid target as in secondary prevenon: 
LDL-cholesterol <70 mg/dL
Stage IV (creanine 
clearance 15–29 ml/min)
Stans with minimal renal 
excreon
Atorvastatin
Simvastatin
Fluvastatin
No stans
Figure 4 Patients with chronic kidney disease.
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In patients with severe side effects or statin toxicity,
the prescription of 10mg of ezetimibe may represent a
therapeutic option that is undeniably less efficacious
than statins but that has a lower side effect incidence; in
these cases, it will be more difficult to reach the thera-
peutic target. Each case should be evaluated in terms of
global risk–benefit ratio, patient’s quality of life and
expectations, clinical complexity and the expected
adherence.
The incidence of side effects (myopathy and transami-
nase elevation) increases considerably with an increase in
the dose of each statin. High-dose statins are associated
with a slight but statistically significant increase (mean 9%;
CI 2–17%) in the incidence of new cases of type 2 diabetes
Familial combined hyperlipidaemia
(prevalence 1–2%): C-LDL ≥ 160 mg/dL 
and/or triglycerides ≥ 200 mg/dL, 
and/or low C-HDL values (<40 mf/dL in  
men and < 50 mg/dL in women)
Heterozygous familial 
hypercholesterolaemia (prevalence 
0.3%): LDL cholesterol ≥ 190 mg/dL with 
HDL cholelsterol and triglycerides
normal after 3 months of appropriate 
diet
Other severe dyslipidaemias: total 
cholesterol >500 mg/dL and/or 
triglycerides >750 mg/dL and/or HDL 
cholesterol <25 mg/dL
AIFA note no. 13:
Atorvastan
Simvastan
Fluvastan
Lovastan
Pravastan 
Rosuvastatin (as second choice)
Statin + ezetimibe (for failure to achieve 
the therapeuc target with the 
maximum dose of stan)
PUFA N3 or fenoﬁbrate (in cases of 
hypertriglyceridaemia)
AIFA note  no. 13:
Atorvastan
Rosuvastan (also as ﬁrst choice)
Simvastan
(Fluvastan, Lovastan, Prvastan)
Referral to a specialist lipid center
Ezemibe 10 mg/day + stans (second 
level)
Addion of bile acid sequestrants, such as 
cholestyramine (third level)
In any case, it is appropriate to look for preclinical signs of atherosclerosis, myocardial 
ischaemia (Doppler study of the supra-aorc vessels, resng ECG, ECG stress bike or treadmill 
in all males aged >30 years and in all females >40 years of age, etc.) and determinaon of the 
lipid proﬁle in ﬁrst degree relaves
High overall cardiovascular risk: 
LDL cholesterol target < 100 mg/dL, 
triglycerides < 150 mg/dL, HDL cholesterol >40 (men) 
and 50 (women) mg/dL
High overall cardiovascular risk: 
LDL cholesterol target < 100 mg/dL
Figure 5 Patients with familial dyslipidaemia.
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Figure 6 Diagram for the comparative assessment of the LDL cholesterol reduction rate. Adapted from NHS Foundation Trust.49
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mellitus, especially in subjects with risk factors for diabe-
tes (family history, obesity, metabolic syndrome, sedentary
lifestyle, and age).
Peculiarities of diabetic dyslipidaemia
Clinical relevance. Diabetes mellitus incidence and preva-
lence are increasing significantly around the world. In Italy,
there are currently 4 million people with diabetes.50
Cardiovascular disease is the main cause of morbidity and
mortality among patients with diabetes, with a risk 1–3
times higher in men and 2–5 times higher in women com-
pared with the non-diabetic population.51–53 It has been es-
timated that diabetic patients have a risk of cardiovascular
events equal to that of the non-diabetic population with
ischaemic cardiopathy, although some evidence is discor-
dant on this point.52,54
The high cardiovascular risk is due to several risk factors
such as obesity, dyslipidaemia, hypertension, and hypergly-
caemia, all of which interact synergistically.
Atherogenic dyslipidaemia in diabetes. Patients with type
2 diabetes are characterized by lipid profile alterations
that constitute a substantial part of the disease: hypertri-
glyceridaemia, reduction in C-HDL, increase in VLDL and
LDL, and postprandial increase in TG-rich lipoproteins.55
The combination of these alterations constitutes the condi-
tion known as ‘atherogenic dyslipidaemia in diabetes’,
which contributes to the higher cardiovascular risk of dia-
betic patients. Unlike other lipid disorders, the increase in
C-LDL is not strictly related to the presence of diabetes,
though it constitutes the main lipid factor of cardiovascular
risk in these patients. In an attempt to take into account
both C-LDL and the other lipid alterations typical of diabe-
tes so as to better define the cardiovascular risk of the dis-
ease, other indices have been proposed, such as non-HDL
cholesterol and the apolipoprotein B/apolipoprotein A1 ra-
tio (ApoB/ApoA1).56
Management of diabetic dyslipidaemia. The reduction of
plasma lipid levels, especially using statins, has been
shown to reduce the risk of cardiovascular events in pa-
tients with diabetes.57 In diabetic patients, the reduction
of C-LDL causes a decrease in all-cause and cardiovascular
mortality and in cardiovascular events at least equal to
that obtained in non-diabetics. This reduction does not de-
pend on the initial C-LDL levels and is present in both pri-
mary and secondary prevention.
All the current guidelines for the treatment of dyslipi-
daemia highlight that patients with diabetes benefit from a
reduction in C-LDL, though they differ with regard to the C-
LDL targets and about the need to guide the treatment on
the basis of lipid targets. The recent American guidelines
recommend using medium-/high-intensity statins in pa-
tients with diabetes, regardless of the C-LDL goal,16
whereas the European and Italian guidelines (SID/AMD)
recommend lowering LDL cholesterol to precise levels.8,58
Non-HDL cholesterol can be used as a secondary target
(30mgmore than C-LDL values), especially in patients with
TG>200mg/dL. The ApoB/ApoA1 ratio may constitute an-
other index of cardiovascular risk in diabetic subjects
(high-risk values: inmen>0.9 and in women>0.8).
In diabetes with dyslipidaemia, both lifestyle changes
(reducing saturated fats and cholesterol, increasing fibre
intake, and exercise) and the correction of all cardiovascu-
lar risk factors (optimization of glycaemic compensation
and blood pressure and smoking cessation) are fundamen-
tal. Statin therapy should be the first-choice treatment for
patients with type 1 and type 2 diabetes, with C-LDL levels
that are off-target with non-pharmacological intervention
(recommended target <100mg/dL). In patients with car-
diovascular disease and/or multiple non-modifiable cardio-
vascular risk factors, the therapeutic target is C-LDL
<70mg/dL.
In individuals that do not achieve C-LDL targets, despite
the use of statin therapy, a combination of statins plus
second-line agents, such as ezetimibe in particular, may
help to obtain the set target. In mixed dyslipidaemia, the
combination of statins with fibrates can be considered,
avoiding gemfibrozil. In the case of statin intolerance (SI),
ezetimibe, resins, or statin at the minimum-tolerated dose
plus ezetimibe can be used.
In subjects with TG >500mg/dL, a fibrate should be
used in order to reduce the risk of pancreatitis.
Pharmacological therapy for dyslipidaemia ismore effec-
tive if associated with an optimal control of glycaemia and
lifestyle intervention, optimal nutritional strategies, and a
reduction in alcohol consumption.
Statins. By inhibiting the synthesis of intracellular choles-
terol, primarily in the liver, and reducing cholesterol de-
posits, statins cause an increased expression of hepatic
LDLRs. This causes increased endocytosis of the circulating
LDL particles, with a consequent reduction in the C-LDL of
30% to over 50%. Both the Heart Protection Study (HPS)59
and the Collaborative Atorvastatin Diabetes Study
(CARDS)60 provided convincing evidence for supporting the
use of statins in diabetic patients over 40 years of age.
During the 5 years of the HPS study, simvastatin (40mg) re-
duced C-LDL by 1mmol/L (39mg/dL), cardiovascular
events by 27%, and stroke by 25%.59 The risk reduction was
present regardless of the type of diabetes, levels of glyco-
sylated haemoglobin, or baseline levels of C-LDL. The
CARDS study was interrupted because of the obvious bene-
fits achieved in the treated group.60 After an average
follow-up of 3.9 years, atorvastatin (10mg) reduced the
risk of a first cardiovascular event by 37% and of stroke by
48%. The Cholesterol Treatment Trialists’ Collaboration
(CTTC) meta-analysis of 14 RCTs of statin therapy involving
18686 people with diabetes (1466 with type 1 and 17220
with type 2 diabetes) revealed, during an average treat-
ment period of 4.3 years, a 9% reduction in mortality and a
21% decrease in myocardial infarction, coronary death,
coronary revascularization, and stroke for every 1.0mmol/
L (39mg/dL) reduction in C-LDL.57
These results support the guideline recommendations
that state that patients with diabetes are a high-risk group
and receive substancial benefit from statin treatment.
The very clear benefit of statins is tempered by concerns
regarding the adverse events, even if these are relatively
mild in most patients.61 Recent RCT meta-analyses seem to
indicate an increased risk of new-onset diabetes associated
with statin treatment.62,63 However, this risk is small, age
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related, and more consistent with higher doses of statins.
Indeed, it seems to accelerate by a few months the clinical
expression of diabetes in predisposed patients, i.e. those
who a have metabolic syndrome, for whom the increased
risk of developing diabetes is greatly outweighed by the
benefit of the reduction in cardiovascular events.63
Ezetimibe. When a higher dose of statins is unable to
achieve the target C-LDL values, simultaneous treatment
with ezetimibe should be considered. Ezetimibe reduces
cholesterol absorption by blocking the Niemann-Pick C1-
Like Protein 1 sterol transport protein. The IMPROVE-IT
study conducted on patients with recent ACS showed that
the combination of ezetimibe with a statin caused a further
reduction in LDL cholesterol compared with statins alone
(54 vs. 70mg/dL) and was associated with a small but sig-
nificant improvement in the primary endpoint composite
of cardiovascular death, non-fatal infarction, unstable an-
gina requiring hospitalization, coronary revascularization
30 days from randomization or non-fatal stroke (32.7% in
the simvastatin–ezetimibe group vs. 34.7% in the simva-
statin monotherapy group; hazard ratio 0.936; 95% CI 0.89–
0.99; P¼ 0.016).27 This result is in line with the findings of
the CTTC meta-analysis. Twenty-seven per cent of the pa-
tients included in the study had diabetes (n¼ 4933). It is in-
teresting to note that the only subgroup analysis that
showed a statistically significant effect was the one that
compared the presence of diabetes [relative risk (RR) 0.86,
95% CI 0.78–0.94] vs. absence of diabetes (RR 0.98, CI 95%
0.92–1.04). One possiblemechanism underlying the greater
efficacy in diabetic patients could be related to the effects
of ezetimibe on the atherogenic potential of the fasting
and postprandial lipoprotein profile in these patients.64
Resins. Resins are another class of lipid-lowering drugs that
act on the intestinal level, albeit in a different site respect
to ezetimibe (terminal ileum vs. duodenum/jejunum for
ezetimibe) and through a different mechanism (inhibition
of the enterohepatic circulation of bile acids). The Lipid
Research Clinics Coronary Primary Prevention Trial study
showed that the reduction in C-LDL obtained with chole-
styramine (20%) was associated with an approximately
20% reduction in cardiovascular events.65 A systematic re-
view of 36 studies showed that low-intensity statins plus
resins reduced C-LDL levels by up to 14% more than
medium-intensity statin monotherapy.66 Bile acid seques-
trants can be useful in diabetes because they improve gly-
caemic control, probably through an incretin-like effect.67
Therefore, despite the poor compliance observed with cho-
lestyramine and its side effects, such as constipation, in-
crease in plasma triglycerides, and reduction in the
absorption of drugs, including statins, resins represent an
additional therapy that could be useful for reducing C-LDL
in patients with diabetes, although an RCT is still needed to
determine the net effects of resins on cardiovascular out-
comes in diabetic patients.
Fibrates. Some decades ago, RCTs such as the Helsinki Heart
Study (HHS)68 and the Veterans Affairs High-Density
Lipoprotein Cholesterol Intervention Trial (VA-HIT)69 showed
a reduction in cardiovascular risk with fibrates compared
with a placebo. However, since statins became the standard
of care for individuals at high cardiovascular risk, RCTs with
fibrates have been unable to avoid the simultaneous use of
statins, such as in the Bezafibrate Infarction Prevention reg-
istry70 and Fenofibrate Intervention and Event Lowering in
Diabetes (FIELD) study.71 These studies did not show any
benefit to therapy with fibrates compared with placebo
groups inwhich statins were largely used. The same observa-
tionwas found in the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study72 when fenofibrate was added to
statins.
However, the advantages of fibrates should be recon-
sidered, firstly due to the positive effects observed in the
older HHS and VA-HIT studies, which make its use possible
in patients who are unable to take statins, but also be-
cause, in meta-analyses of the most important studies us-
ing fibrates, the subgroup of patients with high TG
(>2.3mmol/L) and low C-HDL (<0.9mmol/L—35mg/dL)
showed a reduction in cardiovascular risk of up to 35%, re-
gardless of the background therapy with statins.73,74
Fibrates would therefore appear to be ideal for the dyslipi-
daemia profile commonly observed in patients with diabe-
tes. This type of patient has been routinely excluded from
trials such as the FIELD and ACCORD studies, and, there-
fore, it would be appropriate to conduct a trial with
fibrates in patients with high TG and low C-HDL. In the
meantime, fibrates are still recommended in patients with
very high TG levels (>10mmol/L—387mg/dL) for pancrea-
titis prophylaxis.75 In addition, fibrates appear to be associ-
ated with reduced retinopathy progression, regardless of
their effects on lipids76; however, this unexpected effect
on microvascular disease warrants confirmation in ad hoc
studies.
Niacin. Niacin, which is currently not available in Italy, has
a positive effect on the lipid profile of diabetic patients.77
Forty years ago, the Coronary Drug Project showed a reduc-
tion in cardiovascular events and mortality with short-
acting niacin compared with placebo.78 This beneficial ef-
fect was not observed when sustained-release niacin was
added to background therapy with statins in either the
Atherothrombosis Intervention in Metabolic Syndrome with
Low HDL/High Triglycerides and Impact on Global Health
Outcomes (AIM-HIGH) study79 or the Heart Protection Study
2–Treatment of HDL to Reduce the Incidence of Vascular
Events (HPS2-THRIVE) study,80 in which a third of partici-
pants had diabetes (8299 of 25 673). In this latter study, in
order to reduce hot flushes, niacin was co-administered
with laropiprant, a prostaglandin receptor antagonist,
which may have inhibited some of the beneficial effects of
niacin.81 The niacin–laropiprant combination was also asso-
ciated with a greater incidence of perturbations in diabe-
tes control (absolute excess compared with placebo, 3.7%;
P< 0.001) and with a higher incidence of diabetes diagno-
ses (absolute excess 1.3%; P< 0.001).
It has been said that the duration of the AIM-HIGH study
was too short and that the sample was too small to reveal
an effect and that we still need to see the analysis of the
subgroups of the AIM-HIGH and HPS2-THRIVE studies before
we set niacin aside for good.82 Moreover, as niacin lowers
C-LDL by 20–30%, it could be beneficial in monotherapy;
however, this must be weighed against its tolerability and
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side effects, especially in patients with diabetes. Lastly, ni-
acin may help reduce TG and could, therefore, be useful in
people with high TG levels in order to reduce the risk of
acute pancreatitis, as already discussed for fibrates. It is
important to remember the effect of niacin on glycaemia,
which is increased after treatment.
PCSK9 inhibitors. Proprotein convertase subtilisin/kexin
type 9 (PCSK9) inhibitors are a new class of drugs approved
in Europe for the reduction of C-LDL in high-risk patients.
Although there are no available studies conducted exclu-
sively on patients with diabetes, one meta-analysis based on
three studies showed that evolocumab caused an average
reduction in C-LDL of 60% in 413 patients with type 2 diabe-
tes vs. placebo and of 39% vs. ezetimibe, and of 66% in 2119
non-diabetic patients vs. placebo and of 40% vs. ezetimibe.
In diabetic patients, evolocumab was associated with a de-
crease in non-C-HDL (55% vs. placebo and 34% vs. ezeti-
mibe), and lipoprotein(a) [Lp(a); 31% vs. placebo and 26%
vs. ezetimibe], and an increase in C-HDL (7% vs. placebo and
8% vs. ezetimibe). The results were irrespective of glycae-
mia, insulin use, renal function, and degree of cardiovascu-
lar disease.83 Side effects had the same frequency as among
the non-diabetics and consisted primarily of neurocognitive
events (1% vs. 0.5% with placebo, regardless of the C-LDL
levels achieved), injection site reactions (6% vs. 4%), myal-
gia (6% vs. 3%), and ophthalmological events (3 vs. 2%).
Two studies that enrolled a relatively high number of
subjects with diabetes provided very similar results in
terms of reduction in cholesterol and cardiovascular
events, without the differences between subjects with and
without diabetes.84,85 In the Long-term Safety and
Tolerability of Alirocumab in High Cardiovascular Risk
Patients with Hypercholesterolemia Not Adequately
Controlled with Their Lipid Modifying Therapy (ODYSSEY
LONG TERM) study, which randomized 2341 patients at high
risk of cardiovascular disease, of whom 818 had diabetes
(34.9% of the study sample), to alirocumab 150mg or pla-
cebo administered subcutaneously every other week for a
period of 78weeks, the decrease in C-LDL observed with
alirocumab was 62%.84 The incidence of cardiovascular
events (death from coronary disease, non-fatal myocardial
infarction, fatal or non-fatal ischaemic stroke, or unstable
angina requiring hospitalization) was low but significantly
lower with alirocumab than with placebo (1.7 vs. 3.3%;
P¼ 0.02). In the Open-Label Study of Long-Term Evaluation
against LDL Cholesterol (OSLER)-1 and -2 studies combined,
in 4802 patients at high risk of cardiovascular disease, of
whom 802 had diabetes (17.7% of the study sample), the
addition of evolocumab reduced C-LDL by 61% compared
with the standard therapy alone.85 The effect on C-LDL,
non-C-HDL, Lp(a), and TG was similar to that in non-
diabetic subjects, and it was not influenced by gender,
type of statin used, insulin treatment, presence of cardio-
vascular disease, GFR, or degree of glycaemic compensa-
tion. The incidence of cardiovascular events at 1 year was
significantly lower in the evolocumab group (0.95 vs.
2.18%; P¼ 0.003).
Considerations for diabetic patients. Patients with diabe-
tes have a high risk of cardiovascular disease. Statins
remain a fundamental therapy for the prevention of cardio-
vascular events in these patients, according to a number of
RCTs conducted specifically on patients with diabetes and
meta-analyses on a large number of subjects with diabetes
enrolled in many randomized studies involving statins. The
aforementioned analysis of the IMPROVE-IT study86 sug-
gests that adding ezetimibe could be particularly advanta-
geous for high-risk diabetic patients. A lower degree of
evidence suggests that fibrates could reduce cardiovascu-
lar risk in subgroups of patients with high TG and low C-
HDL. Of the various emerging treatments, PCSK9 inhibitors
have demonstrated to be very significantly effective in
lowering C-LDL. Until the results of studies conducted di-
rectly on diabetic patients87 are available, it can be pre-
sumed that PCSK9 inhibitors can be used in diabetic
patients with certain characteristics, such as, e.g. concom-
itant familial dyslipidaemia, recurrent episodes of cardio-
vascular events, persistence of high C-LDL levels despite
high doses of statins, or SI.
The role of dietary supplements in the treatment of
dyslipidaemia
Nutraceuticals and dyslipidaemia. A nutraceutical (a neol-
ogism coined in 1989, by uniting the terms nutritional and
pharmaceutical) is, according to its original definition, a
food product or part of a food product whose sole purpose
is to maintain good health. Nutraceuticals comprise a great
number of compounds, including dietary supplements and
functional foods (food products enriched with ingredients
with specific protective functions), and preparations con-
taining medicinal plants. Most nutraceuticals are of plant
origin; however, some substances are animal derivatives
(e.g. fish oil). From a regulatory standpoint, marketing a
product as a medicinal product is significantly different
from marketing a dietary supplement. This is clearly dem-
onstrated, e.g. by the information provided on the label:
the only products that can boast therapeutic or preventa-
tive properties are medicinal products and medical de-
vices. Supplements, according to Italian regulations
(assimilating [EC] Regulation no. 1924/2006 issued by the
European Parliament and European Council on 20
December 2006), have the sole purpose of maintaining a
good state of health, with an exclusively nutritional or
physiological effect. For this reason, medicinal products
have to follow a far more complex regulatory procedure in
order to ensure patients and doctors that the information
provided concerning their therapeutic efficacy has been
proved by specific clinical studies. The clinical studies (to-
gether with all the documentation constituting themarket-
ing authorization dossier) are submitted to regulatory
authorities who, after approving them, authorize market-
ing for those indications for which the medicinal product
has shown a favourable risk–benefit assessment.
Nutraceuticals are almost always used in the absence of
valid clinical studies documenting their efficacy and safety.
Indeed, the natural derivation of a nutraceutical does not
represent a guarantee that it is harmless; in addition, the
absence of post-marketing monitoring does not make it
possible to evaluate the onset of adverse effects related to
the use of these products. Medicinal productsmust beman-
ufactured in sites that have been approved by AIFA and
D16 M.M. Gulizia et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article-abstract/19/suppl_D
/D
3/3792742 by guest on 22 January 2020
must follow standards of good manufacturing practice
(GMP), which involve, in addition to hygiene and sanitary
inspections, also stringent technical assessments such as
the guarantee of batch reproducibility, assessment of the
incoming starting materials, and validation of all
manufacturing processes. The manufacture of a supple-
ment, on the other hand, may take place in a site that does
not have to comply with GMP, merely with Hazard Analysis
and Critical Control Points, a set of procedures only aimed
at preventing food contamination hazards and therefore
essentially a hygiene and sanitary assessment similar to
that performed on food.
A great many functional foods or dietary supplements
are promoted as benefits for subjects with dyslipidaemia
or to reduce cardiovascular risk. Although some of these
products appear to have potential functional effects, they
have never been studied in long-term clinical studies and
should therefore only be used if clinical evidence is avail-
able that clearly shows their safety and positive effects on
plasma lipids. Generally speaking, they should only be used
in those subjects whose overall cardiovascular risk does not
justify the use ofmedicinal products.
We must also remember that, in general, an individual
who eats a healthy and balanced diet does not need to add
any dietary supplements and that the use of these types of
products must not substitute consumption of ‘real’ foods
through a suitable diet.
Polyunsaturated omega-3 fatty acids. Omega-3s are a cat-
egory of essential fatty acids known as polyunsaturates be-
cause their chain comprises a number of double bonds. The
term omega-3 derives from the position of the first double
bond, which is the third from the terminal carbon atom
(carbonx).
The three main PUFA n-3s, alpha-linolenic acid (ALA),
eicosapentaenoic acid (EPA), and docosahexaenoic acid
(DHA), differ in the length of their chain (comprising 18,
20, and 22 carbon atoms, respectively) and in the number
of double bonds present (3, 5, and 6, respectively).
Omega-3s can be derived directly from food sources or
synthesized by chain elongation and anaerobic desatura-
tion using ALA. This acid is present in certain seeds (flax
seeds), in walnuts and in vegetable oils, whereas the main
sources of EPA and DHA come from the sea (mainly certain
types of fish, such as blue fish, tuna, and salmon).88
A number of epidemiological studies have confirmed the
relationship between a high dietary intake of omega-3 and
a reduction in cardiovascular risk. The American Heart
Association (AHA) recommends including at least two por-
tions of fish a week in the diet in order to reduce cardiovas-
cular events and reduce the progression of atherosclerosis
in patients with coronary disease.89
The GISSI-Prevenzione study34 showed that the adminis-
tration of a pharmaceutical formulation containing a highly
purified concentration of omega-3 (ethyl esters) equal to
at least 85% significantly and clinically relevantly reduces
the incidence of mortality for cardiovascular causes.
However, this effect cannot be attributed to an effect on
the lipid profile, rather, presumably, to an antifibrillatory
action, documented by the significant reduction in the
events validated in the trial as ‘sudden death’. In actual
fact, no significant changes in the lipid profile were ob-
served compared with the baseline, with the exception of
a modest (3.4%) but significant reduction in the concen-
tration of TG in the group treated with omega-3. The use of
pharmacological doses of >2 g of omega-3 a day reduces
TG levels. The average reduction in TG with a dose of 2–
4 g/day is approximately 30% and the benefit would appear
to be dose dependent; the reduction in TG is approximately
45% in subjects with baseline values>500mg/dL.90
Management of high cardiovascular risk patients with
hypercholesterolaemia
In managing patients at high and very high cardiovascular
risk in general medicine, a number of preliminary consider-
ations must bemade.5,8,16,91–100 First and foremost, the pa-
tient’s clinical condition must be clearly defined. In the
vast majority of cases, these patients are on polytherapy
and have co-morbidities. The main problems posed are the
need for transverse clinical monitoring for all the condi-
tions present and of the choice and management of the
pharmacological treatments, in particular with regard to
their efficacy, but also considering adverse reactions,
drug–drug interactions, and treatment compliance. The
targets to be met must be considered in the light of the
many clinical, anagraphical, cultural, and motivational
variables that each subject presents. In light of this mana-
gerial complexity and the great interindividual variability
associated with the conditions indicated above, the physi-
cian must evaluate, on a case-by-case basis, whether to set
ideal targets, or rather targets that are ‘realistic’ in real
life. How should one behave in the choice of medicinal
products and in the complex management of therapeutic
strategies (polytherapy, doses, interference, and motiva-
tional counselling)? We believe that the answer is to find
the right balance between the guidelines/evidence-based
medicine, regulatory standards such as those proposed in
AIFA notes, and good clinical practice, i.e. patient-centred
medicine.
On the one hand, we possess data that show how very
low C-LDL levels correlate with significant reductions in
cardiovascular events, and, on the other hand, we are
aware of the great difficulty experienced by most patients
in reaching these C-LDL levels. Attempting to reach targets
is, however, just part of the management of patients at
high cardiovascular risk: lifestyle monitoring is extremely
important and, as regards pharmacological therapy, it is es-
sential to monitor, when indicated, antiplatelet and/or
antiaggregant therapy, inotrope, anti-arrhythmia, and di-
uretic therapy. If we then consider the patient from the
complex management standpoint, caring for one aspect or
reaching a target is a mere part of a whole; it is part of the
protocol, but it is not the centre of the protocol.
Why AIFA [Italian Medicines Agency] note number 13
must be abolished
AIFA note number 13 has been the subject of great debate,
as shown by the three very different versions issued in a rel-
atively short amount of time.
The last version of circular 13 takes the form of a guide-
line for the treatment of dyslipidaemia that is to a large ex-
tent repetitive in certain parts and with certain specific
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issues with regard to consistency that have already been
appropriately summarized in documents issued by the
Italian Society for the Study of Atherosclerosis (SISA),
Italian Society of General Medicine (SIMG), and Emilia-
Romagna Regional Authority published in literature.101–103
Indeed, the aims of regulatory notes are very different
from those of the guidelines. Guidelines are the result of
an in-depth assessment of existing evidence; they pro-
vide a useful foundation on which to base the clinical de-
cisions and are not binding. On the other hand, being a
regulatory note, the AIFA note number 13 does have a
binding nature, with the main aim of rationalizing, espe-
cially from an economic point of view, prescriptions for
the correction of dyslipidaemia. Although this type of
rationalisation may have been indispensable a few years
ago when the economic commitment of the NHS relating
to the prescription of statins was very great, in the cur-
rent context, characterized by the availability of a great
many equivalent medicinal products, this type of ratio-
nale undoubtedly has much less reason to exist. In other
words, the guidelines should be more than sufficient for
guiding the clinical decisions of a prescribing physician,
without having a significant impact, from an economic
point of view, on NHS costs.
Diagnosis of familial dyslipidaemia: AIFA
note number 13 and clinical algorithms
Dyslipidaemia is a clinical condition in which there are
qualitative and quantitative alterations in plasma lipids
and lipoproteins. The increase in lipid levels may be abso-
lute and indicative of the presence of a primary (genetic)
dyslipidaemia or a secondary dyslipidaemia related to
other conditions. However, the concentration of plasma
lipids may also be relatively high in relation to the overall
cardiovascular risk of a specific patient.
Familial dyslipidaemias comprise a large group of lipid
metabolism alterations, and those that are themost impor-
tant because they are the most common are polygenic
hypercholesterolaemia, FH and FCHL.
Hypercholesterolaemia
Polygenic hypercholesterolaemia is the most common
cause of an increase in cholesterolaemia. The increase in
C-LDL is moderate, whereas triglyceridaemia usually is
in the normal range. Most patients with polygenic hyper-
cholesterolaemia present an LDL clearance alteration.
There is an underlying genetic predisposition associated
with the presence of numerous allele variants with a
cholesterol-raising effect in genes able to influence
plasma levels of C-LDL. This genetic predisposition is, in
many cases, worsened by environmental factors such as
a diet rich in saturated fats and a sedentary lifestyle.
Total cholesterolaemia is usually between 240 and
350mg/dL and its familial transmission does not present
the characteristics of monogenic diseases (i.e. family
members present either very high or absolutely normal
levels of C-LDL). For this condition, there are no specific
diagnostic criteria.
FH is a monogenic disease caused by a defect in the func-
tion of the LDLRs, with consequent absent or slowed re-
moval of these lipoproteins from the plasma and an
increase in the blood levels of C-LDL. FH is transmitted as a
co-dominant trait, therefore expressing with both a het-
erozygous phenotype (HeFH) and a homozygous phenotype
(HoFH). FH is caused by several different gene mutations.
Mutations may affect the gene encoding for the LDLR
(LDLR), or for ApoB (APOB), a specific ligand of the LDLR,
or that encoding for protein PCSK9 (PCSK9), which regu-
lates the amount of receptors present on the cell surface
or the gene encoding for LDLR adaptor protein 1
(LDLRAP1), which is essential for the correct LDLR func-
tion. Mutations of the LDLR gene are known to be the most
common cause of FH (accounting for approximately 90% of
cases).
In the heterozygous form, LDLR activity is only partly
compromised (by about 50%). It therefore manifests with
C-LDL values between 200 and 350mg/dL. In addition, pa-
tients may have tendon xanthomas, especially of the
Achilles’ tendon and extensor tendons of the hands.
Patients with HeFH often experience premature coronary
events (<55 years) and severe hypercholesterolaemia is
common in first-degree relatives.
A diagnosis of HeFH can be suspected on the basis of high
TC and C-LDL levels according to the following values:
• in adults: C-LDL 190mg/dL;
• in pre-puberty: C-LDL 160mg/dL.
In addition, at least one of the following criteria must be
satisfied for the diagnosis:
• presence of hypercholesterolaemia in a first-degree
relative (parents, siblings, and offspring);
• presence of tendon xanthomas; and
• presence of CHD in the patient or in a first-degree rel-
ative before the age of 55 years in men and 65 years
in women.
This is the set of criteria proposed by the Simon Broome
Register and adopted by AIFA note number 13.93 There is
another algorithm for diagnosing FH that would appear to
be more accurate and, indeed, it has been adopted by sev-
eral international guidelines. This is the score algorithm
based on the criteria of the Dutch Lipid Clinic Network
(DLCN) (Table 5).104
In the rarer homozygous form, there is an almost total
absence of receptor activity and TC is particularly high,
reaching values as high as 500–1200mg/dL. In this case, a
diagnosis is usually made in the paediatric age, and tendon
and/or skin xanthomas, signs of severe cardiovascular sys-
tem impairment, are present before the age of 10. The cri-
teria for the diagnosis of homozygous FH (Table 6) are
those suggested by the recent EAS document.104
The HoFH group may also include a severe form of FH
with recessive transmission (the parents of affected pa-
tients have normal or slightly high cholesterol values)
known as ‘autosomal recessive hypercholesterolaemia’.
This form is caused by the presence of homozygous muta-
tions in the LDLRAP1 gene and it is extremely rare. Studies
have shown that it is particularly common in Sardinia.
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Prevalence and diagnosis of familial
hypercholesterolaemia in Italy: sensitivity and
specificity of AIFA’s diagnostic algorithm in
general medicine
When diagnosing familial dyslipidaemia, general practi-
tioners (GPs) are faced with several critical issues:
• the need for a low level of ‘diagnostic suspicion’ for
certain borderline forms of familial dyslipidaemia;
• objective difficulties in identifying, in certain cases,
the presence of premature hypercholesterolaemia
and/or ischaemic cardiomyopathy in the patient’s
family;
• the non-univocal and/or complex and/or often contra-
dictory diagnostic criteria and/or different C-LDL/TC
threshold values adopted by the various algorithms,
meaning that application in the general medicine set-
ting is not practical or immediate;
• the absence, in some cases, of a specific International
Classification of Diseases–Ninth Revision (ICD9) classifica-
tion of the different forms of familial dyslipidaemia and,
in particular, of FH. Indeed, in this last case, the code
(272.0) is common to other, less severe, forms of hyper-
cholesterolaemia (e.g. the polygenic form). This causes
a diagnostic overlap and makes it impossible to calculate
with precision the true prevalence of the disease and,
therefore, to assess diagnostic appropriateness;
• the non-systematic and non-widespread use of
Friedewald’s formula to calculate LDL; and
• the variations in reporting the lipid profile by the dif-
ferent laboratories;
Themain consequences of these issues are:
• possible presence of undiagnosed cases with familial
dyslipidaemia (under-diagnosis);
• over-recording of diagnoses of heart failure (HF) (due
to the absence of aspecific ICD9 code, which, as men-
tioned previously, also includes other forms of hyper-
cholesterolaemia such as the polygenic form);
• possible inappropriate diagnoses of familial
dyslipidaemia.
Therefore, the problem has been investigated by evalu-
ating the sensitivity and specificity of the diagnostic algo-
rithms most commonly used by GPs for the diagnosis of FH
and calculating more precisely the prevalence of FH in
Italy. Three algorithms were tested:
• Algorithm 1: ICD9CM-based algorithm. This algorithm
adopts the specific ICD9CM code (ICD9CM subcode:
Table 6 Diagnostic criteria of homozygous familial
hypercholesterolaemia
LDL cholesterol levels  500mg/dL.a
Childhood presentations including premature coronary heart
disease and aortic valve disease.
Xanthomas in the tendons of the hand and Achilles’ tendon.
aHomozygous familial hypercholesterolaemia can also be observed
in the presence of lower levels of LDL cholesterol, considering the re-
cent recognition of the clinical and genetic heterogeneity of familial
hypercholesterolaemia.
Table 5 Dutch Lipid Clinic Network criteria for the diagnosis of familial hypercholesterolaemia in adults
Score
Family history
First-degree relatives with premature CHD (<55 years in men; <60 years in women)or
ﬁrst-degree relatives with cholesterol >8mmol/L (310mg/dL) (or> 95 percentile)
1
First-degree relatives with tendon xanthomas and/or arcus senilis or offspring <18 years
with cholesterol >6mmol/L ( 230mg/dL) (or> 95 percentile)
2
Patient history
Subject with premature CHD (<55 years in men; <60 years in women) 2
Subject with premature cerebral or peripheral vascular disease (<55 years in men; <60 years in women) 1
Physical examination
Tendon xanthomas 6
Arcus senilis in a subject <45 years 4
LDL cholesterol plasmatic levels
>325mg/dL 8
251–325mg/dL 5
191–250mg/dL 3
155–190mg/dL 1
Known causal gene mutation 8
Stratiﬁcation Total score
Certain diagnosis of FH  8
Probable diagnosis of FH 6-7
Possible diagnosis of FH 3-5
Unlikely diagnosis of FH 0-2
CHD, coronary heart disease; FH, familial hypercholesterolaemia; LDL, low-density lipoprotein.
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272.0/09 or 272.0/10, or 272.0 adding the comment
‘familial’), which is available in the modified version
of the Health Search ICD9CM thesaurus.
• Algorithm 2: SIMG/SISA. This algorithm was developed
by the SIMG and the SISA to provide GPs with a
straight-forward tool to use in clinical practice. A case
of FH is identified by a value of C-LDL 190mg/dL as-
sociated with a history of premature (<55 for men
and <60 for women) cardiovascular events (coronary,
cerebral, or peripheral vascular event) or the pres-
ence of xanthoma or early coronary events in the pa-
tient’s family (with the same age limits indicated
above). It is important to remember that this algo-
rithm also corresponds with the diagnostic criteria
recommended by AIFA note number 13.93
• Algorithm 3: SIMG/SISA algorithm plus familial history
of premature events. This algorithm defines a case of
FH using the same criteria as Algorithm 2, but by iden-
tifying family cases of premature cardiovascular
events by searching medical records for the following
free-format words: ‘premature’, ‘juvenile’, ‘under
60’, associated with the words ‘cardio’, ‘cerebro’,
and ‘vascular’. However, the cases were identified
manually one by one. The results of this algorithm are
identical to those obtained for Algorithm 2.
Of the sample of 1 240000 subjects present in the Health
Search database on 31 December 2014, all patients with
the following characteristics were recruited:
• presence of C-LDLa recorded in 2014 but without a
prescription for statins and/or ezetimibe;
• presence of C-LDLa in the year prior to the prescrip-
tion of statins and/or ezetimibe.
aNB: the C-LDL could be recorded or calculated using
Friedewald’s formula if the data were available.
The prevalence of FH obtained with the algorithms and
their sensitivity and specificity were evaluated using as a
landmark and gold standard the modified DLCN score104
(Table 7), so that it could be applied to the data available
in the Health Search database. This algorithm defined as
certain cases those with a score >8, as probable cases
those with a score of 6–8, and as possible cases those with a
score of 3–5.
With the DLCN score, the ‘certain’ cases (n¼ 99) had a
prevalence of 0.01%. The addition of ‘probable’ and
‘possible’ cases increased the prevalence to 0.18 and
1.48%, respectively. Algorithms 1 and 2, on the other
hand, gave a prevalence of 0.9 and 0.13%, respectively.
Although there are no substantial differences, females
usually have a higher prevalence than males, and the
highest prevalence was observed in the middle age sub-
group (Table 8).
Considering the ‘certain’ cases, Algorithm 1 showed a
sensitivity of 10.10% (95% CI 5–17.8%) and a specificity of
99.10% (95% CI 99.10–99.10%). Otherwise, Algorithm 2 bet-
ter identifies the true positives [sensitivity 85.90% [95% CI
77.40–92.00%)] while maintaining the same specificity as
Algorithm 1 (99.9%). By including the ‘probable’ or ‘possi-
ble’ cases, the sensitivity of both algorithms was signifi-
cantly reduced to 5.90% (95% CI 5.50–6.20%) and 8.20% (95%
CI 7.80–8.60%), respectively (Table 9).
The results obtained with Algorithm 2 were more or less
in line with published literature where the prevalence re-
ported is 1:200–1:500, as observed in studies in which the
genetic test was also used. Indeed, Algorithm 2 is signifi-
cantly more efficacious in identifying ‘certain’ cases.
Table 7 Dutch Lipid Clinic Network criteria modiﬁed by the application of the data available in the Health Search database
Score
Family history
First-degree relatives with premature CHD (<55 in men; <60 in women) (ICD9CM:410a–414a) and/or premature
cerebrovascular disease (ICD9CM: 342a, 433a–436a, 438a), or peripheral vascular disease (ICD9CM: 093.0, 440a,
443.1–443.9, 447.1, V43.4).
1
Patient history
Patient with premature CHD (<55 years in men; <60 in women) (ICD9CM: 410a–414a). 2
Patient (<55 years in men; <60 years in women) with premature cerebrovascular disease (ICD9CM: 342a, 433a–436a,
438a) or peripheral vascular disease (ICD9CM: 093.0, 440a, 443.1–443.9, 447.1, V43.4).
1
Physical examination
Tendon xanthoma (ICD9CM: 272.7 associated with ‘xanthomaa’ in the description of the code or in free-format
words; ICD9CM: 374.51).
6
Arcus senilis (ICD9CM: 371.0a; to be veriﬁed in the description of the code) in a subject <45 years 4
Laboratory tests
C-LDL >320mg/dL 8
C-LDL 250–319mg/dL 5
C-LDL 193–249mg/dL 3
C-LDL 155–192mg/dL 1
Diagnosis of FH Total score
Certain >8
Probable 6–8
Possible 3–5
CHD, coronary heart disease; C-LDL, LDL cholesterol; FH, familial hypercholesterolaemia.
aIndicates all codes starting with the number reported.
D20 M.M. Gulizia et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article-abstract/19/suppl_D
/D
3/3792742 by guest on 22 January 2020
Despite the fact that specificity is also high for Algorithm 1,
this method produces a lot of false negatives.
These results show that the ICD9CM for FH is probably of-
ten used to indicate ‘suspected’ cases requiring further di-
agnostic investigation. On the contrary, Algorithm 2, which
includes more specific criteria that are more similar to the
DLCN score, appears to be more precise for the diagnosis
(almost 90% sensitivity). This algorithm also showed better
accuracy in identifying probable and possible cases that re-
quire further investigation.
The results of the Health Search survey lead to the con-
clusion that:
• the systematic application of the DLCN score using of
a score of 4 for FH diagnosis (as recommended in the
SISA-SIMG consensus96) would hypothetically lead to a
rate prevalence of FH in Italy greater than 1%.
However, this rate also includes probable and possible
cases and therefore, particularly in those cases with
the lowest scores (e.g. between 4 and 6), the GP
should seek diagnostic confirmation with a genetic
test referring the patient to a second-level centre;
• the prevalence of FH according to the ICD9 classifica-
tion (Algorithm 1) performed by GPs applying mainly
the AIFA criteria and, to a lesser extent the other al-
gorithms, is 0.9%, very close to the rate previously
reported and therefore the same operating consider-
ations are valid;
• the very low prevalence of FH (0.13%) provided by the
automatic application of Algorithm 2 and AIFA criteria
is likely due to the test’s low sensitivity and to the
aforementioned difficulties in obtaining information
on the clinical and biochemical data of the patient’s
family;
• both algorithms guarantee high specificity, indeed
they exclude almost all true negatives, whereas a high
sensitivity in the identification of true positives was
only shown for ‘certain’ cases using Algorithm 2, while
the sensitivity remains low for all other situations.
This means that, with the exception of a few certain
cases, in all other cases, there is a high possibility of
identifying cases that are merely ‘suspected’ and
therefore require further tests to confirm the
diagnosis.
Table 8 Prevalence of FH based on the Dutch Lipid Clinic Network (DLCN) score and tested algorithms
DLCN score Tested algorithms
Certain Certain/probable Certain/probable/possible Algorithm 1 Algorithm 2
Sex
Male 37 (0.01) 591 (0.11) 6485 (1.21) 3770 (0.7) 551 (0.1)
Female 62 (0.01) 1452 (0.25) 10 002 (1.73) 6272 (1.09) 917 (0.16)
Age range (years)
15–24 0 (0) 22 (0.02) 66 (0.06) 156 (0.14) 2 (0)
25–34 0 (0) 67 (0.04) 260 (0.17) 382 (0.25) 11 (0.01)
35–44 6 (0) 237 (0.12) 1076 (0.55) 1005 (0.52) 64 (0.03)
45–54 26 (0.01) 521 (0.25) 3225 (1.56) 2117 (1.02) 262 (0.13)
55–64 35 (0.02) 618 (0.37) 4881 (2.94) 2743 (1.65) 500 (0.3)
65–74 24 (0.02) 382 (0.28) 4099 (2.96) 2216 (1.6) 413 (0.3)
75–84 7 (0.01) 149 (0.15) 2275 (2.28) 1145 (1.15) 190 (0.19)
85 1 (0) 47 (0.11) 605 (1.43) 278 (0.66) 26 (0.06)
Total 99 (0.01) 2043 (0.18) 16 487 (1.48) 10 042 (0.9) 1468 (0.13)
Data are expressed as n (%).
Table 9 Accuracy of the tested algorithms in relation to certain and total cases identiﬁed by the Dutch Lipid Clinic Network score
Algorithm 1 Algorithm 2
Certain cases (DLCN) All cases (DLCN) Certain cases (DLCN) All cases (DLCN)
Sensitivity 10.10 (95% CI 5.00–17.80) 5.90 (95% CI 5.50–6.20) 85.90 (95% CI 77.40–92.00) 8.20 (95% CI 7.80–8.60)
Speciﬁcity 99.10 99.20 99.90 100
PPV 0.10 (95% CI 0.00–0.20) 9.60 (95% CI 9.10–10.20) 5.80 (95% CI 4.70–7.10) 91.90 (95% CI 90.40–93.20)
NPV 100 98.60 100 98.60 (95% CI 98.60-98.70)
AUC 0.55 (95% CI 0.52–0.58) 0.53 (95% CI 0.52–0.53) 0.93 (95% CI 0.89–0.96) 0.54
The CIs are not indicated if the upper or lower limit correspond with the proportion.
AUC, area under the curve; DLCN, Dutch Lipid Clinic Network; CI, conﬁdence interval; NPV, negative predictive value; PPV, positive predictive
value.
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Epidemiology of heterozygous familial
hypercholesterolaemia in Italy
HeFH is a frequent genetic cause of premature CHD, i.e.
myocardial infarction and angina pectoris, due to lifelong
exposure to high C-LDL levels.105,106 If not treated, men
and women with HeFH with cholesterol levels of 8–
15mmol/L (310–580mg/dL) develop CHD before 55 and 60
years of age, respectively; whereas those with the homozy-
gous form, with cholesterol levels of 12–30mmol/L (460–
1160mg/dL) develop CHD at a lower age and, unless
treated, die before the age of 20 (60%). However, once
they have been identified, patients with the heterozygous
form can be efficaciously treated with cholesterol-
lowering agents, attenuating the development of athero-
sclerosis and preventing CHD. Indeed, if the HeFH (usually
indicated using simply FH) is diagnosed relatively early in
life and the patients are treated efficaciously with statins,
their risk of myocardial infarction comes close to that of
the general population.107
Among the Caucasian population, the prevalence of
HeFHis is estimated to be 1/500 and of HoFH 1/
1000000105,106; however, in most countries these individ-
uals are not identified.108 Therefore, this theoretically es-
timated prevalence is likely to be underestimated, as it is
based on the prevalence rates in hospitalized patient and
disease-register samples, furthermore, it is biased by pre-
mature death of patients with FH. Indeed,many individuals
and families with FH are not identified and are conse-
quently underdiagnosed and therefore under-treated.109
Recent data indicate a prevalence of 1/250 for HeFH and
1/16000–-1/360000 for HoFH.110–112
The degree of underestimation and under-treatment of
individuals with FH in the general population is largely un-
known. The recent OEC/HES survey 2008–20127 (see
Section 1 for a description of the OEC/HES) listed the prev-
alence of the different plasmatic levels of LDL in the popu-
lation examined (35–79 years). LDL cholesterolaemia was
calculated using Friedewald’s formula and excluding sub-
jects with triglyceridaemia>400mg/dL on a serum sample
collected after 12h fasting and processed by the same lab-
oratory. Sixty men and 10 women, corresponding to 0.08%
of the total sample, were excluded from the statistical
analysis due to excessively high values of TGs. Table 10 in-
dicates prevalence according to the LDL value classes.
Twenty-five per cent of men and 27% of women were seen
to have high C-LDL values (155mg/dL).
In the same population sample, a family history of coro-
nary events (angina pectoris, myocardial infarction, coro-
nary artery bypass grafting, or angioplasty) at a young age
(<55 years) in first-degree relatives (parents, siblings, or
offspring) was reported in 8.2% (95% CI 7.4–9.0) of men and
10.7 (95% CI 9.8–11.6) of women. The average C-LDL value
in those who had a family history positive for premature
CHD was 130mg/dL in men and 130mg/dL in women and
was not significantly different to that found in those with-
out a positive family history (131mg/dL in men and
134mg/dL in women, respectively). If the diagnosis of
HeFH depended on the contemporaneous presence of
three conditions: a family history of premature CHD, a de-
clared family history of hypercholesterolaemia, and/or
hypertriglyceridaemia in first-degree relatives and a LDL
value >190mg/dL, the HeFH prevalence dropped to 3.2%
in men (95% CI 2.7–3.7) and 3.6% (95% CI 3.1–4.1) in
women.
We therefore applied the DLCN criteria for the diagnosis
of familial dyslipidaemia (as indicated in Section 3 regard-
ing the Health Search data); however, in our analysis, we
could not use the presence of tendon xanthomas and arcus
senilis as diagnostic criteria because these data were not
available in our study. Of the 70 people excluded for super-
seding LDL cholesterolaemia values, 6 men and 1 woman
had a family history of a premature coronary event. The re-
sults of our analysis are provided in Table 11. The sample of
the Italian population between 35 and 79 years analysed in
this study included 16734434 men and 17856380 women
(ISTAT 2010 census).
The different number obtained from the OEC/HES and
Health Search estimates can be attributed to the differ-
ence in the age of the sample considered (the Health
Table 10 OEC/HES Osservatorio Epidemiologico Cardiovascolare/Health Examination 2008–2012
LDL (mg/dL) Men (n¼ 4555) Women (n¼ 4556)
% 95% CI % 95% CI
70 5.0 4.3–5.6 3.1 2.6–3.6
71–100 16.4 15.3–17.5 15.7 14.6–16.7
101–114 12.5 11.5–13.5 13.0 12.1–14.0
115–130 16.7 15.6–17.8 17.3 16.2–18.4
131–154 23.4 22.2–24.7 23.4 22.2–24.7
155–190 19.2 18.0–20.4 20.2 19.1–21.4
191–250 6.7 6.0–7.4 6.7 6.0–7.5
251–325 0.2 0.1–0.3 0.4 0.2–0.6
>325 0.0 — 0.02 0.00–0.1
155 26.1 24.8–27.4 27.4 26.1–28.7
Prevalence of people with different LDL cholesterolaemia levels.
CI, conﬁdence interval.
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Search contains data for over 15 years) and the difficulties
in applying comparable standardized measurements and
criteria.
Clinical criteria for screening
FH screening in children, adults, and families is recom-
mended according to the following criteria:
– presence of FH among family members;
– plasma cholesterol 8mmol/L (310mg/dL) in an
adult subject or in an adult family member (or> 95
age- and sex-specific percentile);
– plasma cholesterol 6mmol/L (230mg/dL) in a child
or in a child in the family (or> 95 age- and sex-
specific percentile);
– premature CHD in the subject or a member of the
family;
– tendon xanthomas in the subject or a member of the
family; and
– premature sudden cardiac death in a member of the
family.
There is a higher likelihood of diagnosing FH when there
are very high levels of C-LDL, tendon xanthomas, and/or
premature CHD in a member of the family. It is essential to
draw up a family tree in order to evaluate the probability
of FH as indicated in Table 5. In the presence of probable or
certain FH, C-LDL tests must be carried out in the family
and the subject. If available, a genetic test should be per-
formed, with subsequent cascade tests in the family if a
causal mutation is observed. The family members to evalu-
ate are mainly the first-degree biological relatives, i.e.
parents, siblings, and offspring. However, second-degree
biological relatives should also be considered, namely
grandparents, aunts and uncles, nieces and nephews,
grandchildren, and half-brothers and half-sisters.
Role of genetic testing
The utility of genetic tests in the diagnosis of HeFH is still a
matter for debate. In the vast majority of cases, a genetic
diagnosis is not believed to be useful unless in cases of
uncertain clinical diagnosis. The genetic variability of FH
(approximately 1700 mutations have been observed113)
means that the systematic application of genetic analysis is
still not cost-effective, despite the fact that recent devel-
opments have allowed savings in terms of time and costs.
In a certain proportion of cases, a polygenic aetiology un-
derlying the FH clinical phenotype has been observed.114
Furthermore, since one of the main determinants of car-
diovascular risk in FH is the biochemical phenotype (high C-
LDL levels from birth) and not the genotype, C-LDL level-
based screening is considered cost-effective, considering
the employment of genetic analyses only in borderline
cases.115
It should also be highlighted that there is a stronger
agreement between clinical diagnoses using DLCN crite-
ria104and genetic diagnoses when the DLCN score is 8
(mutation present in 80% of cases); whereas with a score
>5, the mutation was present in 50% of cases.
The panel unanimously decided to adopt the DLCN score
for the diagnosis of FH with a cut-off of 6, reserving mo-
lecular diagnosis for those with a score of<6 only.
FCHL is most likely the result of a combination of differ-
ent genetic abnormalities. It is primarily caused by an in-
crease in the hepatic synthesis of ApoB, whose plasma
levels are constantly high, and with the consequent in-
crease in VLDL secretion by the liver. In patients with
HeFH, dyslipidaemia does not usually present before the
subject reaches adulthood. It is also known as dyslipidae-
mia with variable phenotype to reflect the presence of dif-
ferent lipoprotein phenotypes in the same individual and in
affected family members.
A diagnosis can be made with the simultaneous presence
of:
• a dyslipidaemia with a variable phenotype, i.e. a pa-
tient that presents with variations in TC and TG levels
over time, with the same clinical conditions (thus ex-
cluding the diagnosis of pure hypercholesterolaemia
or pure hypertriglyceridaemia that have constant plas-
matic values over time) and signs of vascular damage
(e.g. asymptomatic carotid atherosclerosis) and
Table 11 OEC/HES Osservatorio Epidemiologico Cardiovascolare/Health Examination Survey 2008–2012: men and women aged 35–
79 years
Men (n¼ 4555) Women (n¼ 4556)
% 95% CI % 95% CI
LDL >190mg/dL and:
Family history of CHD and family history of
hypercholesterolaemia/hypertriglyceridaemia
3.2 2.7–3.7 3.6 3.1–4.1
Familial hypercholesterolaemia—DLCN score
<3 unlikely diagnosis 93.3 92.6-94.0 92.9 92.2–93.7
3–5 possible diagnosis 6.5 5.8–7.3 6.8 6.1–7.5
6–8 probable diagnosis 0.2 0.0–0.3 0.2 0.1–0.4
>8 certain diagnosis 0.0 — 0.02 0.00–0.1
Familial dyslipidaemia. The two criteria for FH diagnosis reported are: ﬁrst criterion (LDL>190mg/dL associated with a family history of premature
coronary heart disease (<55 years), or family history of hypercholesterolaemia; second criterion: Dutch Lipid Clinic Network score>6 (probable diag-
nosis and certain diagnosis).
CHD, coronary heart disease; DLCN, Dutch Lipid Clinic Network.
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• at least one family member presenting a dyslipidaemia
phenotype that differs from that of the patient (see
above) and/or at least one family member with pre-
mature cardiovascular events (including peripheral
atherosclerotic disease and revascularization
procedures).
These criteria are taken into account by AIFA note num-
ber 13.
Guidance for laboratory reporting of lipid
parameters
Guidance for the reporting of lipid profile
parameters
Reporting is the final step in the laboratory data production
process and has the purpose, in addition to providing the
results of the tests performed, of providing tools for their
interpretation. Lab reports consist of three parts: the first
is the presentation of the results (type of material ana-
lysed, name of the analyte, and unit of measurement)116,
the second part regards the comparison system to allow a
correct interpretation of the results provided,117 and the
third part provides for an interpretative comment to aid
the assessment of the data.
Presentation of the results
Table 12 provides an example of a report with parameters
that must necessarily be present in a lab report: type of
material analysed, name of the analyte, and unit of
measurement.
Reference system
The criteria used for the interpretation of the analytic re-
sults are:
• comparison with normal value ranges,
• comparison with clinically significant values (decision-
making values),
• comparison with previous values for the same subject
(critical difference), and
• comparison with alert values (panic values or critical
values).
Reference values make it possible to compare a mea-
sured value with those obtained in a control population, to
which the subject belongs.118 It is not advisable to adopt
this criterion for the evaluation of a lipid parameter be-
cause it would not be possible to estimate the level of risk
the individual is subject to.119
The decision-making values, as the name suggests, are
those values on the basis of which clinical decisions are
made.117 With dyslipidaemias, these values define the en-
tity of the cardiovascular risk associated with a given con-
centration. They represent a ‘desirable’ value that should
be achieved or not exceeded in order to keep cardiovascu-
lar risk within acceptable limits. These values have been
established by the US120 and European5,8 guidelines and
recommendations issued over time, but they are not uni-
form for all subjects and/or patients as they depend on the
clinical characteristics of the individual (primary preven-
tion, presence of co-morbidities such as diabetes, hyper-
tension, etc.) and the presence of other risk factors (family
history, smoking, sedentary lifestyle, etc.). The lab that
processes the tests and writes the report does not usually
have access to this information. Moreover, the most recent
US guidelines have removed the C-LDL values as treatment
targets.121 In light of this, it is very difficult to indicate
decision-making values on the report. Consequently, we
believe it appropriate to recommend a simplified method
of reporting, based on the desirable values as defined by
the European guidelines. It is also appropriate that this re-
porting method is accompanied by an explanatory note
clarifying how the desirable values indicated refer to low/
Table 12 Method for presenting the results of lipid proﬁle tests (example)
System Component Unit of measurement Traditional Unit of measurement SI unit
S-(serum) Total cholesterol 195mg/dL 5.05mmol/L
P-(plasma)
S-(serum) LDL cholesterol 100mg/dL 2.59mmol/L
P-(plasma)
S-(serum) Non-HDL cholesterol 135mg/dL 3.50mmol/L
P-(plasma)
S-(serum) HDL cholesterol 60mg/dL 1.55mmol/L
P-(plasma)
S-(serum) Triglycerides 75mg/dL 0.84mmol/L
P-(plasma)
S-(serum) Apolipoprotein A-I 150mg/dL 1.50 g/L
P-(plasma)
S-(serum) Apolipoprotein B 90mg/dL 0.90 g/L
P-(plasma)
To convert values expressed in mmol/L into mg/dL, multiply by 38.6 (total, HDL and LDL cholesterol) or by 88.8 (triglycerides).
Heparinized serum or plasma are equivalent materials on which these analytes can be measured. The units of measurement chosen (traditional or
S.I.) depend on the cultural and organizational models adopted in the individual laboratories. There are three signiﬁcant ﬁgures (two decimals in the
case of SI units and an integer for the traditional units) except for HDL cholesterol, triglycerides and apolipoprotein B (traditional units).
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moderate risk subjects/patients and that they should be
even lower in very high-risk patients. This approach is in
line with the recent recommendations of the European
Federation of Clinical Chemistry and Laboratory Medicine/
EAS,122 which uses values obtained in epidemiological stud-
ies conducted on European populations—therefore with
characteristics similar to that of Italy—and suggests a sim-
ple, uniform method of reporting that can be adopted na-
tionwide. For the paediatric population, the reference
standards available are comprised of the US recommenda-
tions.123 The values are presented in Table 13.
In the same subject, the comparison with the previous
values measured serves to check whether the therapeutic
goal is achieved due to pharmaceutical intervention or life-
style changes.117 Only if the difference between the ob-
served value and the previous value exceeds a critical
value124 could the two values be considered to differ from
one another (with a 95% probability). This reporting method
is usually used for tumour markers, with advantages for the
clinical management of patients125; however, it has not
been confirmed whether this approach is useful also with
lipid parameters. Consequently, the decision to include the
critical difference values in the report is left to the individ-
ual laboratory. In this sense, it would be preferable for the
report to include at least the two previous results.
Critical values are unexpected results that should be
promptly brought to the clinician’s attention because they
require an immediate intervention.126 They are usually
used for lab tests (e.g. such as glucose, potassium, haemo-
globin, and cardiac troponins), for which considerable vari-
ations may constitute an immediate threat to the patient’s
health. In dyslipidaemia, the concept of rapid notification
may apply to TC and C-LDL values that are indicative of fa-
milial hypercholesterolaemia [in adults 310mg/dL
(8.00mmol/L) and190mg/dL (4.90mmol/L), respec-
tively]5,112,127 and TG values indicative of a risk of acute
pancreatitis880mg/dL (10.0mmol/L).75 In the paedi-
atric age, a value of TC 230mg/dL (6.00mmol/L)
requires further evaluation. These values must be indi-
cated on the report in an appropriate manner, with a spe-
cific note, if necessary, and, if possible, the treating
clinician should be informed.
Reporting
The Panel suggests expressing lipid parameter values as in-
dicated in Table 12.
As a comparison system, it has been suggested to use the
decision-making values, represented by the desirable values
defined in the European guidelines and presented in Table
13. These values should be accompanied by the explanatory
comment indicated in the table. It should be clearly indi-
cated in the report that the reference is constituted by
decision-making values rather than reference values.
We suggest that TC and C-LDL values indicative of FH as
well as TG values associated with a risk of acute pancreati-
tis are highlighted in the report, accompanied by an ex-
planatory note and that the clinician is promptly informed.
Examples of accompanying notes:
TC 310mg/dL (8.00mmol/L): value requiring clinical
evaluation for FH.
C-LDL 190mg/dL (4.90mmol/L): value requiring clin-
ical evaluation for FH.
TG 880mg/dL (10.0mmol/L): value requiring clinical
assessment due to a possible risk of acute pancreatitis.
The therapeutic target for C-LDL depends on the individ-
ual cardiovascular risk profile, information that can be ob-
tained from the patient’s physician care giver.
Unmet clinical needs in the management of
hypercholesterolaemia
Statin intolerance
In clinical practice, we refer to SI in those cases in which
the onset of clinically significant side effects and/or
Table 13 Desirable values and corresponding comment to be included in the report according to the European guidelines for
adults5,8,122 and according to the indications of the US National Heart, Lung, and Blood Institute for children and adolescents123
Desirable value Adults Children and adolescents
mg/dL mmol/L g/L mg/dL mmol/L g/L
Total cholesterol 190 5.00 170 4.40
LDL cholesterol 115 3.00 110 2.85
Non-HDL cholesterol 145 3.80 120 3.10
HDL cholesterol 45 1.15
Males 40 1.00
Females 45 1.20
Triglycerides 150 1.70 75
0–9 years 90 0.84
10–19 years 1.01
Apolipoprotein A-I 125 1.25 120 1.20
Apolipoprotein B 100 1.00 90 0.90
The desirable values indicated refer to subjects at low/moderate cardiovascular risk. For subjects at high or very high risk, the desirable values
should be lower.
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relevant adverse reactions require treatment discontinua-
tion. However, to date, there is no univocal and universally
accepted definition of this phenomenon in Italy. This issue
is particularly important, given its clinical and regulatory
implications, especially in view of the introduction of new,
non-statin lipid-lowering agents (PCSK9 inhibitors) that
could be useful in the presence of SI. The occurrence of ad-
verse events during statin treatment may require posology
changes (dose and/or a reduction in the frequency of ad-
ministration) or treatment discontinuation either tempo-
rarily or permanently.
SI could be defined as a condition in which, during ther-
apy with statins, the patient experiences unacceptable
symptoms and/or lab parameter alterations, suggesting
the possibility of a significant clinical risk. Both symptoms
and lab test alterations must be reversible and indisputably
associated with statin therapy. The occurrence of these ad-
verse events may require treatment interruption.128 In the
vast majority of cases, the SI condition is characterized by
the patient’s perception of the impossibility of continuing
therapy due to the presence of disabling symptoms,
whereas cases in which SI is associated with asymptomatic
alterations in lab parameters are less common. In a non-
negligible percentage of cases, the clinician discontinues
the drug due to an abnormal perception of the clinical risk
associated with treatment, even in the absence of signifi-
cant clinical issues.129 The correct identification of a true
condition of SI is particularly important in order to avoid in-
appropriate interruptions in treatment. Indeed, statin dis-
continuation can expose patients to the risk of adverse
cardiovascular events.129–131
International definitions
In recent years, a number of different scientific and profes-
sional associations have attempted to define the charac-
teristics of the clinical condition known as SI. Several
possible definitions for this complex phenomenon have
been proposed.132,133 More specifically, in 2013, the
Canadian Working Group Consensus Conference on
Diagnosis, Prevention and Management of Statin Adverse
Effects and Intolerance published an article on the SI is-
sue.132 The Canadian group suggested defining SI as a clini-
cal syndrome characterized by:
(1) the inability to use statins to reduce C-LDL and car-
diovascular risk due to the presence of symptoms
and/or lab test alterations that can be temporally
associated with the start of statin treatment or the
increase in the dose. The relationship between sta-
tins and disorders should be confirmed by the inter-
ruption and subsequent reintroduction of the
treatment (rechallenge intervention);
(2) SI can be either complete (intolerance to any statin
and at any dose) or partial (intolerance to certain
statins at certain doses); and
(3) SI is not associated with modifiable clinical condi-
tions (hypothyroidism, drug-drug interactions and
intercurrent conditions).
In 2014, the US National Lipid Association (NLA) pub-
lished a document about SI.133 The NLA suggests identifying
SI as a set of symptoms, signs, and lab test alterations that
the patient and/or doctor attribute to statin treatment.
The patient finds these disorders invalidating as they inter-
fere in an unacceptable way with normal daily activities
and require a treatment interruption or dose reduction. In
some cases, the decision to interrupt or reduce the dose of
the medication may be made by the doctor due to the on-
set of asymptomatic blood test alterations [elevation in
creatine kinase (CK) or transaminase values], suggesting
the presence of a significant risk of adverse events. The
NLA highlights the need for an in-depth assessment of each
individual case that should take into account all the as-
pects of communication between the doctor and patient
(with a ‘patient-centred approach’), thereby avoiding in-
appropriate interruptions for symptoms that are not actu-
ally related to statin toxicity. The NLA also suggests an
operative definition of SI:
Inability to tolerate at least 2 statins: one at
the lowest starting daily dose AND another at
any daily dose, due to either objectionable
symptoms or abnormal lab determinations
which are temporally related to statin treat-
ment and reversible when the statin is discon-
tinued, but reproducible by re- challenge. Any
modifiable possible cause of SI should be ex-
cluded (hypothyroidism, drug-drug interac-
tions, intercurrent conditions, intense physical
exercise, underlying muscle disease). More
specifically, the lowest starting doses for sta-
tins are: rosuvastatin 5mg per day, simvastatin
10mg per day, atorvastatin 10mg per day, lov-
astatin 20mg per day, pravastatin 40mg per
day and fluvastatin 40mg per day.
Lastly, despite avoiding terms such as ‘intolerance’,
the EAS recently published an in-depth review contain-
ing a classification of the adverse events affecting the
skeletal muscles that could be associated with statin
therapy.134 The EAS experts focus their attention on the
potential muscle disorders caused by statin therapy,
making a detailed distinction between the various possi-
ble forms (Table 14).
Operative synopsis for clinical practice
Considering the challenges, in many cases, of achieving a
diagnosis of a true SI, a simplified approach aimed at the
identification and characterization of this condition can be
of great help in clinical practice. The Panel believes that
the suspicion of SI should be based on the characteristics of
muscle symptoms, the presence of an increase in CK and/
or transaminases, and temporal association with the use of
statins, their interruption and treatment reintroduction
(rechallenge).
More specifically, in the SI document proposed by
ANMCO (see ‘The proposals in ANMCO consensus docu-
ments’ section subsequently), the following definitions are
suggested:
(1) ‘statin-associated muscle symptoms’: the patient
presents clinically relevant muscle symptoms that
may or may not be associated with a significant
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increase in CK and that regress after statin discon-
tinuation but recur after a ‘rechallenge’;
(2) ‘statin-related liver damage’: the patient presents
a significant increase in transaminases (>3 times
the upper limit of normal range) that regress after
statin therapy discontinuation and recur after
‘rechallenge’;
(3) ‘complete intolerance’ signifies that the adverse
reactions occur with all statins at any dose; and
(4) ‘incomplete intolerance’ indicates that the patient
is able to tolerate low doses of any statin.
Failure to meet therapeutic goals: the lower, the
better; the sooner, the better
The large-scale epidemiological studies conducted since
the 1960s (Seven Countries Study, Framingham Heart
Study, MRFIT) reported the existence of a direct relation-
ship between plasma cholesterol levels and the incidence
of clinical presentations of atherosclerotic cardiovascular
disease. Overall, the clinical and epidemiological evidence
indicates the presence of a linear relationship between
cardiovascular morbidity and cholesterolaemia. The num-
ber of adverse cardiovascular events grows progressively
with an increase in plasma cholesterol values. In the MRFIT
study, e.g. for every 20mg increase in the total cholestero-
laemia values, there is an increase of approximately two
deaths for ischaemic cardiomyopathy per 1000 inhabitants
over a 6-year observational period.118 The most recent
large-scale studies on pharmacological intervention with
statins completed over the past 25 years confirmed the ob-
servational evidence previously reported.25 The introduc-
tion of these pharmacological agents into clinical practice
significantly revolutionized the approach to patients with
high cardiovascular risk in both primary and secondary pre-
vention. Indeed, in all clinical studies, the reduction in
cholesterolaemia values obtained with statins is associated
with a significant reduction in cardiovascular morbidity.25
More specifically, an approximately 40mg/dL reduction in
C-LDL corresponds to an approximately 25% reduction in
the relative risk of ischaemic cardiovascular events
(Figure 7).
Large-scale studies also made it possible to define the
optimal C-LDL levels to achieve in each patient in order to
reduce cardiovascular adverse events in a clinically rele-
vant manner. Indeed, in patients with very high cardiovas-
cular risk, such as in cases of a prior myocardial infarction,
C-LDL values must be reduced to below 70mg/dL. This
therapeutic target is recommended both in the cardiovas-
cular prevention guidelines issued by the ESC8 and in the
most recent AIFA note (Table 15).
Even the last version of AIFA note number 13, published
in July 2014, recommends reaching and maintaining C-LDL
values<70mg/dL in subjects with very high cardiovascular
risk and at least <100mg/dL in high-risk subjects.93 In ad-
dition, AIFA note number 13 also indicates that in order to
maintain therapeutic appropriateness without unnecessar-
ily using limited NHS resources, lipid-lowering pharmaco-
logical interventions must achieve and maintain the lipid
targets established. Only in this way will it be possible to
Table 14 Deﬁnition of the muscle symptoms associated with statin therapy proposed by the Consensus Panel of the European
Atherosclerosis Society134
Symptoms Biomarker Comment
Muscle pain, muscle weakness,
cramps
Normal CK values Commonly deﬁned as ‘myalgia’; causal relationship with statin ther-
apy not always certain and obvious. Clinical investigation
necessary.
Muscle pain, muscle weakness,
cramps
Increase in CK< 4 ULN The appearance of symptoms associated with a modest elevation in
CK values can usually be attributed to exercise. Clinical investiga-
tion is necessary (i.e. thyroid function tests) with redeﬁnition of
the cardiovascular risk proﬁle. Possible interruption of statin
therapy.
Muscle pain, muscle weakness,
cramps
Increase in CK 4–10 ULN Condition of greater clinical importance, associated with greater
risk of signiﬁcant muscle problems. Interruption of statin therapy
appropriate.
Muscle pain, muscle weakness,
cramps
Increase in CK> 10 ULN Referred to as ‘myopathy’ or ‘myositis’ by international regulatory
authorities. Incidence of 1 in every 10,000 treated patients/year.
Intense proximal muscle pain with loss of strength. Signiﬁcant
pre-existing muscle condition often present. Statin therapy must
be discontinued.
Muscle pain, muscle weakness,
cramps
Increase in CK> 40 ULN Known as ‘rhabdomyolysis’ if accompanied by a reduction in renal
function and/or myoglobinuria.
None Increase in CK< 4 ULN Incidental ﬁnding of CK elevation in patient on statin therapy. The
assessment of thyroid function and of the relationship with exer-
cise are appropriate.
None Increase in CK> 4 ULN Situation of uncertain clinical signiﬁcance, requiring repeated tests
and in-depth clinical assessment.
CK, creatine kinase; ULN, upper limit of normal range.
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effectively reduce cardiovascular events in the populations
at greatest risk.
In light of the points summarized above, it is clear that
C-LDL reduction is a fundamental priority in the manage-
ment of patients with high or very high cardiovascular risk.
The lipid targets indicated in the guidelines and in AIFA
note number 13 should be reached and maintained over
time. However, statins alone are not always adequate.
Indeed, these drugs do not make it possible to achieve the
therapeutic targets in all patients, especially when it is
necessary to reduce C-LDL under 70mg/dL. More specifi-
cally, patients with initial C-LDL values >150mg/dL will
have difficulties in achieving the recommended target,
even if the highest efficacy statins are used. Indeed, only
the highest doses of atorvastatin (80mg) and rosuvastatin
(20–40mg) make it possible to achieve a 50% reduction in
C-LDL values.8 In addition, the use of high doses of statins
can cause the onset of significant side effects and adverse
reactions. More specifically, available data135,136 indicate
that just 60–70% of patients with a high cardiovascular risk
achieve the lipid targets set by the guidelines, despite be-
ing correctly treated with highly efficacious statins and
complying with their treatment prescriptions.
In recent years, ezetimibe, a new non-statin molecule
that is effective in reducing plasma levels of C-LDL, has be-
come available.137 This drug is a selective inhibitor of the
intestinal absorption of cholesterol. When used alone, eze-
timibe reduces C-LDL by 5–22%. However, when combined
with a statin, it favours a further 15–20% reduction in C-LDL
levels.138 In addition, the recent IMPROVE-IT trial27 has
shown that combining ezetimibe with a statin is associated
not only with a greater reduction in C-LDL values but also
with a significant improvement in clinical prognosis.
Precisely because of these results, a recent consensus doc-
ument issued by the American College of Cardiology (ACC)
proposes ezetimibe as first-choice therapy in patients who
are unable to achieve a reduction in C-LDL values adequate
to their level of cardiovascular risk, despite statin
therapy.139
Non-compliance with treatment prescriptions
Over the past 20 years, several clinical studies have shown
a widespread underutilization of the pharmacological
treatments recommended by international guidelines for
the treatment of cardiovascular diseases.140–142 This obvi-
ous lack of intervention results in a failure to achieve the
therapeutic targets recommended by international guide-
lines and is caused by a combination of factors associated
Reducon in the relave risk of ischaemic events
30 5040
10%
20%
30%
40%
LDL cholesterol reducon (mg/dL)
Every 40 mg/dL reducon in C-LDL 
is associated with an approximately 25% reducon 
in relave risk.
Figure 7 Relationship between reduction in LDL cholesterol (C-LDL) lev-
els and the reduction in the relative risk of ischaemic cardiovascular
events. Modiﬁed from Baigent et al.25
Table 15 Risk categories in AIFA note number 13 and in ESC guidelines of various clinical types of patients and related treatment
targets
Clinical type AIFA circular number 13 ESC guidelines
Risk level Treatment target Risk level Treatment target
C-LDL C-LDL
Diabetes mellitus Very high <70mg/dL and/or reduction
in C-LDL of 50%
Very high <70mg/dL and/or reduction in C-
LDL of 50%Type 1 and type 2 with other
risk factors or organ damage
Diabetes mellitus High <100mg/dL High <100mg/dL
Type 1 and type 2 without other
risk factors or organ damage
Ischaemic cardiomyopathy Very high <70mg/dL and/or
reduction in C-LDL of 50%
Very high <70mg/dL and/or reduction in C-
LDL of 50%Prior infarction, prior coronary
artery bypass grafting, prior PCI
Prior stroke, prior TIA Very high <70mg/dL and/or reduction
in C-LDL of 50%
Very high <70mg/dL and/or reduction in C-
LDL of 50%
Peripheral occlusive arterial dis-
ease, aortic aneurysm
Very high <70mg/dL and/or reduction
in C-LDL of 50%
Very high <70mg/dL and/or reduction in C-
LDL of 50%
Severe chronic kidney disease
(eGFR<30mL/min)
Very high <70mg/dL and/or reduction
in C-LDL of 50%
Very high <70mg/dL and/or reduction in C-
LDL of 50%
Moderate chronic kidney disease
(eGFR<60mL/min)
High <100mg/dL High <100mg/dL
AIFA, Agenzia Italiana del Farmaco (Italian Medicines Agency); C-LDL, LDL cholesterol; eGFR, estimated glomerular ﬁltration rate; ESC, European
Society of Cardiology; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack.
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with the complex operation of health care systems, as well
as the behaviour of individual patients.140–142 In current
clinical practice, the clinical management of the main car-
diovascular risk factors appear to be inadequate because
of the inertia of physicians. This inertia can be
characterized by one or more of the following143:
(1) The failure to prescribe treatments recommended
for the control of risk factors (antihypertensive and
lipid-lowering therapy).
(2) The prescription of lower and potentially inade-
quate doses of the various pharmacological agents.
(3) The absence of adequate intervention and effective
therapeutic modifications in cases of failure to
achieve therapeutic targets recommended by
guidelines.
The lack of adherence to therapeutic prescriptions has
now become a proper ‘additional occult risk factor’.144
Indeed, preventive interventions reach their favourable ef-
fects over a period of time that is significantly longer than
acute-phase therapies, and it is therefore necessary for pa-
tients to followmedical prescriptions in a continuous manner
and for drugs to be taken at the doses shown to be efficacious
in clinical studies. Patients are considered to be ‘treatment
compliant’ when they take more than 80% of the medication
prescribed, ‘partially compliant’ if they take between 20%
and 70%, and ‘non-compliant’ if they take less than 20%.
Extent of the phenomenon
Non-compliance is a widespread phenomenon among pa-
tients with cardiovascular risk factors or cardiovascular dis-
ease. This phenomenon is estimated to involve 50–60% of
patients in primary cardiovascular prevention and 30–40%
of those in secondary prevention.145–147
Studies conducted in the US and Canada suggest that
lipid-lowering treatment with statins is interrupted in 30–
40% of cases within 6months of the first prescription.147 In
the Dutch PHARMO database, of the approximately 60 000
patients who had been prescribed a statin over a 13-year
period, more than 50% interrupted the drug intake within 2
years from the start of treatment.148 Similar data have also
been recorded in Italy129,149.
In clinical studies, the interruption of treatment or inter-
mittent use are caused by several factors, which can be di-
vided into five categories (Table 16).
Clinical assessment
In clinical practice, treatment adherence is usually as-
sessed by direct patient interviews, they are asked what
drugs they are taking and how. This assessment is highly
subjective and significantly conditioned by the quality of
the doctor–patient relationship, with a possible 20–30%
overestimation of the drug actual use.144 A direct question
cannot provide accurate assessments, especially if a closed
answer is expected (‘do you always take your medication
as it was prescribed?’). On the contrary, however, problems
of non-compliance can be better identified using directly
administered questionnaires, such as the Morisky scale
(Table 17).150
Interventions to improve therapeutic adherence
Different types of interventions have been proposed in or-
der to improve patient adherence (Table 18). Interventions
to improve compliance can be classified into four types:
(1) interventions regarding prescription, with simplifi-
cation and modification of drug posology;
Table 16 Factors associated with non-adherence to therapeutic prescriptions
Patient related Related to the
clinical condition
Therapy related Health Service related Related to socio-
economic system
• Old age
• Female
• Cognitive, sight or
hearing deﬁcits
• Depression
• Chronic illness
• Multiple
co-morbidities
• Frequent administration
• High number of drugs
• Efﬁcacy cannot be
assessed
• Side effects
• Poor prescribing physician
authoritativeness
• Inadequate information
on the disease and drugs
• Uncertainty about
treatment duration
• Limited time dedicated
to the patient
• Follow-up frequency
• Low education status
• Absence of spouse
• Low income
• Need to contribute
to medical expenses
Table 17 Morisky Medication Adherence Scale
Morisky scale
Have you ever forgotten to take your medication?
Are you occasionally a little careless about taking your
medication?
When you feel better, do you stop taking your medications?
When you feel worse, do you stop taking your medications?
Each positive response has a score of 0 and each negative re-
sponse a score of 1. Patients with scores of 0–2 are consid-
ered non-adherent, those with scores of 3–4 are considered
adherent.
Adapted from Morisky et al.150
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(2) programmes aimed at informing and educating the
patient;
(3) initiatives aimed at changing patients’ individual
behaviour; and
(4) ‘complex and combined’ interventions split into dif-
ferent levels and implemented through combined
multidisciplinary approaches.
Overall, the quality of communication between health
care staff (doctors and nurses) and patients represents the
most important element in conditioning effective treat-
ment adherence. Only clinical meetings of an appropriate
duration and frequent follow-up appear successful in im-
proving adherence.144
The proposals in ANMCO consensus documents
Diagnostic-therapeutic pathways in patients with
statin-induced myalgia
In the event that a patient complains of muscle symptoms
during statin treatment, it is necessary to first of all check
the CK levels (Figure 8). In general, it is always advisable to
assess the CK values before starting treatment with any
statin.
If high CK levels are found (CK values in the rhabdomyol-
ysis range), it is necessary to withhold drug intake, care-
fully monitor renal function, and, if needed, to arrange
hospitalization. When CK values are >5 times higher than
the normal upper limit, it is recommended to stop the drug
Table 18 Intervention intended to improve prescription adherence
Changes to therapeutic
prescriptions
Training initiatives Behavioural intervention ‘Complex’ intervention
1. Reduction in the
number of doses
2. Transdermal administration
3. Adapt treatment
regimen to patient’s lifestyle
4. Facilitate access to
medication stocks
5. Audiovisual material
6. Information sheets
7. Telephone contacts
8. Mailing
9. Short motivational counselling
10. Frequent check-ups
after start of therapy
11. Use of reminder aids
(calendars, diaries,
pillboxes, and alarms)
12. Scheduled residual pill counts
13. Home visits
14. Combination of two or more
initiatives belonging to
the other categories
Myalgia
CK tests
Exclude other causes of myopathyAsyntomac CK elevaon
• Mild–moderate asymptomac CK
elevaon (<5×ULN) 
or
• Tolerable muscle pain with 
mild-moderate CK elevaon (<5×ULN)
• Connue the stan at the same or a 
lower dose depending on the  symptoms 
and CK levels
• Guarantee close follow-up
• Assess symptoms and CK levels as a guide 
for connuing treatment
Tolerable muscle 
pain, but CK>5× ULN
Intolerable muscle pain 
with or without CK 
elevaon
• Marked CK value 
elevaons (>10× ULN)
or
• Rhabdomyolysis
Disconnue therapy
When muscle symptoms disappear:
• Check CK levels
• prescribe another stan at a low dose (rechallenge)
Disconnue therapy
Carefully consider the 
clinical context and assess 
the appropriateness and 
need for stan therapy
If the symptoms and CK abnormalies reappear, 
consider:
• Low-dose rosuvastan (2.5–5 mg)
• Rosuvastan (5–10 mg) or atorvastan (10–20 mg) on 
non-daily dosing regimen.
If muscle symptoms reappear use ezemibe or ﬁbrates 
(alone or in combinaon)
If the paent is unable to tolerate non-stan drugs, 
consider nutraceucals (monacolin K 5–10 mg) or 
vegetable sterols alone or in combinaon
Figure 8 Diagnostic and therapeutic pathways in patients with statin-induced myopathy. ULN, upper limit of normal.
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and evaluate the presence of factors that increase myopa-
thy/myalgia risk. More specifically, it is necessary to ex-
clude the presence of hypothyroidism, rheumatic
polymyalgia, osteo-articular disease, or recent intense
physical activity. If there are not secondary causes, a
rechallenge, using the same statin previously used or a dif-
ferent one based on the pharmacokinetic characteristics,
is encouraged. In the event that muscle symptoms recur
(regardless of whether or not they are associated with CK
increase), the presence of an SI can be considered
confirmed.
If CK levels are <5 times normal values, but the patient
considers the myalgia symptoms to be intolerable, the sta-
tin may be discontinued. Once the symptoms have disap-
peared, a ‘rechallenge’ must be performed by re-
prescribing a statin (either one that has already been used,
or a different one, depending on pharmacokinetic charac-
teristics). If the muscle symptoms (with or without CK ele-
vation) reappear, the presence of intolerance can be
considered confirmed.
The management of patients with ‘confirmed SI’ should
contemplate:
(1) a further attempt at prescribing another statin, dif-
ferent from that/those initially used (hydrophilic
vs. lipophilic molecules) and/or with different me-
tabolism (CYP3A4 or CYP2C9), starting with a mini-
mum dosage then increasing the dose until the
optimal dose is achieved;
(2) prescription of a low statin dose combined with
ezetimibe (intestinal cholesterol absorption
inhibitor);
(3) prescription of statins with longer half-life (atorva-
statin and rosuvastatin) administered on alternate
days or every 2 days at low/minimum dosages; and
(4) ezetimibe prescription as monotherapy or com-
bined with nutraceuticals, based on the target of C-
LDL reduction.
The sequence of these interventions must take into ac-
count the relative efficacy of single options. Indeed, using
ezetimibe or nutraceutical allows only a modest C-LDL re-
duction when compared with statin treatment. In conclu-
sion, an additional possibility is offered by the new non-
statin lipid-lowering agents, particularly the PCSK9
inhibitors.
Diagnostic–therapeutic pathways in patients with
statin-induced liver injury
It should be take into account that an increase of transami-
nases values <3 times the normal upper limit is not a con-
traindication to statin therapy (Figure 9). Several patients
with diabetes, metabolic syndrome, or obesity have trans-
aminases values fluctuating around 1–3 times the normal
upper limit values151 because of a non-alcoholic steatohe-
patitis. In the case that an increase >3 times the normal
value occurs during statin treatment, it is recommended to
discontinue the drug. There is not a consensus on when the
best time is to recheck transaminases values. In some clini-
cal trials with statins, hepatic function tests were
rechecked after 2–3weeks, and in 70% of these cases the
values had normalized. Some authors suggest repeating
the tests after 6weeks.152
After verifying the absence of other factors that could be
responsible for transaminase increases, a rechallenge
should be considered in which the new intake of a statin is
prescribed (either the same previously used or a different
one based on pharmacokinetic characteristics). If a trans-
aminase increase reoccurs, different options should be
contemplated. Since a greater incidence of hepatic abnor-
malities occurs when higher statin doses are used, it may
be more appropriate to prescribe low doses or non-daily
dosing regimens. Transaminase levels should be checked
monthly during the first 3–4months and then every
3months thereafter. In addition, the use of statins not me-
tabolized in the liver (rosuvastatin or pravastatin) or non-
statin compoundsmay also be considered.
New drugs for the treatment of
dyslipidaemia
Introduction
Aimed at optimizing the treatment of patients at a high
risk of cardiovascular disease, several new lipid-lowering
drugs are in ongoing development and in various clinical
trial phases. The need for new therapeutic strategies ismo-
tivated by the fact that the therapies currently available
for the treatment of dyslipidaemia, including statins,
which represent the milestone in hypercholesterolaemia
treatment and in the primary and secondary prevention of
atherosclerotic disease, do not make it possible to achieve
the target lipid level in all patients. Indeed, just 20% of pa-
tients with FH treated with statins reach target C-LDL lev-
els. Furthermore, there is a subgroup of patients who are
intolerant to high-dose statins due to the occurrence of
Transaminase (ALT, AST) elevaon
< 3× ULN
Rechallenge with the same stan at 
a lower dose or another stan with 
a diﬀerent type of metabolism
< 3× ULN
Connue stans and monitor liver 
enzymes every 4–6 weeks
Suspend stans and retest liver 
enzymes aer 6 weeks
Normalizaon Persistence of 
hypertransaminasaemia
Check any secondary 
causes Consider other causes of 
liver damage (alcohol, 
hepas, drug–drug 
interacons)
Figure 9 Diagnostic and therapeutic pathways in patients with statin-in-
duced liver injury. ULN, upper limit of normal.
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adverse effects, especially myotoxicity and
hepatotoxicity.153,154
In light of the limits of current dyslipidaemia treatment,
the introduction of new lipid-lowering therapies, such as
TG microsomal transfer protein (MTP) inhibitors, antisense
oligonucleotides directed against ApoB, ApoA1 mimetic
peptides, cholesterol ester transfer protein (CETP) inhibi-
tors and PCSK9 inhibitors, may represent an important
complement or alternative to statin therapy in reducing C-
LDL.154,155
Drugs for the treatment of severe genetic
dyslipidaemia
MTP, which is expressed primarily by hepatocytes and
enterocytes, plays a key role in the synthesis of the lipopro-
teins containing ApoB. MTP is responsible for the transfer
of TG, phospholipids, and cholesterol esters to ApoB in the
endoplasmic reticulum. MTP inhibition causes a reduced
synthesis and secretion of VLDL in the liver and a reduction
in overall plasma TG levels. Lomitapide, an oral MTP inhibi-
tor, was approved by the Food and Drug Administration
(FDA) in December 2012 for the treatment of patients with
HoFH. Figure 10 shows the mechanism of action of
lomitapide.154 In preclinical studies, lomitapide caused a
dose-dependent decrease in VLDL and C-LDL values in the
range of 19–89% and a decrease in TG in the range of 8–
49%.156,157 The effects of lomitapide in humans were evalu-
ated in a Phase 3 clinical study that enrolled 29 HoFH pa-
tients with mean baseline values of C-LDL equal to 336mg/
dL. The drug caused a 50% reduction in C-LDL after
26weeks of treatment and a reduction of 38% after
52weeks.158 Regarding the tolerability profile, lomitapide
seems to be associated mainly with gastrointestinal ad-
verse events (as diarrhoea, nausea, and abdominal
pain).154
The antisense oligonucleotides directed against ApoB
are another emerging group of lipid-lowering agents. The
ApoB is the most important structural protein of the ath-
erogenic lipid particles and plays a key role in the assembly
and secretion of VLDL by the liver.159 Mipomersen is a
second-generation antisense oligonucleotide constituting
of 20–22 bases that targets messenger RNA (mRNA) encod-
ing ApoB, thereby preventing mRNA transcription. Figure
10 shows the mechanism of action of mipomersen.154 This
medicinal product, administered in weekly subcutaneous
doses of 200mg, was approved by the FDA in January 2013
as an additional lipid-lowering treatment in patients al-
ready on treatment for HoFH. Many preclinical studies
have evaluated the effects of mipomersen in several ani-
mal species, showing that this drug reduces, in a dose-
dependent manner, hepatic mRNA ApoB-100, plasma con-
centrations of ApoB, C-LDL, and TC levels.160 In patients
with mild dyslipidaemia, the administration ofmipomersen
for 12weeks at a dose of 50–400mg every 3weeks caused a
dose-dependent reduction of ApoB and C-LDL of 50% and
35%, respectively.161 Other Phase 3 clinical studies have
also confirmed the beneficial effects of mipomersen.162
With regard to mipomersen tolerability, this drug is often
associated with the occurrence of injection site reactions,
‘flu-like’ reactions and hepatic enzyme elevation. Since
the therapeutic indication of lomitapide and mipomersen
is the HoFH, a rare hereditary form that affects approxi-
mately 1/1 000 000 patients in the USA, these medicinal
products have been authorized as orphan drugs.
Another novel class of lipid-lowering drugs are the ApoA1
mimetic peptides. ApoA1 is one of the main structural apo-
lipoproteins present in mature HDL. ApoA1 picks up choles-
terol from the macrophages of atherosclerotic lesions
through the adenosine triphosphate-binding cassette
transporter A1 (ABCA1), a membrane cholesterol transpor-
ter. ApoA1 mimetic peptides imitate the effects of ApoA1
and C-HDL and favour the regression of atherosclero-
sis.163,164 ApoA1 mimetic peptides include ApoA1 Milano,
known as ETC-216, which is obtained by combining mutant
HDL and phospholipids. Clinical data on the efficacy of
ETC-216 in reducing the volume of the atheroma remain
controversial.165,166
A further therapeutic alternative in lipid-lowering treat-
ment is eprotirom, a thyroid hormone analogue with mini-
mal extrahepatic uptake that has been shown to reduce C-
LDL plasma concentration in Phase 1 and 2 clinical studies.
The long-term efficacy and safety of eprotirom, adminis-
tered at doses of 50–100lg/day, have recently been evalu-
ated in a Phase 3 clinical study. The Efficacy and Safety
Study of Eprotirome in HeFH Patients Who Are on Optimal
Standard of Care (AKKA) study included 236 patents with
HeFH who did not reach target C-LDL values after 8weeks’
statin treatment with or without ezetimibe. This study
showed that the mean plasma concentrations of C-LDL in-
creased by 9% in the group of patients treated with pla-
cebo, decreased by 12% in the group of patients receiving
eprotirom 50lg, and decreased by 22% in the group of pa-
tients treated with eprotirom 100lg. However, although it
is efficacious in reducing C-LDL, this drug may cause liver
damage,167 as its employment was associated with a signif-
icant increase in alanine transaminase, aspartate
Figure 10 Mechanism of action of lomitapide and mipomersen.
Lomitapide blocks the synthesis of lipoproteins containing apolipoprotein
B (ApoB) by inhibiting the triglyceride microsomal transfer protein (MTP),
the protein responsible for the transfer of triglycerides (TGs), phospho-
lipids, and cholesterol esters to the ApoB in the endoplasmic reticulum;
mipomersen is an antisense oligonucleotide that reduces the hepatic se-
cretion of VLDL by binding messenger RNA encoding ApoB and preventing
its transcription. Reproduced from Ahn and Choi.154
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transaminase and gamma-glutamyl transferase. Because
Phases 2 and 3 clinical studies showed an unacceptable
risk/benefit ratio, the development of this drug has been
discontinued.
Lastly, other therapeutic strategies for reducing the risk
of cardiovascular events include CETP inhibitors, such as
torcetrapib, dalcetrapib, anacetrapib, and evacetrapib.
CETP is a plasma protein that promotes the transfer of the
cholesteryl ester from C-HDL to VLDL or LDL.168 CETP inhi-
bition is thought to increase the concentration of C-HDL,
thereby reducing the risk of CHD.169 However, the data ob-
tained from clinical studies do not confirm the efficacy of
these products in reducing cardiovascular risk, with the ex-
ception of anacetrapib, which is currently being examined
in the Phase 3 Randomized EValuation of the Effects of
Anacetrapib Through Lipid-modification (REVEAL) clinical
study.170,171
PCSK9 inhibitors
The discovery of mutations in the gene encoding for PCSK9
associated with a ‘gain of function’, identified as the ge-
netic causes of FH, dates back to 2003. Since the discovery
of PCSK9, over 50 mutations/variations in the gene encod-
ing for this protein have been identified as the genetic
causes of FH. The subsequent characterization of PCSK9
‘loss-of-function’ mutations, which translate intomarkedly
reduced plasma levels of C-LDL, paved the way for the de-
velopment of a new class of lipid-lowering drug, the mono-
clonal antibodies against PCSK9.172
In physiological conditions, LDLR has a domain for ApoB
that allows binding with C-LDL and the internalization of
the LDL/LDLR complex in a clathrin-coated vesicle. Inside
the endosome, the LDL/LDLR complex is dissociated due to
the presence of an acidic environment. This dissociation
leaves the LDLR free to return to the cell surface by means
of a recirculation mechanism, whereas the LDL particles
are transported to the lysosomes, where they are de-
graded. PCSK9 is a key protein in the metabolism of choles-
terol and is expressed primarily in the liver and intestine.
Circulating PCSK9 binds with LDLR on the cell surface.
When LDL binds LDLR in the presence of PCSK9, the recircu-
lation of LDLR on the cell surface is inhibited, the amount
of LDLR on the cell surface drops, and circulation clearance
of LDL is decreased. Therefore, the density of LDLR on the
surface of the hepatocytes is inversely proportionate to
PCSK9 levels, whereas there is a directly proportionate re-
lationship between the levels of C-LDL and those of PCSK9
(Figure 11A).173,174
The monoclonal antibodies that inhibit PCSK9 by binding
circulating PCSK9 neutralize this protein, inhibit the degra-
dation of LDLR, and increase its expression on the surface
of hepatocytes (Figure 11B).172 Over the past 5 years,
many monoclonal antibody PCSK9 inhibitors have been de-
veloped including evolocumab, alirocumab, and
bococizumab.175
Alirocumab: the pharmacodynamic and
pharmacokinetic aspects
Alirocumab is a human monoclonal immunoglobulin G1
(IgG1) antibody that binds to PCSK9 with high affinity and
specificity. By inhibiting PCSK9 binding with LDLR,
alirocumab increases the number of LDLR available to elim-
inate LDL and therefore lowers the levels of C-LDL.176 As
the LDLR also binds to the residues of VLDL and
intermediate-density lipoprotein, alirocumab can also
cause a reduction in these residues, which is demonstrated
by decreases in ApoB, non-HDL cholesterol, and TG.
Alirocumab also causes a reduction in Lp(a), a form of LDL
bound to ApoA. The pharmacokinetic characteristics of
alirocumab are described in Table 19.
This drug received a favourable review from the
Committee for Medicinal Products for Human Use (CHMP)
in July 2015; it was approved by the FDA in July 2015 and
by the European Medicines Agency (EMA) in September
2015. Alirocumab is approved for subcutaneous administra-
tion at a starting dose of 75mg every 2weeks for the treat-
ment of HeFH, of non-familial hypercholesterolaemia and
of mixed dyslipidaemia. In patients requiring greater re-
ductions in C-LDL levels, therapy with alirocumab may be
started at a dose of 150mg every 2weeks.176
Clinical studies on alirocumab. The ODYSSEY clinical trial
programme for the development of alirocumab included 17
Phase III clinical studies, of which 12 have been completed
(7 placebo-controlled, 3 controlled vs. ezetimibe, and 2
controlled vs. ezetimibe and statins) and 5 are currently
ongoing (2 double-blind placebo-controlled studies and 3
open-label extension studies). The results of 10 of the 12
completed studies have been published and included in the
Assessment report for PraluentVR (Table 20). These studies
Figure 11 (A) PCSK9 function. (B) effects mediated by PCSK9 inhibitor
therapy. Reproduced from Do et al.173
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Table 20 Pre-authorization clinical studies evaluating the efﬁcacy of alirocumab
Forms of hypercholesterolaemia Clinical studies in the ODYSSEYprogramme
Clinical trial Population/comparison Results at week 24
Heterozygous
familial
FH I: 78week, multi-centred,
double-blind, controlled
trial
485 patients alirocumab (75–
150mg/EOW) þ lipid-lowering
therapy vs. placebo þ lipid-
lowering therapy
58% reduction in C-LDL
FH II: 78-week, multi-centred,
double-blind, controlled
trial
247 patients alirocumab (75–
150mg/EOW) þ lipid-lowering
therapy vs. placebo þ lipid-
lowering therapy
51% reduction in C-LDL
HIGH FH: 78week, multi-cen-
tred, double-blind, con-
trolled trial
106 patients alirocumab (150mg/
EOW) þ lipid-lowering therapy
vs. placebo þ lipid-lowering
therapy
39% reduction in C-LDL
Statin-intolerant
patients
ALTERNATIVE: 24week, multi-
centre, double-blind, con-
trolled trial
248 patients alirocumab (75–
150mg/EOW) vs ezetimibe
30% reduction in C-LDL
Patients at moder-
ate cardiovascu-
lar risk
MONO: 24week, multicentre,
double-blind, controlled
trial
103 patients alirocumab (75–
150mg/EOW) vs. ezetimibe
32% reduction in C-LDL
Patients at high car-
diovascular risk
LONG TERM: 78week, multi-
centre, double-blind, con-
trolled trial
2310 patients alirocumab
(150mg/EOW) þ lipid-lowering
therapy vs. placebo þ lipid-
lowering therapy
62% reduction in C-LDL
COMBO I: 52week, multi-
centre, double-blind, con-
trolled trial
311 patients alirocumab (75–
150mg/EOW) þ lipid-lowering
therapy vs. placebo þ lipid-
lowering therapy
46% reduction in C-LDL
COMBO II: 104week, multi-
centre, double-blind, con-
trolled trial
707 patients alirocumab (75–
150mg/EOW) þ statins vs. eze-
timibe þ statins
30% reduction in C-LDL
OPTIONS I: 24week, random-
ized, double-blind, con-
trolled trial
355 patients Alirocumab (75–
150mg/EOW) þ atorvastatin
(20–40mg) vs. ezetimibe þ
atorvastatin vs. high-dose ator-
vastatin vs. rosuvastatin
Alirocumab þ atorvastatin (20mg)
reduced C-LDL by 24% vs. ezeti-
mibe and by 39% vs. statins;
Alirocumab þ atorvastatin (40mg)
reduced C-LDL by 31% vs. ezeti-
mibe, by 49% vs. statins and by 33%
vs. rosuvastatin
OPTIONS II: 24week, random-
ized, double-blind, con-
trolled trial
300 patients alirocumab (75–
150mg/EOW) þ rosuvastatin
vs. ezetimibe þ rosuvastatin
vs. high-dose rosuvastatin
Alirocumab þ atorvastatin (10mg)
reduced C-LDL by 36% vs. ezeti-
mibe, by 34% vs. statins
Alirocumab þ rosuvastatin (20mg)
reduced C-LDL by 25% vs. ezeti-
mibe and by 20% vs. statins
C-LDL, LDL cholesterol.
Table 19 Pharmacokinetic characteristics of alirocumab and evolocumab
Monoclonal
antibody
Tmax
(days)
Bioavailability
(%)
Distribution
value (L)
Half-life
(days)
Metabolism
Alirocumab 3–7 85 2.8–3.5 17–20 It is eliminated through
the immunoglobulin clearance
pathways and broken down into
small peptides and single amino acids.
Evolocumab 3–4 72 3.3 11–17 It is eliminated through the
immunoglobulin clearance
pathways and broken down
into small peptides and single amino acids.
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included a total of 5172 patients with HeFH, non-familial
hypercholesterolaemia, and mixed dyslipidaemia. Three of
the 10 studies enrolled only patients with HeFH; the
OPTIONS I and II studies enrolled both patients with HeFH
and non-familial hypercholesterolaemia at high cardiovas-
cular risk. In all the 10 studies, patients were treated with
a starting dose of 75mg every 2weeks and titrated at Week
12 to 150mg, with the exception of the LONG TERM and
HIGH FH studies, which used a 150mg dose from the out-
set. All studies showed stable reductions in C-LDL up until
their end.176 The remaining two completed studies
(CHOICE I and EFC13672) evaluated the efficacy and safety
of alirocumab in monotherapy or in combination with sta-
tins or other lipid-lowering therapy. The CHOICE I study
compared alirocumab vs. placebo in patients with hyper-
cholesterolaemia and moderate-to-high cardiovascular
risk, whereas study EFC13672 compared alirocumab with
placebo in Japanese patients with HeFH or at high cardio-
vascular risk with hypercholesterolaemia not adequately
controlled by lipid-lowering therapy. The Phase III clinical
studies of the ODYSSEY programme currently ongoing are
the CHOICE II study that will end in June 2017; the
OUTCOMES study that will end in February 2018; and the
OLE, ALTERNATIVE, and CHOICE open-label extension
studies.
Tolerability of alirocumab. Overall, the drug is well toler-
ated. The adverse events observed during the studies are
shown in Table 21.
Evolocumab: pharmacodynamic and pharmacokinetic
aspects
Evolocumab is a human monoclonal antibody belonging
to the IgG2 class and has been shown to reduce circulat-
ing PCSK9, C-LDL, TC, ApoB, non-HDL cholesterol, TC/C-
HDL, ApoB/ApoA1, VLDL cholesterol, TG, and Lp(a) and
to induce an increase in C-HDL and ApoA1 in patients
with primary hypercholesterolaemia and mixed dys-
lipidaemia.177 The kinetic characteristics of alirocumab
are described in Table 19. Evolocumab received a favour-
able review from the CHMP in May 2015 and was ap-
proved by the EMA in June 2015 and by the FDA in August
2015. This drug is approved for subcutaneous administra-
tion at a dose of 140mg every 2weeks or 420mg once a
month for primary hypercholesterolaemia and mixed
dyslipidaemia or at a dose of 420mg once a month for
FH. In the absence of a clinically relevant response in HF,
this latter dose can be increased to 420mg every 2weeks
after 12weeks of treatment.177
Clinical studies on evolocumab. The Program to Reduce
LDL-C and Cardiovascular Outcomes Following Inhibition of
PCSK9 In Different Populations (PROFICIO) clinical trial pro-
gramme for evolocumab development included 16 Phase 3
clinical studies. Of these studies, 8 have been completed
and introduced as registration studies, enrolling a total of
4409 patients with HeFH, HoFH, primary hypercholestero-
laemia, or mixed dyslipidaemia (Table 22). Of these stud-
ies, one included only patients with HeFH and one only
patients with HoFH. In all the studies, patients were
treated with evolocumab at a dose of 140mg every other
week or 420mg once a month. All the studies showed sta-
ble reductions in C-LDL up until their end. In the FLOREY
study, evolocumab as a monotherapy or in combination
with atorvastatin was compared with a placebo in patients
with primary hyperlipidaemia or mixed dyslipidaemia; in
the YUKAWA-2 study evolocumab was compared with a pla-
cebo in Japanese patients with hyperlipidaemia or mixed
dyslipidaemia and at high cardiovascular risk. Six studies
are still ongoing and include the GLAGOV Phase III clinical
study, which is due to end in July 2016; the FOURIER and
EBBINGHAUS studies, which will end in February 2018; the
OSLER-2, which will end in August 2018; the GAUSS-3,
which will end in November 2017; and the TAUSSIG, which
will end in March 2020.177,178
Tolerability of evolocumab. Overall, evolocumab is well
tolerated. The adverse events observed during the studies
are shown in Table 21.
Table 21 Adverse events associated with alirocuman and evolocumab therapy
System and organ classification
according to MedDRA
Alirocumab Evolocumab
Infections and infestations — Nasopharyngitis, upper airway
infections, inﬂuenza
Immune system disorders Hypersensitivity reactions,
hypersensitivity vasculitis
Rash, urticaria
Gastrointestinal disorders — Nausea
Musculoskeletal and
connective tissue disorders
— Back ache, joint pain
General disorders and
administration site conditions
Injection site reactions,
erythema/redness, swelling, pain
Injection site reactions, such as
redness, pain and bruising
Respiratory, thoracic
and mediastinal disorders
Oropharyngeal pain,
rhinorrhoea, and sneezing
—
Skin and subcutaneous
tissue disorders
Pruritus, urticaria, nummular eczema —
Data provided on the printed materials for PraluentVR (alirocumab) and RepathaVR (evolocumab).
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Other PCSK9 inhibitors
The PCSK9 inhibitor class includes bococizumab. This is a
humanized monoclonal IgG2 antibody, which is currently
being evaluated in a Phase III trial. This drug, administered
subcutaneously at a dose of 150mg every 2weeks, is cur-
rently being evaluated against a placebo in the SPIRE-1 and
SPIRE-2 clinical studies. The first study will enrol 12000
high-risk patients who are on lipid-lowering therapy and
have laboratory C-LDL values between 70 and 100mg/dL or
non-HDL cholesterol values between 100 and 130mg/
dL.179 The study aim is to evaluate the reduction in major
cardiovascular events, including cardiovascular death,
myocardial infarction, stroke, and unstable angina. The
SPIRE-2 study will evaluate the same outcomes in 6300
Table 22 Pre-authorization clinical studies evaluating the efﬁcacy of evolocumab
Forms of hypercholesterolaemia Clinical studies in the PROFICIO programme
Clinical trial Population/comparison Results
Heterozygous familial TESLA: 12-week, multicentre,
randomised, double-blind,
controlled trial
49 patients evolocumab
(420mg/month) þ lipid-
lowering therapy vs. pla-
cebo þ lipid-lowering
therapy
At week 12 there was a 32%
reduction in C-LDL
Heterozygous familial RUTHERFORD-2: 12-week,
multicentre, randomised,
double-blind, controlled
trial
329 patients evolocumab
(140mg/EOW and 420mg/
month) þ lipid-lowering
therapy vs. placebo þ lipid-
lowering therapy
At weeks 10 and 12, evolocu-
mab 140mg/EOW and
420mg/month had reduced
C-LDL by an average of 61%
and 66%, respectively.
Primary hypercholesterolaemia
and mixed dyslipidaemia
LAPLACE-2: 12-week, multi-
centre, randomised, dou-
ble-blind, controlled trial
1896 patients evolocumab
(140mg/EOW and 420mg/
month) þ statins vs placebo
or ezetimibe
At weeks 10 and 12, evolocu-
mab 140mg/EOW and
420mg/month had reduced
C-LDL by an average of 72%
and 69%, respectively vs.
placebo and by 43% and 46%
vs. ezetimibe
MENDEL-2: 12week, multi-
centre, randomised, dou-
ble-blind, controlled trial
614 patients evolocumab
(140mg/EOW and 420mg/
month) vs. placebo or
ezetimibe
At weeks 10 and 12, evolocu-
mab 140mg/EOW and
420mg/month had reduced
C-LDL by an average of 40%
and 41%, respectively vs.
ezetimibe and at week 12
by 57% and 55% vs. placebo
DESCARTES: 52week, multi-
centre, randomised, dou-
ble-blind, controlled trial
901 patients evolocumab
420mg/month þ diet or sta-
tins or ezetimibe vs. pla-
cebo þ diet or lipid-
lowering therapy
At week 52 there was a 59% re-
duction in C-LDL
THOMAS: 14week, multi-
centre, randomised, open-
label trial
149 patients evolocumab
(140mg/EOW) pre-ﬁlled sy-
ringe þ lipid-lowering ther-
apy vs. evolocumab
(140mg/EOW) pre-ﬁlled
pen þ lipid-lowering
therapy
At week 6 evolocumab pre-
ﬁlled syringe and evolocu-
mab pre-ﬁlled pen reduced
C-LDL by 61% and 64%,
respectively
THOMAS: 28week, multi-
centre, randomised, open-
label trial
164 patients evolocumab
(420mg/month) automatic
microinfusion pump þ lipid-
lowering therapy vs. evolo-
cumab (420mg/month) pre-
ﬁlled pen þ lipid-lowering
therapy
At weeks 10 and 12, the evolo-
cumab automatic microinfu-
sion pump and evolocumab
pre-ﬁlled pen had reduced
C-LDL by an average of 69%
and 67%, respectively
Statin-intolerant patients GAUSS-2: 12-week, multi-
centre, randomised, dou-
ble-blind, controlled trial
307 patients evolocumab
(140mg/EOW and 420mg/
month) vs. ezetimibe
At weeks 10 and 12, evolocu-
mab 140mg/EOW and
420mg/month had reduced
C-LDL by an average of 38%
and 39%, respectively
C-LDL, LDL cholesterol.
D36 M.M. Gulizia et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article-abstract/19/suppl_D
/D
3/3792742 by guest on 22 January 2020
patients on treatment with maximum statin doses or with
other lipid-lowering drugs, and with C-LDL and non-HDL
cholesterol levels higher than 100 or 130mg/dL,
respectively.180
The other medicinal products belonging to the monoclo-
nal antibody class that are inhibitors of PCSK9, such as
RG7652, LGT-209, ALN-PCS02, LY3015014 and BMS-962476,
are currently undergoing Phase 2 and 3 trial.154
Conclusions
As shown by the clinical studies conducted up to now, the
new therapeutic strategies for the treatment of dyslipidae-
mia have favourable effects on the reduction of C-LDL
when administered either as a monotherapy or in combina-
tion with statins. Although lomitapide and mipomersen-
have shown their efficacy in patients with HoFH, some
doubts remain regarding their safety profiles. Indeed, be-
cause of the mechanism of action of these medicinal prod-
ucts, namely their inhibition of hepatic VLDL secretion,
they cause an accumulation of TG in the liver and therefore
require long-term monitoring of their safety. Further stud-
ies on ApoA1 mimetics and CETP inhibitors are required in
order to confirm their efficacy and safety. Lastly, to date,
PCSK9 inhibitors appear to be one of the most important
pharmacological innovations for reducing hypercholestero-
laemia, both in combination with statins and as an alterna-
tive to them in intolerant patients, as these drugs have
shown a good safety profile and, above all, good efficacy in
achieving C-LDL values <70mg/dL. To conclude, the new
pharmacological classes for the treatment of dyslipidaemia
could represent a valid option for improving anti-
atherosclerotic therapy.
Eligibility for treatment with PCSK9
inhibitors
How to identify patients to be treated
Until further data are available from clinical studies show-
ing that PCSK9 inhibitors have an impact on clinical out-
comes, it would be appropriate to identify the categories
of patients in which these new drugs could have the great-
est clinical benefits. On the basis of the scientific evidence
available, international regulatory authorities—the FDA in
the USA and the EMA in Europe—have posed some general
indications for the use of PCSK9 inhibitors in clinical prac-
tice. Despite acknowledging the absence of data support-
ing the efficacy of PCSK9 inhibitors in reducing the
incidence of adverse cardiovascular events, the EMA con-
siders the use of these drugs indicated in patients with pri-
mary hypercholesterolaemia (heterozygous familial or
non-familial) and mixed dyslipidaemia who are unable to
meet the recommended C-LDL target despite using the
maximum tolerated dose of statins.181,182 The EMA also
states that PCSK9 inhibitors can be used in patients with
hypercholesterolaemia who do not tolerate or who have
specific contraindications for the use of statins.181,182 The
FDA, on the other hand, allows PCSK9 inhibitor use in addi-
tion to the maximum tolerated dose of statins in patients
with HeFH and in patients with atherosclerotic cardiovas-
cular disease requiring a further reduction in C-LDL.183,184
Lastly, both regulatory authorities believe that evolocumab
can be used in patients with HoFH.181,183
Overall, the approach adopted by the FDA appears to be
far stricter than that adopted by the European Agency. The
North American regulations do not consider statin intoler-
ance and the use of PCSK9 inhibitors is limited to the ge-
netic forms of hypercholesterolaemia and the secondary
prevention of atherosclerotic cardiovascular disease.
Primary prevention in high- or very high-risk subjects is
neglected.
These decisions of the FDA appear to be affected by the
widespread debate in progress in the USA concerning the
cost-effectiveness of these new drugs. The publication of a
preliminary cost-effectiveness analysis for PCSK9 inhibitors
by the Institute for Clinical and Economic Review (ICER), an
independent, non-profit organization, triggered a large,
heated debate on the high costs of this new pharmacologi-
cal therapy.185,186 ICER analysed all the evidence available
(8 Phase II studies, 16 Phase III studies, 1 long-term follow-
up study, and a meta-analysis) regarding the predicted
costs of the new therapy (approximately $14000/year/pa-
tient). The conclusion was that PCSK9 inhibitors would be
cost-effective only if there was an 80% reduction in the pre-
dicted drug price.187 This evaluation could change if the
ongoing clinical studies show that PCSK9 inhibitors have a
particularly favourable effect on the incidence of athero-
sclerotic cardiovascular disease.
The considerable costs of these new therapies (between
e5000 and 7000/year/patient in Europe) pose serious
doubts as to the cost-effectiveness of their use also in the
complex setting of the Italian NHS.
Possible criteria for National Health Service
reimbursement of PCSK9 inhibitors
(1) Prescription restricted to specialists (cardiologists,
internal medicine specialists, and lipidologists).
(2) Establishment of an easy to use web-based register
for the assessment of prescriptive appropriateness
and the efficacy/safety of treatment in the first
6months of use (the register should have a limited
duration of no more than 2 years or until data on
clinical events becomes available).
(3) Target population:
a. FH patients (using validated score for the defini-
tion of the probability of the disease);
b. patients with very high cardiovascular risk (re-
cent atherothrombotic event within 1 year) not
meeting C-LDL targets on optimum C-LDL-lower-
ing therapy; and
c. very high-risk patients, after the first reoccur-
rence of a cardiovascular event;
(4) Pharmaceutical dispensing billed to the NHS.
Assessment of co-morbidities: the internal
medicine patient
Introduction
Most internal medicine patients are elderly or very elderly,
they usually have multiple co-morbidities, including acute
conditions, but more commonly chronic ones, that restrict
their degree of autonomy.188,189 In these patients, it is
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important to look for co-morbidities, however, this is often
not enough to explain the overall patient complexity and
frailty.190 In clinical practice, there is no co-morbidity indi-
cator or parameter to define patient complexity, which
relies solely on the specific skills that internal medicine
specialists possess191,192 on account of their training.
Co-morbidity and polymorbidity
The presence of multiple conditions in the same individual
constitutes a challenge for all clinicians treating elderly
people.193–196 A distinction should be made between co-
morbidity and polymorbidity and the complications that
arise during hospitalization,197 which make defining co-
morbidity in a patient a matter that is far from simple.198–
200 For example, in the REgistro POliterapie SIMI (REPOSI)
study, the term ‘cluster’ of illnesses is used to describe the
presence of two or more specific chronic illnesses.201 In ac-
tual fact, we need to have a fully comprehensive definition
of polymorbidity, especially in long-term care settings,
which would also be of use to general practitioners.
Functional dependence
In individuals aged over 75 years, polymorbidity is more
often associated with disability,202 to the extent that in
one large Swedish study, the presence of a functional dis-
ability was observed in almost 20% of participants, with a
prevalence that rose with the number of chronic condi-
tions. The prevalence of disability varies significantly for
the different clusters of illnesses: from 6.7% in those with
hypertension and atrial fibrillation to 82.4% in those with
dementia and hip fractures.203 The World Health
Organization’s International Classification of Impairments,
Disabilities, and Handicaps (ICIDH)204 defined the taxon-
omy of the consequences of an illness with three main con-
ditions: impairments, disability, and handicap. Another
scheme describes four fundamental situations: active ill-
ness, impairment, functional limitation, and disability.205
Functional dependence refers to people who are not self-
sufficient in at least one activity of daily living (ADL, e.g.
washing, getting dressed, eating, getting into or out of
bed, getting on to a chair, getting around, using the toilet,
and sphincter continence) or in an instrumental ADL (pre-
paring meals, doing the shopping, managing money, using
the telephone, doing housework, and going out).
Frailty
Complexity and frailty can be present in the same subject;
however, these terms are often used incorrectly and should
be considered separately.206,207 It is not easy to define
frailty according to a univocal concept, to the extent that
certain authors208 define it as a vulnerable state of health,
deriving from the complex interaction of medical and so-
cial issues, with a reduced ability to respond to stress, asso-
ciated with a functional reduction in performance.
Generally speaking, frail elderly subjects are debilitated
individuals who are either old or very old, with disabilities
of varying severity and associated geriatric syndromes.
From a strictly clinical standpoint, frailty is characterized
by a high susceptibility to developing illnesses often with
an atypical clinical course, limitation of motor capacities,
propensity to immobility, rapid fluctuations in health,
events with a domino effect, risk of adverse events and
complications, need for constant medical observation and
increased risk of death.209 In clinical practice, doctors use
the Clinical Frailty Scale to evaluate the diagnosed ill-
nesses, patient motivation, symptom control, functional
status, and the degree of dependence.210
The definition of complexity
What makes patients complex and how can we measure
their complexity? These questions are yet to receive an ad-
equate answer,211 to the extent that in hospitalized pa-
tients, the complexity of the case mix is an expression used
by clinicians and administrators to describe a series of mul-
tiple attributes that include, more than co-morbidity it-
self, the severity of the disease, the risk of death,
prognosis, treatment difficulty, health care needs, and the
entity of the health care resources involved. For clinicians,
it refers to the patient, his or her overall needs and the
methods used to guarantee the necessary health care, tak-
ing into account different aspects such as the severity of
disease, increased risk of mortality, therapy and patient
management difficulties, worse prognosis, and overall
greater health care needs. Administrators and providers
tend to emphasize in the complexity of the case mix the
greater consumption of resources, with an increase in the
cost of care. The concept of complexity is not univocal212
and extends from clinical to psychosocial and economic to
organizational spheres. The term complexity refers to un-
certainty, dynamicity, unpredictability, and risk. When
dealing with complex patients, we do not need centric
approaches that would be excessively simple and reduc-
tive. On the contrary, we need eccentric approaches, able
to decentralize know-how regarding the many facets of the
patient.213 In reality, the concept of complexity lacks a
precise definition and often includes interrelations be-
tween each component of a complex system, in relation to
their number, interfaces, contingent conditions, and possi-
ble decision-making options.214 A complex system is
characterized by a vast quantity of interacting elements
with great variability and is burdened by considerable
risks.215 Complexity is the real world, and it requires an al-
ternative outlook in health care, based on a fair judgement
of the dynamics of the possible interactions between the
different parts considered. Complexity means the impossi-
bility to reduce to linear terms not so much the situation
being studied, but rather the different ways in which the
situation is studied. A physician treating complex patient
should aim for multidimensional and multidisciplinary
knowledge but is aware of the impossibility of full knowl-
edge. Complexity makes medicine a probabilistic science,
with a high risk of error, due to the uncertainty that perme-
ates medical decisions, which must in any case be made
within a limited time frame and in a context of knowledge
that is not always defined.216 The definition of a complex
patient, adopted by the Agency for Healthcare Research
and Quality (AHRQ), refers to a person with two or more
chronic illnesses, in whom each of the conditions is able to
influence the outcome of the treatment of the other co-
morbidities, in various ways: limitation of life expectancy,
increased intercurrent morbidity, drug–drug interactions,
and the impossibility of making full use of adequate
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treatment due to contraindications.217 In the most com-
plete concept of complexity, the biological, socio-
economical, cultural, behavioural, and environmental
components all become important determinants of
health,218 although—paradoxically—these elements are
considered in the inclusion/exclusion criteria of clinical
studies as potentially confounding factors for an objective
evaluation of the results. In the internal medicine setting,
the management of a complex patient means, depending
on his/her specific characteristics, possessing special skills
for tackling the challenges posed by the single case in the
specific clinical context. Complex patients often represent
a grey area and require individualized treatments, based
on suitable clinical judgement and adequate decisions at
the highest levels of knowledge of the context. Complexity
of care can also require that more time be dedicated to pa-
tients in order to evaluate and deal with the health care
needed,219,220 with a varied case mix and a vast range of
possible decisions to bemade.
Overdiagnosis and the increase in co-morbidities
Overdiagnosis occurs when an illness that will not cause
any symptoms, morbidity, or premature mortality is identi-
fied.221,222 Overdiagnosis is often the result of an exasper-
ated quest for a diagnosis at all costs, where the
identification of a hypothetical disease is sought and con-
stantly evaluated improperly. In other cases, the thresholds
for the assessment of the illness or risk, such as blood pres-
sure or cholesterol, are shifted to the point where people
who are healthy or have very mild problems or who are at
low risk of illness are considered sick.223 Overdiagnosis in-
evitably entails exposure to potential damage caused by
treatment, without receiving any benefit.224 Moreover,
broadening the frontiers of illnesses that can be potentially
cured using medication causes an expansion in profit-
making markets,225 thereby generating a further waste of
public health resources. In this scenario, it is therefore
necessary to identify those subjects at greatest cardiovas-
cular risk on the basis of set and universally accepted pa-
rameters, an approach that becomes all the more evident
in light of the Ministerial Decree on prescriptive appropri-
ateness that recently came into force.
Complexity constitutes a daily challenge for physicians
and in order to obtain efficacious results they should sys-
tematically evaluate patient needs and prognoses, going
beyond the individual treatments to consider the health
care process as a whole,226 by filtering useful specialist
opinions with monitoring and systematic feedback of the
interactions existing between the elements and the poten-
tial associated risks.227,228 The illusion of simplicity re-
quires a review of the methods with which clinicians today
deal with complex patients188; however, simplifying com-
plexity does not mean standardizing it or dealing with
problems in a simplistic manner. For this reason, an overall
patient-oriented assessment of problems, integration, co-
operation and coordination, and communication are some
of the simple rules that can prove useful to obtaining tangi-
ble results in a complex system.229,230 These concepts, to-
gether with a specific attempt to investigate, in a
multidimensional manner, the topic of complexity and co-
morbidity, must become tools to be used by the internal
medicine specialist in order to reconsolidate his/her natu-
ral vocation as a ‘physician of the person’.
Co-morbidity assessment: common clinical cases
The European Commission has approved the use of the first
PCSK9 inhibitor in adult patients with primary hypercholes-
terolaemia or mixed dyslipidaemia, in addition to diet and
in combination with a statin and/or other lipid-lowering
therapies in patients who are unable tomeet the C-LDL tar-
gets with the maximum tolerated dose of a statin or in
combination with other lipid-lowering agents in subjects
with statin intolerance or for whom statins are contraindi-
cated. The assessment of these co-morbidities in this type
of patient has a number of implications.
Firstly, the identification and characterization of co-mor-
bidities are the first element for the estimation of cardiovas-
cular risk and therefore for the establishment of the target
C-LDL value. The presence of myocardial ischaemia, hyper-
tension, or cardiac insufficiency are important elements for
the identification of subjects at the highest cardiovascular
risk.231 On the basis of the data provided by the 2001–2006
NHANES survey,232 the most common cardiovascular co-mor-
bidities among dyslipidaemic subjects 65 years of age are
CHD (27.0%), diabetes mellitus (26.5%), prior stroke (10.4%),
and congestive HF (9.9%), with 51.2% of these subjects hav-
ing at least one of these co-morbidities.
Among the patients enrolled in the ODYSSEY LONG TERM
study,84 68.9% had a history of coronary heart disease and
the average age was 60 years. The inclusion criteria were
based not only on cholesterol levels (>70mg/dL despite
treatment with statins) but on a high cardiovascular risk as-
sociated with the presence of a documented coronary dis-
ease or a coronary artery disease equivalent (defined as
peripheral arterial disease, prior ischaemic stroke, moder-
ate chronic kidney disease with GFR 30–60mL/min/1.73m2
body surface area), or diabetes mellitus plus two or more
additional risk factors (hypertension; ankle–brachial index
0.90; microalbuminuria, macroalbuminuria, or urine dip-
stick>2þ proteins; retinopathy; or a family history of pre-
mature coronary disease).84 In the USA, 47.5% of high-risk
adult dyslipidaemics are currently not on statins and just
25% of high-risk patients receive high-intensity statins.233
This rate is even lower in Europe, where a high-intensity
statin is prescribed in less than 10% of all high-risk pa-
tients.234 Dedicating greater attention to the assessment
of co-morbidities may modify an incorrect perception of
the degree of cardiovascular risk.
Furthermore, the identification of co-morbidities has spe-
cific relevance. As PCSK9 inhibitors allow a reduction in C-
LDL levels that is greater than that obtained with statin ther-
apy, it is important to pay attention to certain co-morbidities
that could be associated with drug safety aspects. In the
studies performed to date, the number of adverse events ob-
served was no higher than for conventional therapy or in
those with a C-LDL level <25mg/dL (0.6mmol/L). However,
the follow-up periods were somewhat short, and hence, spe-
cific neurocognitive function assessment is required.235
Atherogenic dyslipidaemia
Of the various lipid metabolism disorders, the profile
characterized by the presence of small, dense LDL
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particles, low HDL levels (<1.0mmol/L in men and
<1.3mmol/L in women) and high levels of TG (>1.7mmol/
L), and VLDL has been defined the ‘atherogenic lipid pro-
file’, or ‘atherogenic dyslipidaemia’ and is associated with
a three- to six-fold increase in the risk of cardiovascular
disease.236
The lipid components that define atherogenic dyslipi-
daemia, in particular HDL and TG and their remnants, have
a complex pathogenic role in relation to the progression of
the atherosclerotic process, which is still in part unclear.
Observational studies have shown that a 1mg/dL increase
in HDL is associated with a 2–3% reduction in cardiovascular
risk and that high levels of HDL, even in the presence of C-
LDL levels >160mg/dL, protect against cardiovascular
events, as shown by the Framingham study237 and the
Prospective Cardiovascular Mu¨nster (PROCAM) study.238
Furthermore, a series of observations from clinical studies
and meta-analyses suggest that high TG levels are an inde-
pendent cardiovascular risk factor.238 Prospective studies
have shown that a 1mmol/L increase in TG is associated
with a 14% increase in the risk of CHD in men and a 37% in-
crease in women, regardless of the C-HDL levels.239
Moreover, an increase in the concentration of lipoproteins
rich in TG, such as VLDL, kilomicrons and catabolism prod-
ucts are associated with a greater risk of atherosclerotic
plaque and CHD progression.236
Given the marked increase in cardiovascular risk in sub-
jects with an atherogenic lipid profile, especially those
with type 2 diabetes, a therapeutic approach that acts on
the non-LDL components of the lipid profile is required.
It has been proved that an efficacious reduction in ab-
dominal fat reduces the prevalence of small dense LDL par-
ticles and increases the levels of HDL; thus, lifestyle
changes combining diet and regular exercise represent the
first aspect of therapy for atherogenic dyslipidaemia.240
Current ESC/EAS guidelines on dyslipidaemia8 recommend
regular daily exercise (at least 30min) in order to improve
atherogenic dyslipidaemia, insulin resistance, and C-HDL
levels.
From a pharmacological standpoint, the approach to the
treatment of atherogenic dyslipidaemia in patients on sta-
tin therapy can involve the addition of fenofibrate, the
only fibrate approved by the EMA that is compatible, from
a safety point of view, with statin co-administration.
Although there are not ad hoc interventional studies on the
treatment of atherogenic dyslipidaemia, a series of obser-
vations from previous clinical studies, especially in dia-
betic subjects, clearly indicate that fibrates have a
favourable effect on the reduction of cardiovascular
events in patients with atherogenic dyslipidaemia and dia-
betes mellitus. In the FIELD study, which recruited diabetic
patients with or without ischaemic cardiomyopathy, al-
though no significant reduction was observed in coronary
events, myocardial infarction, the Study’s primary end-
point, decreased by 24% in patients treated with fibrate.71
Moreover, in a post hoc analysis of the FIELD study, over 5
years of fenofibrate therapy reduced cardiovascular events
by 27% in the subgroup of subjects with atherogenic dyslipi-
daemia (hypertriglyceridaemia and low HDL levels).241
These results were confirmed by the ACCORD Lipid study,72
which enrolled patients with high cardiovascular risk, type
2 diabetes mellitus, and high levels of C-LDL, who were on
simvastatin therapy. At the end of the study, the primary
outcome of non-fatal myocardial infarction, non-fatal
ischaemic stroke, and cardiovascular death occurred in
12.4% of patients treated with fenofibrate against 17.3%
(31% reduction in relative risk) of patients treated with a
placebo. On the other hand, no significant differences
were observed in patients without atherogenic dyslipidae-
mia: in this case, adding fenofibrate to statin therapy did
not cause a reduction in cardiovascular events compared
with those subjects treated with simvastatin monotherapy.
Lastly, in a meta-analysis on patients with atherogenic dys-
lipidaemia enrolled in five large-scale interventional stud-
ies with fenofibrate, the use of fibrates was associated
with a 35% reduction in coronary events. The use of fenofi-
brate is currently approved by the EMA in patients with
severe hypertriglyceridaemia, in those with mixed dyslipi-
daemiawho are intolerant to statins, and in those with ath-
erogenic dyslipidaemia and currently on statin therapy, if
at high cardiovascular risk.
The hypercholesterolaemic patient with neurological
co-morbidities
The relationship between lipid-lowering therapies and neu-
rological disorders has always been the object of heated
debate. As far as acute cerebrovascular events are con-
cerned, the benefit of cholesterol-lowering therapies
would appear to be irrefutable. Indeed, statins have been
shown to reduce the progression of atherosclerotic carotid
lesions, induce (when used at high doses) lesion regression,
and modify the composition of atherosclerotic plaques, fa-
vouring their stabilization. Similar results are also ex-
pected to be observed with PCSK9 inhibitors, as during the
long-term safety studies (ODYSSEY LONG TERM and OSLER
II) a reduction in cardio- and cerebrovascular events was
observed. If this trend is confirmed by the ongoing outcome
studies, the protective role of these drugs will be defini-
tively confirmed in patients with both symptomatic [prior
transient ischaemic attack (TIA)/stroke] and asymptomatic
hypercholesterolaemia and atherosclerotic carotid artery
disease.
However, the relationship between cholesterol-lowering
therapy and cognitive deterioration is a far more contro-
versial matter. Indeed, cholesterol is the main component
of myelin, which is known to play a fundamental role in the
transmission of neuronal signals and in the integrity of the
blood–brain barrier. The decrease in serum cholesterol
caused by PCSK9 inhibitors, as was suspected in the past
for statins, could, therefore, potentially cause an alter-
ation in the myelin sheath and therefore in signal transmis-
sion. Currently, this hypothesis is not supported by
dedicated studies, as no observational studies on subjects
with genetic PCSK9 defects have shown any reduction in
cognitive functions.242 However, concerns regarding a pos-
sible unfavourable impact of PCSK9 inhibitors on neurologi-
cal function were rekindled by a recent meta-analysis of all
the RCTs comparing PCSK9 inhibitors with a placebo. This
meta-analysis reconfirmed the extreme efficacy of these
medicinal products in reducing cardio- and cerebrovascular
outcomes [odds ratio (OR) 0.43; 95% CI 0.22–0.82; P¼ 0.01)
but also showed that therapy with PCSK9 inhibitors is
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associated with adverse neurocognitive events when com-
pared with a placebo (OR 2.34; 95% CI 1.11–4.93;
P¼ 0.02).243
On the other hand, therapy with PCSK9 inhibitors may
also be associated with neurological protective effects in
the very long term. Indeed, PCSK9 binds with LDLR causing
its deterioration. This receptor, which is also present in the
central nervous system, would also seem to be responsible
for the degradation of ApoE, which is known to increase
the accumulation of amyloid B (the peptide responsible for
Alzheimer’s disease). PCSK9 inhibition could, therefore,
theoretically cause an increase in LDLR and, consequently,
a reduction in the accumulation of amyloid substance. This
mechanism was also observed for statins, which also in-
crease LDLR expression, and which, in a number of studies,
have been associated with a reduction in the development
of Alzheimer’s disease.
Future randomized, double-blind studies with a long du-
ration and having cognitive deterioration as a primary end-
point will be needed to definitively clarify this aspect.
The hypercholesterolaemic patient with thrombophilic
status
Lp(a) is an independent cardiovascular risk factor. EAS/ESC
guidelines on the treatment of dyslipidaemia recommend
testing Lp(a) in high-risk patients and in those with a family
history of premature cardiovascular events.
Lp(a), a particle similar to LDL, which contains a single
molecule of ApoB-100 bound to a specific glycoprotein,
Apo(a), seems to be involved in the atherosclerotic process
due to its richness in cholesterol and to Apo(a)’s similarities
to plasminogen. These two processes could explain why a
number of studies have shown a relationship between
Lp(a) levels and cardiovascular risk.
Unfortunately, unlike the other modifiable cardiovascu-
lar risk factors, the treatment options for Lp(a) are cur-
rently limited. Indeed, unlike the potent effect that statins
have on C-LDL levels, these drugs have very little effect on
Lp(a) levels, reducing them just a few percentage points.
Among the drugs currently available for dyslipidaemia,
only nicotinic acid causes a substantial decrease in lipid
levels; however, this medicinal product has been almost
shelved in clinical practice on account of its significant side
effects.
In light of these observations, a great deal of interest has
been generated by the evidence that in several Phase II and
III studies the new lipid-lowering agents, PCSK9 inhibitors
(alirocumab, evolocumab, and bococizumab) have been
shown to cause a statistically significant reduction in the
levels of Lp(a).244 More specifically, these drugs have
shown a significant reduction in Lp(a) compared with a pla-
cebo (reduction of approximately 25–30%), with a similar
percentage reduction regardless of Lp(a) baseline values,
but with a higher absolute decrease in patients with higher
baseline values, especially in high-risk patients with base-
line Lp(a) values>125nmol/L.245
Furthermore, significant and dose-dependent reductions
in Lp(a) compared with the controls have been observed,
regardless of background statin therapy. The reduction in
Lp(a) was also seen to be reversible when therapy was dis-
continued, whereas it persisted over time during the
treatment. The reduction was also seen to be regardless of
sex, age, and baseline levels of C-LDL.
The mechanism by means of which Lp(a) is synthesized,
metabolized, and removed from circulation is still unclear.
One of the hypotheses is that LDLR upregulation, combined
with the low levels of circulating LDL obtained with PCSK9
inhibitors, allows greater Lp(a) uptake by the LDLR, for
which, under normal conditions, Lp(a) has a low affinity.
To conclude, the effect of PCSK9 inhibitors on the con-
centration of Lp(a), in addition to that on C-LDL, could
have a beneficial effect on the prevention of cardiovascu-
lar events in patients with thrombophilic status; however,
it is yet to be clarified to what extent the reduction in
Lp(a) influences these events regardless of the reduction in
LDL cholesterol.
The role of statin therapy in elderly patients
The gradual ageing of the population and better survival
following ACS increasingly require a solution to the issue of
cardiovascular risk in the elderly population, both in pri-
mary and in secondary prevention settings. Indeed, more
than 80% of individuals who die from ischaemic cardiomy-
opathy are aged over 65 years.246 The high absolute cardio-
vascular risk associated with age, the frequent presence of
co-morbidities, and/or the presence of a prior ischaemic
cardiovascular event make the elderly population that in
which the benefits of statin therapy are the most obvious.
However, the elderly population, which is often on poly-
drug regimens, is also that which is most exposed to the
side effects of drugs, including statins and in which lower
doses should be used.
Because of the shortage of data concerning the use of
statins for primary prevention in elderly patients, their em-
ployment in these patients without a prior ischaemic car-
diovascular event (primary prevention) has a Class II
recommendation with a B level of evidence in the ESC
guidelines.8 Indeed, just one study, the Prospective Study
of Pravastatin in the Elderly at Risk (PROSPER) study,247
prospectively assessed the use of pravastatin 40mg vs. pla-
cebo in patients with no prior cardiovascular events and
aged between 70 and 82 years, showing a reduction in coro-
nary death, non-fatal myocardial infarction, and stroke
risk at 3 years, though without a reduction in all-causemor-
tality. However, one recent meta-analysis,248 which in-
cluded 24674 elderly individuals (>65 years) in primary
prevention and at high cardiovascular risk enrolled in 8
large trials on statins, showed that there was a 39% reduc-
tion in the risk of myocardial infarction and a 24% reduction
in the risk of stroke in patients randomized to statins when
compared with the control group, though there was no ef-
fect on all-cause mortality, cardiovascular death, and on
the risk of newmalignancies. Failure to reducemortality in
the elderly population undergoing primary prevention in-
tervention is, of course, expected, given the high preva-
lence of other potentially fatal age-related medical
conditions that outweigh the advantage of statin therapy.
However, in order to guarantee the quality and not merely
the quantity of life in the elderly population, reducing po-
tentially disabling events such as stroke and myocardial in-
farction, which are also related to significant health care
costs, represents an aspect that should guide
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cardiovascular prevention in the elderly population.
Moreover, this evidence should influence the recommenda-
tion of future guidelines regarding primary prevention with
statin therapy in the elderly and is of particular importance
considering the current increase of the elderly population.
Data regarding the use of statins in the elderly popula-
tion with prior ischaemic cardiovascular events are more
numerous. The 4S study (Scandinavian Simvastatin Survival
Study)249 showed a reduction in 5-year mortality in pa-
tients randomized to simvastatin vs. placebo, aged over 60
years and undergoing secondary prevention. In the
Cholesterol and Recurrent Events (CARE),250 pravastatin
reduced the risk of major coronary events, death by coro-
nary disease, and stroke in elderly patients with a reported
history of myocardial infarction. This evidence was con-
firmed by a meta-analysis that included subjects over 65
years of age (19 569 patients) recruited in nine RCTs and re-
ported a 22% reduction in the risk of all-cause death at 5
years, a 30% reduction in death by coronary disease, a 26%
reduction in non-fatal myocardial infarction, a 30% reduc-
tion in revascularization procedures and a 25% reduction in
stroke with statin treatment.251 Based on these data, cur-
rent guidelines suggest statin treatment in elderly patients
in secondary prevention settings as a Class I recommenda-
tion with a level B of evidence, such as for the secondary
prevention in the population<65 years.8
The diabetic patient
Diabetic patients, especially those with type 2 diabetes,
are characterized by specific lipid profile alterations that
constitute a substantial part of the disease: hypertriglycer-
idaemia, reductions in C-HDL, increases in LDL, smaller
and denser LDL and HDL, and a postprandial increases in
TG-rich lipoproteins. The combination of these alterations
constitute what is known as ‘atherogenic dyslipidaemia in
diabetes’, which contributes to the increased cardiovascu-
lar risk of diabetic patients.
Although C-LDL elevation is not strictly dependent on
the presence of diabetes, it represents the main lipid fac-
tor of cardiovascular risk in diabetic patients.
Statin therapy is the treatment of choice for diabetic pa-
tients with C-LDL values that are off-target with non-
pharmacological intervention alone. If full-dose statin
therapy is unable to achieve optimal C-LDL values, combi-
nation with ezetimibe should be considered. Recently, the
IMPROVE-IT study,27 which included approximately 5000
patients with diabetes, confirmed the efficacy of ezeti-
mibe in the diabetic sub-population (RR 0.86 vs. 0.98). The
IMPROVE-IT study results support the hypothesis that
achieving a more ambitious therapeutic target in terms of
C-LDL determines further cardiovascular benefit.
With regard to the effect of PCSK9 inhibitors in patients
with type 2 diabetes, there are currently no data from clin-
ical studies that have been conducted exclusively on these
subjects. In the studies published with alirocumab
(ODYSSEY LONG TERM)84 or evolocumab (OSLER),85 the per-
centage of diabetic subjects was 35% and 13%, respectively.
The sub-analyses conducted on diabetic subjects showed
that the effect on C-LDL, non-HDL cholesterol, Lp(a), and
TG is similar to that of subjects without diabetes and irre-
spective of gender, type of statin used, insulin treatment,
presence of cardiovascular disease, reduced GFR, and de-
gree of glycaemic compensation. The most common side
effects reported with these drugs were neurocognitive (re-
gardless of the levels of C-LDL achieved), injection site re-
actions (6 vs. 4%), myalgia (6 vs. 3%), and ophthalmological
events (3 vs. 2%), without a difference in incidence rates
between the diabetic and the non-diabetic groups.
More recently, other safety and efficacy studies con-
ducted in subjects with high cardiovascular risk were pub-
lished in which the percentage of patients with diabetes
was approximately 50% (ODYSSEY OPTIONS I and OPTIONS II
with alirocumab and YUKAWA-2 with evolocumab). In these
studies, PCSK9 inhibitors were more effective in reducing
C-LDL values than statin dose increases or their combina-
tion with ezetimibe, even in diabetic subjects.
Clinical and laboratory criteria for prescriptive
appropriateness pending outcome data
Taking into account the evidence currently available, the
use of PCSK9 inhibitors could be reasonably considered in
the following conditions.
Heterozygous familial hypercholesterolaemia
PCSK9 inhibitors could be used in patients with HeFH who
are unable to achieve the C-LDL target recommended by
the guidelines,8 despite a substantiated use of statins at
the maximum tolerated dose combined with ezetimibe.
More specifically, the lipid objectives should be as follows:
• C-LDL< 100mg/dL in patients in primary prevention,
who do not present clinical or instrumental signs of
atherosclerotic cardiovascular disease and
• C-LDL< 70mg/dL in patients is secondary prevention,
who present clinical or instrumental signs of athero-
sclerotic cardiovascular disease.
For the clinical diagnosis of FH (prevalence of 1:200–
1:500 subjects in the general population), the Italian
Regulatory Agency, AIFA, has issued the following
criteria93:
• baseline C-LDL> 190mg/dL and
• vertical disease transmission, confirmed by the pres-
ence of hypercholesterolaemia (with C-LDL> 190mg/
dL) among patient’s first-degree relatives.
If data regarding the lipid profile of the patient’s family
are not available, FH can be diagnosed in the presence of
C-LDL> 190mg/dL in combination with at least one of the
following conditions:
(1) patient presenting tendon xanthoma;
(2) evidence of premature ischaemic cardiomyopathy
in at least one first-degree relative (earlier than 55
years of age in men and 60 years of age in women);
and
(3) severe hypercholesterolaemia in prepubescent chil-
dren among first-degree relatives.
The AIFA diagnostic criteria indicated above are prefera-
ble to others, such as the DLCN score,104 due to their sim-
plicity and their regulatory values.
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Patients with atherosclerotic cardiovascular disease
and diabetes mellitus
PCSK9 inhibitors could be used in patients with atheroscle-
rotic cardiomyopathy (those with ischaemic cardiomyopa-
thy, ischaemic cerebrovascular disease (CVD), and
peripheral occlusive arterial disease), and/or diabetes
mellitus with evidence of organ damage (e.g. microalbumi-
nuria) who do not reach the C-LDL target <70mg/dL, as
recommended by the guidelines,8 despite the use of the
maximum tolerated dose of statin in combination with
ezetimibe.
Closing comments
At present, statins remain the main therapeutic strategy
for the treatment of hypercholesterolaemia.8 The diagnos-
tic and therapeutic pathway of each patient starting treat-
ment with PCSK9 inhibitors should be carefully recorded.
More specifically, the ‘maximum tolerated dose of statin’
should be adequately verified and each therapeutic change
recorded. In this way, it will be possible to guarantee the
best use of NHS resources. For the diagnosis of statin intol-
erance, which may restrict or prevent statin use, the
ANMCO position paper on this specific subject should be
consulted.252 This document defines the pathway for the
diagnosis of a condition that actually limits the clinical use
of statins.
‘Real-world’ data regarding the use of
cholesterol-lowering agents in patients with
recent cardiovascular events in Italy
Introduction
Atherothrombotic cardiovascular diseases have now come
to be the most common cause of death in both men and
women and in all parts of the world, not merely in
industrialized countries. Indeed, we are currently witness-
ing a globalization, not just in economic and cultural terms
but also in terms of clinical epidemiology.253,254 The spread
of cardiovascular disease is expected to increase further as
the population ages: in Europe, the number of subjects
aged >65 years is expected to rise from 85 million in 2008
to 151 million in 2060.255 Another determinant of this in-
crease is the improvement in the quality and efficiency of
care for acute cardiovascular diseases, which are able to
increase the survival of affected patients, but at the same
time, increase the size of the population of subjects requir-
ing secondary prevention intervention.256
Over the past three decades, several clinical studies
have highlighted the efficacy of various pharmacological
treatments able to reduce the incidence of new athero-
thrombotic episodes in subjects surviving a first episode;
more specifically, antiplatelet drugs, renin–angiotensin sys-
tem blockers, beta–blockers, and cholesterol-lowering
drugs have shown significant efficacy. In particular, statins
have been shown to reduce cardiovascular mortality and
non-fatal atherothrombotic events in heterogeneous pa-
tient populations in primary and secondary prevention.
These treatments are recommended according to both US
and European guidelines and should be prescribed to all
patients who have already had a cardiovascular event and
do not have any specific contraindication.5,16
Clinical studies reporting this evidence were conducted
in patients populations selected according to the eligibility
criteria of each trial, whereas the positive results of these
studies are transferred to real-world patients who often
have different characteristics than those of clinical re-
search. In addition, the levels of physician adherence to
guideline recommendations may vary not only with patient
characteristics but also with different sociocultural and
economic situations.
For these reasons, it is interesting to evaluate the CORE
report that used an administrative database to describe: (i)
the characteristics of real-world patients with a recent
atherothrombotic event; (ii) statin treatments at dis-
charge, an essential decision-making time point for sec-
ondary prevention strategies; (iii) their doses and
prescriptive continuity; (iv) the rate and causes of
rehospitalization; and (v) the overall costs for the Italian
NHS for patients with these conditions in the year following
the acute event.
Analysis methodology
The CORE report analyses were conducted using data from
the ARNO (CINECA) database, a clinical Data Warehouse
that combines, for each patient, data from various admin-
istrative databases (prescriptions for the medication dis-
pensed by the NHS to each citizen, hospital discharge
extracts, specialist ambulatory services, etc.), demo-
graphical data, and other information (socio-demographic
data). The ARNO database is currently composed of a net-
work of 32 local health authorities from all over Italy and
reports data for approximately 11million inhabitants.
The CORE report provides a very extensive and detailed
analysis concerning resource utilization and the costs for
patients with cardiovascular events. Reported data are ex-
tracted from two abstracts presented at the 18th
International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) Annual European Congress
held in 2015.257,258
The cohort analysed
Patients with cardiovascular events were defined as those
hospitalized with a main diagnosis of ACS or CVD (including
stroke and TIA) or peripheral occlusive arterial disease
(POAD) or who had had a coronary artery bypass grafting or
coronary angioplasty procedure.
From a population of 2 989512 potential patients from
seven Italian local health unities, a cohort was extracted
consisting of patients hospitalized from 1 January 2011 to
31 December 2011 (on an ordinary admission or day hospi-
tal basis) with ACS, CVD, or POAD as a main diagnosis.
All selected patients were observed for a follow-up pe-
riod of 12months following the index hospitalization, with
the aim of quantifying the resource utilization and health
care costs.
Statin use and cost assessment
The analyses regarding the quantitative use of resources
(statin consumption and treatment adherence and cases of
hospitalization) refer to the follow-up period alone (and
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therefore exclude the index hospitalization) and conse-
quently only refer to patients who were discharged alive.
More specifically:
(1) regarding statin use, the analysis focuses on the
first month of follow-up, as the most important de-
cisions concerning secondary prevention strategies
are made at discharge (additionally, for certain
treatments, prescriptions at discharge are different
from those issued subsequently, e.g. higher doses of
statins, dual antiplatelet therapy, etc.);
(2) compliance with statin therapy was attributed to
those patients who in the 12-month follow-up pe-
riod received a total of posology units compatible
with the daily treatment indicated in the summary
of product characteristics (SPC) for the statin in
question (considering a 20% tolerance over 365
days). Therefore, in this case, the assessment was
carried out on a whole year’s follow-up; and
(3) the new cases of hospitalization were analysed
from the day following the index hospitalization for
the whole year’s follow-up.
The overall costs refer to the initial cohort (not merely
those discharged alive) at the 1 year follow-up and include
the cost of the index hospitalization and co-morbidity. The
index hospitalization was taken into account because to at-
tribute an average cost to patients with cardiovascular
events, it is important to also consider the cost of the first
hospitalization, regardless of its outcome.
Results
Overall, the cohort recruited for the analysis (17 213 pa-
tients) represented almost 0.6% of the total potential pop-
ulation (2 989512 patients) (Table 23). The average age
was 73 years and males accounted for a bit more than half
the population (56%).
The subgroup of patients with CVD is the largest (9939
patients), with characteristics that were significantly dif-
ferent (P< 0.001) from those of the other two subgroups.
They had a higher average age (75 years), lower male pres-
ence (less than half, whereas in the other subgroups it was
approximately two-thirds), and higher baseline in-hospital
mortality (6.9%). Among patients with CVD, diabetes is pre-
sent with a lower frequency (26%), whereas its frequency is
highest among patients with POAD (35%).
Statin use
Statin use in the first month’s follow-up is expressed in
terms of patients treated. It is therefore analysed in terms
of prescription rates on two levels: by active substance and
active substance/dose.
Among patients admitted for a cardiovascular event who
were discharged alive (16 226), almost half (7220 or 44%)
were treated with statins (Table 24). The highest prescrip-
tion rate was observed among patients with ACS (more
than two-thirds: 70%), whereas rates were approximately
one-third in patients with CVD (29%) and POAD (37%).
More than half (51.4%) of treated patients received ator-
vastatin. Almost all patients were treated with atorva-
statin, simvastatin, or rosuvastatin, which combined
account for 97% of the market in question. Treatment with
atorvastatin was preferred among patients with ACS
(60.8%) and POAD (35.6%), whereas simvastatin was pre-
ferred among those with CVD (42.7%, if we also consider
the combination with ezetimibe).
Compliance to treatment with statins
The evaluation of compliance is based on the whole year’s
follow-up. On average, treatment compliance is main-
tained by two patients of the every three (64.5%). Peak
compliance is achieved among patients with ACS (71.7%).
There are more compliant patients than non-compliant
ones only among patients treated with atorvastatin and
rosuvastatin (at least considering the whole cohort level
and the ACS subgroup).
Among diabetics, the distribution of the frequency of
compliant patients among the three subgroups is very simi-
lar to that in the overall population: 68.7 vs. 71.7% in pa-
tients with ACS; 58.7 vs. 57.4% in those with CVD; and 54.7
vs. 55.8% in those with POAD.
New admissions
During the year of follow-up, more than half of all patients
(55.7%) were readmitted (at least once, for various rea-
sons). Of these, 63.3% of patients were from the ACS
Table 23 General characteristics of the sample cohort (potential patient population n¼ 2 989 512)
Characteristics ACS CVD POAD Sum/mean
Enrolled patients (n) 6226 9939 1048 17 213
(% of the population) 0.21 0.33 0.04 0.58
Mean age, years 71 75 73 73
Mean age M 68 73 71
Mean age F 77 77 76
Gender (M %) 65% 49% 68% 56%
Patients with diabetes 31% 26% 35% 28%
Patients who died during index hospitalization (n) 289 688 10 987
Intrahospital mortality for all causes (%) 4.6% 6.9% 1.0% 5.7%
Patients at follow-up (n) 5937 9251 1038 16 226
F, females; M, males; CVD, cerebrovascular disease; POAD, peripheral occlusive arterial disease; ACS, acute coronary syndrome.
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subgroup (the subgroup with the highest rehospitalization
rate), 49.1% were from the CVD subgroup, and 57.6% were
from the POAD subgroup. Each patient had an average of
two hospitalizations (Table 25).
It is important to stress that the proportion of hospital-
izations for causes other than cardiovascular events is not
negligible: 3 patients of the 10 (29.1%) were hospitalized
for non-cardiovascular causes during the follow-up,
Table 25 Admissions during follow-up for cardiovascular and other events in the three groups of patients
ACS CVD POAD Sum/mean
Patients at follow-up (n) 5937 9251 1038 16 226
Hospitalised patients
Admission diagnosis Pt hosp Hosp/pt Pt hosp Hosp/pt Pt hosp Hosp/pt Pt hosp Hosp/pt
ACS 1347 1.3 147 1.2 36 1.4 1530 1.3
(% of patients at follow-up) 22.7% 1.6% 3.5% 20.2%
CVD 165 1.2 1512 1.2 35 1.3 1712 1.2
(% of patients at follow-up) 2.8 16.3% 3.4% 14.8%
POAD 1 2 1 1 2 1.5
(% of patients at follow-up) 0% 0.1% 0.1%
Other CV causesa 2653 1.4 1614 1.3 452 1.6 4719 1.4
(% of patients at follow-up) 44.7% 17.4% 43.5% 35.3%
Total CV causes 2994 1.9 2781 1.5 457 1.8 6232 1.7
(% of patients at follow-up) 50.4% 30.1% 44% 40.9%
Total non-CV causes 1703 1.6 2714 1.6 300 1.7 4717 1.6
(% of patients at follow-up) 28.7% 29.3% 28.9% 29.1%
Total for all causes 3761 2.2 4541 1.9 598 2.2 8900 2
(% of patients at follow-up) 63.3% 49.1% 57.6% 55.7%
A patient admitted more than once with different diagnoses (causes) will count in the incidence rate of each diagnosis. Total CV causes is net of du-
plications when the causes are of a CV nature (and similarly for the total non-CV causes). If the patient was admitted for CV causes and non-CV
causes, he/she is counted once in the ﬁrst total and another in the second. The total for all causes is also net of this duplication.
CV, cardiovascular; CVD, cerebrovascular disease; POAD, peripheral occlusive arterial disease; Pt hosp, patients hospitalised; Hosp/pt, average
number of hospitalizations per hospitalized patient; ACS, acute coronary syndrome.
aCoronary artery bypass grafting/coronary angioplastyþ decompensated heart failureþ other CV causes.
Table 24 Use of statins in patients with cardiovascular events by active substance (in the ﬁrst month follow-up)
ACS CVD POAD Sum/mean
Patients at follow-up (n) 5937 9251 1038 16 226
Of whom were treated with statins (n) 4148 2684 388 7220
Percentage 70% 29% 37% 44%
Of whom were treated with:
Simvastatin 695 1088 117 1900
(% of those treated) 16.8% 40.5% 30.2% 26.3%
Lovastatin 4 17 0 21
(% of those treated) 0.1% 0.6% 0.0% 0.3%
Pravastatin 37 114 14 165
(% of those treated) 0.9% 4.2% 3.6% 2.3%
Fluvastatin 8 14 3 25
(% of those treated) 0.2% 0.5% 0.8% 0.3%
Atorvastatin 2524 1048 138 3710
(% of those treated) 60.8% 39.0% 35.6% 51.4%
Rosuvastatin 885 405 96 1386
(% of those treated) 21.3% 15.1% 24.7% 19.2%
Simvastatin and ezetimibe 93 63 24 180
(% of those treated) 2.2% 2.3% 6.2% 2.5%
In each subgroup, adding together the number of patients treated according to the single active substances identiﬁed would provide a total higher
than the corresponding value in the second row (which, e.g. for patients with ACS is equal to 4148). This can be explained by the fact that this total
would count patients treated with more than one active substance more than once because of a switch during the month considered; whereas the to-
tal indicated in the second row is net of duplications.
CVD, cerebrovascular disease; POAD, peripheral occlusive arterial disease; ACS, acute coronary syndrome.
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compared with 4 of the 10 (40.9%) for cardiovascular
causes. The proportion of admissions for non-
cardiovascular causes is similar in all three subgroups,
whereas there are differences between the three groups in
the proportion of hospital admissions for cardiovascular
causes: 50.4% in patients with ACS, 30.1% in patients with
CVD, and 44% in patients with POAD.
The probability of being readmitted with the same diag-
nosis as assigned at the index hospitalization is higher
among patients with ACS (22.7%), lower among patients
with CVD (16.3%), and minimal among patients with POAD
(0.1%).
Rehospitalization rates among diabetic patients for all
causes are higher than the corresponding ones in the gen-
eral population: 69.3 vs. 63.3% (ACS subgroup); 52.3 vs.
49.1% (CVD subgroup); and 65.3 vs. 57.6% (POAD
subgroup).
Cost analysis
The mean annual costs incurred by the NHS for diabetic pa-
tients with ACS was e16897: e14 199 for hospital
admissions, e1691 for medication, and e1008 for diagnostic
procedures and outpatient clinic visits. Figure 12 shows
how the costs are allocated between the two cohorts. It is
important to remember that the costs refer to all enrolled
patients (not just those discharged alive), during the 1 year
follow-up, and include the cost of the index hospitalization
and co-morbidities. A patient with cardiovascular events
costs the NHS e11617 a year on average, of which 86.6% is
due to hospital admissions—the dominant cost driver
(Table 26).
Patients with ACS have a higher overall mean cost
(e14871) when compared with the e9537 cost for patients
with CVD and the e12004 cost for patients with a POAD.
Patients with CVD cost least. The highest cost for non-
cardiovascular drugs (i.e. those relating to the co-morbid-
ities) and for specialist services, on the other hand, is ac-
crued by patients with POAD (e635 and e887,
respectively).
In the overall expenditure for pharmaceuticals, the cost
for cardiovascular drugs prevails over that for non-
cardiovascular drugs in patients with ACS (e821 vs. e494).
Table 26 Components of health care expenditure for patients with cardiovascular events
ACS CVD POAD Sum/mean
Enrolled patients (n) 6226 9939 1048 17 213
Mean annual spending/patient e % e % e % e %
Expenditure item
Pharmaceuticals (CV drugs)a 821 5.5 353 3.7 571 4.8 536 4.6
Pharmaceuticals (other medication) 494 3.3 442 4.6 635 5.3 473 4.1
Hospitalisations 12 836 86.3 8338 87.4 9911 82.6 10 061 86.6
Specialist services 720 4.8 404 4.2 887 7.4 548 4.7
Total 14 871 100 9537 100 12 004 100 11 617 100
CV, cardiovascular; CVD, cerebrovascular disease; POAD, peripheral occlusive arterial disease; ACS, acute coronary syndrome.
aDrugs with ATC code¼ ‘C’ (cardiovascular system) or¼ ‘B01’ (antithrombotic agents).
3.30%
5.50%
86.30%
4.80%
% of costs for PATIENTS with ACS €14 872 per capita/year
4.70%
5.40%
84%
6%
Non-speciﬁc medicinal products
CV medicinal products
Admissions
Diagnosc/specialist procedures
% of costs for DIABETIC PATIENTS with ACS €16 897 per capita/year
Figure 12 Mean annual cost of diabetic patients with acute coronary syndrome (ACS) incurred by the National Health Service. CV, cardiovascular.
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Conversely, in the other two subgroups, the expenditure
for other drugs is prevalent.
In diabetic patients the mean expenditure is higher—
both for the individual items and the totals—when com-
pared with the overall patient population. Indeed, in dia-
betic patients, the overall mean expenditure (e13045) is
12.3% higher than the mean expenditure in the total pa-
tient population (e11617) as indicated in Table 26.
Discussion and conclusions
Patients in the real world are known to differ from clinical
study populations because the latter have a more careful
follow-up. This gives rise to the need to conduct further re-
search in order to obtain realistic information about the ac-
tual conditions and costs to manage in daily clinical
practice.
A drug utilization study has been conducted that not
only evaluated diagnostic and therapeutic pathways but
also the costs of health care (from an NHS prospective)
for patients with cardiovascular conditions. Here, we re-
cap some of the critical issues that the study brought to
light, starting with those regarding treatment with
statins.
(1) Less than half (44%) of the patients requiring ther-
apy are treated (Table 24). More specifically, only a
few patients with CVD (29%) and with POAD (37%)
are treated; in these groups, the low-dose intensity
treatment prevails.
(2) With regard to statin therapy adherence, two pa-
tientsof every three with cardiovascular disease
(64.5%) can be considered compliant, with a slightly
higher compliance in the ACS subgroup (71.7%).
Adherence is, therefore, unsatisfactory overall, es-
pecially among patients with CVD (57.4%) and POAD
(55.8%).
(3) CORE report results do not provide information con-
cerning the achievement of C-LDL targets in Italy.
(4) Diabetic patients with atherothrombotic events
have a higher cost (þ12.3%), in terms of both phar-
maceutical expenditure (for cardiovascular medica-
tion: þ19.8%; for non-cardiovascular medication:
þ53.4%) and expenditure for hospitalization
(þ8.4%).
(5) Spending for readmission for non-cardiovascular
causes is not negligible (18% of the total), due to
patient age (average age of 73 years for the general
population) and co-morbidities (such as in patients
with POAD).
(6) The annual payment of the NHS for a cardiovascular
patient is high (e11 617) and expenditures for hospi-
talization (86.6% of the total) are the main cost
driver (for a comparison in the general population,
the mean expenditure on health care per capita in
2013 was estimated at e1816).259
As shown by the critical aspects discussed above, there
is still a gap between evidence-based recommendations
and routine clinical practice—a gap that generates a high
social and economic burden for Italy’s health care
facilities.
From efficacy and safety to clinical
effectiveness. The challenge of monoclonal
antibodies in sustainable cardiovascular
prevention: the reuse of savings in
rehospitalizations
The cost-effectiveness of statin therapy has been exten-
sively documented,25 and there is an ongoing debate about
the possible favourable cost-effectiveness of low-potency
statin therapy as a primary prevention strategy in subjects
with a low to moderate risk of events in the next 10
years.260 Indeed, because of the wide use of low-cost sta-
tins, these drugs no longer represent a cost issue. For
PCSK9-inhibiting monoclonal antibodies, on the other
hand, the cost-effectiveness debate has just begun.
In the USA, the New England Comparative Effectiveness
Public Advisory Council (CEPAC) report on behalf of the
ICER entitled ‘PCSK9 Inhibitors for Treatment of High
Cholesterol: Effectiveness, Value, and Value-Based Price
Benchmarks’ was published on 24 November 2015.261
These two institutions are independent non-profit research
organizations working in the medical and economic field
and the published report concludes an in-depth analysis in-
volving researchers, physicians, and the pharmaceutical
industry.
The analysis started from the ‘unmet clinical needs’
(such as the adequate treatment in patients who, despite
maximum dose statin therapy, are unable tomeet the ther-
apeutic target) and considered the data included in a
meta-analysis conducted by Navarese et al.,262 which pre-
dicted costs for the new therapies of between $14 100 and
$14600/year/patient in the USA. The conclusions of this
analysis generate certain concerns, especially considering
the wide range of potential treatment users. Indeed, al-
though these agents make it possible to obtain reductions
in LDL levels of between 52.6% and 63.5% (vs. no PCSK9 in-
hibitors) and between 31.7% and 39.3% (vs. ezetimibe) and
a short-term reduction in OR for total mortality and myo-
cardial infarction of approximately 50% (but with a modest
number of events and a very large 95% CI). PCSK9 inhibitors
would have a cost of $135000–$290000/QALY (the former
figure for statinsþ ezetimibe and the latter for
statinsþ PCSK9 inhibitors) in patients with FH, and of
$145000–$274 000/QALY in patients undergoing secondary
prevention intervention who are statin intolerant and of
$135000–$302 000 for patients undergoing secondary pre-
vention intervention who do not meet their therapeutic
goal with statins. PCSK9 inhibitors would only be cost-ef-
fective if their predicted cost is reduced 80%. Indeed, only
with a cost of $2100–$2600/year/patient would it be possi-
ble to meet the cost-effectiveness threshold of $50000/
QALY. A cost of approximately $5200/year/patient would
meet a more generous threshold of $150000/QALY. It
should be noted that these latter costs are closer to the
current cost of PCSK9 inhibitors proposed in some
European countries ($6800 in the UK, $8200 in Austria, and
$8800 in Finland).
In Italy, we are still lacking an essential element for this
kind of analysis because the amount of reimbursement for
these drugs from the NHS is unknown. It is therefore still
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very difficult to estimate the total economic impact of
PCSK9 inhibitors, and it is impossible to verify whether it is
possible to associate a reduction in events (currently un-
known in the medium and long term) with an acceptable
cost-effectiveness of therapy in the various potential treat-
ment clinical settings: in patients with HeFH, and in pa-
tients undergoing primary (high-risk) and secondary
prevention interventions who despite maximumdose statin
therapy did not reach their therapeutic targets, and in
statin-intolerant patients.
It is, however, worth highlighting the fact that the CORE
report257 revealed that:
• not even half (44%) of the patients requiring therapy
are treated;
• compliance to statin therapy is unsatisfactory;
• spending for readmissions is not negligible; and
• the annual cost to the NHS for a cardiovascular patient
is high and spending for hospitalization is the main
cost driver.
We also know that the aim of reducing LDL by 50% is
rarely possible in both primary preventions in patients at a
high cardiovascular risk [the Statins Target Assessment in
Real practice (STAR) study revealed that this goal is met in
<30% of naive patients263] and in secondary preventions
where the target of C-LDL <70mg/dL is met and main-
tainedwith difficulty.
There is therefore an urgent need to more effectively
treat patients with the high-dose, high-efficacy compounds
currently available, while implementing all potential strat-
egies for reducing SI and improving compliance over time.
It is also necessary that clinical and organizational tools
proved to be useful in the therapeutic optimization of pa-
tients undergoing secondary prevention intervention after
coronary events are implemented and spread out as far as
possible over the whole national territory. A structured sec-
ondary prevention pathway such as that proposed in car-
diac rehabilitation has shown that high statin doses and the
therapeutic target can be maintained at 1 year in almost
70% of patients.264
Conflict of Interest: none declared.
References
1. Nichols M, Townsend N, Scarborough P, et al; European Society of
Cardiology; European Heart Network; British Heart Foundation
Health Promotion Research Group. European Cardiovascular
Disease Statistics, 2012 edition. http://www.ehnheart. org/com
ponent /downloads/ downloads/1436 (19 April 2017).
2. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R,
Shih J, Stamler J, Wentworth D. Serum cholesterol level mortal-
ity findings for men screened in the Multiple Risk Factor
Intervention Trial. Multiple Risk Factor Intervention Trial
Research Group. Arch Intern Med 1992;152:1490–1500.
3. D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovas-
cular risk profile for use in primary care: the Framingham Heart
Study. Circulation 2008;117:743–753.
4. Prospective Studies Collaboration. Blood cholesterol and vascular
mortality by age, sex, and blood pressure: a meta-analysis of in-
dividual data from 61 prospective studies with 55,000 vascular
deaths. Lancet 2007;370:1829–1839.
5. Perk J, De Backer G, Gohlke H, et al; European Association for
Cardiovascular Prevention and Rehabilitation (EACPR); ESC
Committee for Practice Guidelines (CPG). European Guidelines
on cardiovascular disease prevention in clinical practice (version
2012). The Fifth Joint Task Force of the European Society of
Cardiology and Other Societies on Cardiovascular Disease
Prevention in Clinical Practice (constituted by representatives of
nine societies and by invited experts). Eur Heart J
2012;33:1635–1701.
6. Giampaoli S, Vanuzzo D. La salute cardiovascolare degli italiani.
Terzo Atlante Italiano delle Malattie Cardiovascolari. Edizione
2014. G It Cardiol 2014;15(4 Suppl 1):1S–31S.
7. Giampaoli S, Palmieri L, Donfrancesco C, Lo Noce C, Pilotto L,
Vanuzzo D. Osservatorio Epidemiologico Cardiovascolare/Health
Examination Survey Research Group Cardiovascular health in
Italy. Ten-year surveillance of cardiovascular diseases and risk
factors: Osservatorio Epidemiologico Cardiovascolare/Health
Examination Survey 1998-2012. Eur J Prev Cardiol 2015;22(2
Suppl):9–37.
8. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines
for the management of dyslipidaemias: the Task Force for the
Management of Dyslipidaemias of the European Society of
Cardiology (ESC) and the European Atherosclerosis Society (EAS).
Eur Heart J 2011;32:1769–1818.
9. Stamler J. Low risk—and the "No more than 50%" myth/dogma.
Arch Intern Med 2007;167:537–539.
10. Daviglus ML, Liu K, Pirzada A, et al. Favorable cardiovascular risk
profile in middle age and health-related quality of life in older
age. Arch Intern Med 2003;163:2460–2468.
11. Daviglus ML, Liu K, Pirzada A, et al. Cardiovascular risk profile ear-
lier in life and Medicare costs in the last year of life. Arch Intern
Med 2005;165:1028–1034.
12. Liu K, Daviglus M, Loria C, et al. Healthy lifestyle through young
adulthood and the presence of low cardiovascular diseases risk
profile in middle age: the Coronary Artery Risk Development in
(Young) Adults (CARDIA) study. Circulation 2012;125:996–1004.
13. Lloyd-Jones DM, Hong Y, Labarthe D, et al; American Heart
Association Strategic Planning Task Force and Statistics
Committee. Defining and setting national goals for cardiovascular
health promotion and disease reduction: the American Heart
Association’s Strategic Impact Goal through 2020 and beyond.
Circulation 2010;121:586–613.
14. Giampaoli S, Palmieri L, Panico S, et al. Favorable cardiovascular
risk profile (low risk) and 10-year stroke incidence in women and
men: findings on twelve Italian population samples. Am J
Epidemiol 2006;163:893–902.
15. Palmieri L, Donfrancesco C, Giampaoli S, et al. Favorable cardio-
vascular risk profile and 10-year coronary heart disease incidence
in women and men: results from the Progetto CUORE. Eur J
Cardiovasc Prev Rehabil 2006;13:562–570.
16. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guide-
line on the treatment of blood cholesterol to reduce atheroscle-
rotic cardiovascular risk in adults: a report of the American
College of Cardiology/American Heart Association Task Force. On
Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1–S45.
17. Giampaoli S, Rizzo C, Vanuzzo D. L’applicazione italiana delle
linee guida europee sulla prevenzione delle malattie cardiovasco-
lari. G Ital Cardiol 2008;9:60–67.
18. Donfrancesco C, Palmieri L, Coneey MT, et al. Italian cardiovascu-
lar mortality charts of the CUORE Project: are they comparable
with the score charts?. Eur J Cardiovasc Prev Rehabil
2010;17:403–409.
19. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on
coronary events after myocardial infarction in patients with aver-
age cholesterol levels. Cholesterol and Recurrent Events Trial in-
vestigators. N Engl J Med 1996;335:1001–1009.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart
Protection Study of cholesterol lowering with simvastatin in
20,536 high-risk individuals: a randomised placebo controlled
trial. Lancet 2002;360:7–22.
21. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets
(TNT) Investigators. Intensive lipid lowering with atorvastatin in
patients with stable coronary disease. N Engl J Med 2005;352:
1425–1435.
22. Pedersen TR, Faergeman O, Kastelein JJP, et al; Incremental
Decrease in End Points Through Aggressive Lipid Lowering (IDEAL)
D48 M.M. Gulizia et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article-abstract/19/suppl_D
/D
3/3792742 by guest on 22 January 2020
Study Group. High-dose atorvastatin vs usual-dose simvastatin for
secondary prevention after myocardial infarction: The IDEAL
study: a randomized controlled trial. JAMA 2005;294:2437–2445.
23. Kulik A, Brookhart MA, Levin R, Ruel M, Solomon DH, Choudhry NK.
Impact of statin use on outcomes after coronary artery bypass
graft surgery. Circulation 2008;118:1785–1792.
24. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment
Trialists’ (CTT) Collaboration. Efficacy and safety of cholesterol-
lowering treatment: prospective meta-analysis of data from
90,056 participants in 14 randomised trials of statins. Lancet
2005;366:1267–1278.
25. Baigent C, Blackwell L, Emberson J; Cholesterol Treatment
Trialists’ (CTT) Collaboration, et al. Efficacy and safety of more
intensive lowering of LDL cholesterol: a meta-analysis of data
from 170,000 participants in 26 randomised trials. Lancet
2010;376:1670–1681.
26. Catapano AL, Averna M, Faggiano P, Novo S; Federazione Italiana
di Cardiologia; Societa Italiana per lo Studio dell’Arteriosclerosi,
con l’endorsement della European Society of Atherosclerosis e
della European Association of Cardiovascular Prevention and
Rehabilitation. Nuove linee guida americane 2013 ACC/AHA sul
trattamento del colesterolo plasmatico per ridurre il rischio cardi-
ovascolare aterosclerotico: confronto con le raccomandazioni
ESC/EAS per la gestione delle dislipidemie. G Ital Cardiol
2014;15:19–20.
27. Cannon CP, Blazing MA, Giugliano RP, IMPROVE-IT Investigators,
et al. Ezetimibe added to statin therapy after acute coronary syn-
dromes. N Engl J Med 2015;372:2387–2397.
28. The Final Report of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel III):
Executive Summary. Bethesda, MD: US National Heart, Lung, and
Blood Institute, National Institutes of Health; 2001. NIH publica-
tion No. 01-3670.
29. Palmieri L, Bennett K, Giampaoli S, Capewell S. Explaining the de-
crease in coronary heart disease mortality in Italy between 1980
and 2000. Am J Public Health 2010;100:684–692.
30. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, et al. 2013 AHA/ACC
guideline on lifestyle management to reduce cardiovascular risk: a
report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines. Circulation
2014;129(25 Suppl 2):S76–S99.
31. Mente A, de Koning L, Shannon HS, Anand SS. A systematic review
of the evidence supporting a causal link between dietary factors
and coronary heart disease. Arch Intern Med 2009;169:659–669.
32. Mensink RP, Zock PL, Kester ADM, Katan MB. Effects of dietary
fatty acids and carbohydrates on the ratio of serum total to HDL
cholesterol and on serum lipids and apolipoproteins: a meta-
analysis of 60 controlled trials. Am J Clin Nutr
2003;77:1146–1155.
33. Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty
acids: experimental and observational evidence. Eur J Clin Nutr
2009;63(Suppl 2):S5–21.
34. GISSI-Prevenzione Investigators (Gruppo Italiano per la
Sopravvivenza nell’Infarto Miocardico). Dietary supplementation
with n-3 polyunsatured fatty acids and vitamine E after myocar-
dial infarction: results of the GISSI-Prevenzione trial. Lancet
1999;354:447–455.
35. Brown L, Rosner B, Willet W, Sacks SM. Cholesterol-lowering ef-
fects of dietary fiber: a meta-analysis. Am J Clin Nutr
1999;69:30–42.
36. Nordmann AJ, Nordmann A, Briel M, et al. Effects of low-
carbohydrate vs low-fat diets on weight loss and cardiovascular
risk factors: a meta-analysis of randomized controlled trials. Arch
Intern Med 2006;166:285–293.
37. Keys A. Serum cholesterol response to dietary cholesterol. Am J
Clin Nutr 1984;40:351–359.
38. Estruch R, Ros E, Salas-Salvado J, et al; PREDIMED Study
Investigators. Primary prevention of cardiovascular disease with a
Mediterranean diet. N Engl J Med 2013;368:1279–1290.
39. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N.
Mediterranean diet, traditional risk factors, and the rate of car-
diovascular complications after myocardial infarction: final report
of the Lyon Diet Heart Study. Circulation 1999;99:779–785.
40. Keys AB, Keys M. How to Eat Well and Stay Well: The
Mediterranean Way. New York: Doubleday; 1975.
41. Fidanza F, Alberti A, Fruttini D, The Nicotera diet: the reference
Italian Mediterranean diet. In: AP Simopoulos, ed. Nutrition and
Fitness: Mental Health, Aging, and the Implementation of a Healthy
Diet and Physical Activity Lifestyle. Basel: Karger; 2005. p115–21.
42. Appel L, Brands M, Daniels S, Karanja N, Elmer P, Sacks F. Dietary
approaches to prevent and treat hypertension. A Scientific
Statement from the American Heart Association. Hypertension
2006;47:296–308.
43. Giampaoli S, Krogh V, Grioni S, et al; Gruppo di Ricerca
dell’Osservatorio Epidemiologico Cardiovascolare/Health
Examination Survey. Comportamenti alimentari degli italiani:
risultati dell’Osservatorio Epidemiologico Cardiovascolare/Health
Examination Survey. Epidemiol Prev 2015;39:373–379.
44. Stamler J. Toward a modern Mediterranean diet for the 21st cen-
tury. Nutr Metab Cardiovasc Dis 2013;23:1159–1162.
45. Huffman KM, Hawk VH, Henes ST, et al. Exercise effects on lipids
in persons with varying dietary patterns-does diet matter if they
exercise? Responses in Studies of a Targeted Risk Reduction
Intervention through Defined Exercise I. Am Heart J
2012;164:117–124.
46. Piepoli MF, Corra U, Benzer W, et al. Secondary prevention
through cardiac rehabilitation: from knowledge to implementa-
tion. A position paper from the Cardiac Rehabilitation Section of
the European Association of Cardiovascular Prevention and
Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010;17:1–17.
47. Shaw K, Gennat H, O’Rourke P, Del Mar C. Exercise for overweight
or obesity. Cochrane Database Syst Rev 2006;4:CD003817.
48. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood
lipids and lipoproteins: a meta- analysis. Am J Clin Nutr
1992;5:320–328.
49. NHS Foundation Trust. Guidelines on Statin Prescribing in the
Prevention of Cardiovascular Disease. London: University College
London Hospitals; 2006.
50. Rapporto ARNO. 2015. http://www.siditalia.it/images/
Documenti/NEWS/Rapporto_Arno_Diabete_2015.pdf (19 April
2017).
51. Brun E, Nelson RG, Bennett PH, et al. Verona Diabetes Study.
Diabetes duration and cause- specific mortality in the Verona
Diabetes Study. Diabetes Care 2000;23:1119–1123.
52. Vaccaro O, Eberly LE, Neaton JD, et al; Multiple Risk Factor
Intervention Trial Research Group. Impact of diabetes and previ-
ous myocardial infarction on long-term survival: 25-year mortality
follow-up of primary screenees of the Multiple Risk Factor
Intervention Trial. Arch Intern Med 2004;164:1438–1443.
53. Rivellese AA, Riccardi G, Vaccaro O. Cardiovascular risk in women
with diabetes. Nutr Metab Cardiovasc Dis 2010;20:474–480.
54. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary
heart disease in subjects with type 2 diabetes and in nondiabetic
subjects with and without prior myocardial infarction. N Engl J
Med 1998;339:229–234.
55. Verge`s B. Pathophysiology of diabetic dyslipidaemia: where are
we? Diabetologia 2015;58:886–899.
56. Andrikoula M, McDowell IF. The contribution of ApoB and ApoA1
measurements to cardiovascular risk assessment. Diabetes Obes
Metab 2008;10:271–278.
57. Kearney PM, Blackwell L, et al. Cholesterol Treatment Trialists’
(CTT) Collaborator.s Efficacy of cholesterol-lowering therapy in
18,686 people with diabetes in 14 randomised trials of statins: a
meta-analysis. Lancet 2008;371:117–125.
58. Standards SID/AMD. 2014. http://www.standarditaliani.it/skin/
www.standarditaliani.it/pdf/STANDARD_2014_May28.pdf (19 April
2017).
59. Collins R, Armitage J, Parish S, et al; Heart Protection Study
Collaborative Group. MRC/BHF Heart Protection Study of
cholesterol-lowering with simvastatin in 5963 people with diabe-
tes: a randomised placebo-controlled trial. Lancet 2003;361:
2005–2016.
60. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary preven-
tion of cardiovascular disease with atorvastatin in type 2 diabetes
in the Collaborative Atorvastatin Diabetes Study (CARDS): multi-
centre randomised placebo controlled trial. Lancet
2004;364:685–696.
Consensus document on cholesterol and cardiovascular risk D49
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article-abstract/19/suppl_D
/D
3/3792742 by guest on 22 January 2020
61. Armitage J. The safety of statins in clinical practice. Lancet
2007;370:1781–1790.
62. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident di-
abetes: A collaborative meta-analysis of randomised statin trials.
Lancet 2010;375:735–742.
63. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with
intensive dose compared with moderate-dose statin therapy: a
meta-analysis. JAMA 2011;305:2556–2564.
64. Bozzetto L, Annuzzi G, Corte GD, et al. Ezetimibe beneficially in-
fluences fasting and postprandial triglyceride-rich lipoproteins in
type 2 diabetes. Atherosclerosis 2011;217:142–148.
65. The lipid research clinics coronary primary prevention trial re-
sults. I. Reduction in incidence of coronary heart disease. JAMA
1984;251:351–364. DOI: 10.1001/jama.1984.03340270029025.
66. Gudzune KA, Monroe AK, Sharma R, et al. Effectiveness of combi-
nation therapy with statin and another lipid-modifying agent com-
pared with intensified statin monotherapy. A systematic review.
Ann Intern Med 2014;160:468–476.
67. Hansen M, Sonne DP, Knop FK. Bile acid sequestrants: glucose-
lowering mechanisms and efficacy in type 2 diabetes. Curr Diab
Rep 2014;14:482.
68. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-
prevention trial with gemfibrozil in middle-aged men with dyslipi-
demia: Safety of treatment, changes in risk factors, and incidence
of coronary heart disease. N Engl J Med 1987;317:1237–1245.
69. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the second-
ary prevention of coronary heart disease in men with low levels of
high-density lipoprotein cholesterol. Veterans Affairs High-Density
Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J
Med 1999;341:410–418.
70. Haim M, Benderly M, Brunner D, et al. Elevated serum triglyceride
levels and long-term mortality in patients with coronary heart dis-
ease: The Bezafibrate Infarction Prevention (BIP) Registry.
Circulation 1999;100:475–482.
71. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate
therapy on cardiovascular events in 9795 people with type 2 dia-
betes mellitus (the FIELD study): randomised controlled trial.
Lancet 2005;366:1849–1861.
72. Ginsberg HN, Elam MB, Lovato LC, et al; ACCORD Study Group.
Effects of combination lipid therapy in type 2 diabetes mellitus. N
Engl J Med 2010;362:1563–1574.
73. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular
outcomes: a systematic review and meta-analysis. Lancet
2010;375:1875–1884.
74. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in
type 2 diabetes. N Engl J Med 2010;363:692–694.
75. Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature
of hypertriglyceridaemia: implications for definition, diagnosis,
and management. Lancet Diabetes Endocrinol 2014;2:655–666.
76. Morgan CL, Owens DR, Aubonnet P, et al. Primary prevention of di-
abetic retinopathy with fibrates: a retrospective, matched cohort
study. BMJ Open 2013;3:e004025.
77. Ding Y, Li Y, Wen A. Effect of niacin on lipids and glucose in pa-
tients with type 2 diabetes: a meta-analysis of randomized, con-
trolled clinical trials. Clin Nutr 2015;34:838–844.
78. Coronary Drug Project Research Group. Clofibrate and niacin in
coronary heart disease. JAMA 1975;231:360–381.
79. Boden WE, Probstfield JL, Anderson T, et al. AIM-HIGH
Investigators. Niacin in patients with low HDL cholesterol levels
receiving intensive statin therapy. N Engl J Med 2011;365:
2255–2267.
80. Landray MJ, Haynes R, Hopewell JC, et al; HPS2-THRIVE
Collaborative Group. Effects of extended-release niacin with laro-
piprant in high-risk patients. N Engl J Med 2014;371:203–212.
81. McKenney J, Bays H, Gleim G, et al. Safety and tolerability of
extended-release niacin laropiprant: pooled analyses for 11,310
patients in 12 controlled clinical trials. J Clin Lipidol
2015;9:313–325.
82. Ginsberg HN, Reyes-Soffer G. Niacin: a long history, but a ques-
tionable future. Curr Opin Lipidol 2013;24:475–479.
83. Sattar N, Preiss D, Robinson JG, et al. Lipid-lowering efficacy of
the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2
diabetes: a meta-analysis of individual patient data. Lancet
Diabetes Endocrinol 2016;4:403–410.
84. Robinson JG, Farnier M, Krempf M, et al; ODYSSEY LONG TERM
Investigators. Efficacy and safety of alirocumab in reducing lipids
and cardiovascular events. N Engl J Med 2015;372:1489–1499.
85. Sabatine MS, Giugliano RP, Wiviott SD, et al; Open-Label Study
of Long-Term Evaluation against LDL Cholesterol (OSLER)
Investigators. Efficacy and safety of evolocumab in reducing lipids
and cardiovascular events. N Engl J Med 2015;372:1500–1509.
86. Masana L, Pedro-Botet J, Civeira F. IMPROVE-IT clinical implications:
Should the “high-intensity cholesterol-lowering therapy” strategy
replace the “high-intensity statin therapy”. Atherosclerosis 2015;
240:161–162.
87. Santos RD. PCSK9 inhibition in type 2 diabetes: so far so good, but
not there yet. Lancet Diabetes Endocrinol 2016;4:377–379.
88. DeFilippis AP, Sperling LS. Understanding omega-3’s. Am Heart J
2006;151:564–570.
89. Kris-Etherton PM, Harris WS, Appel LJ; Nutrition Committee. Fish
consumption, fish oil, omega-3 fatty acids, and cardiovascular dis-
ease. Arterioscler Thromb Vasc Biol 2003;23:e20–e30.
90. Balk EM, Lichtenstein AH, Chung M, et al. Effects of omega-3 fatty
acids on serum markers of cardiovascular disease risk: a system-
atic review. Atherosclerosis 2006;189:19–30.
91. Ballantyne C, Abate N, Zhong Y, et al. Dose comparison study
of the combination of ezetimibe and simvastatin (Vytorin) ver-
sus atorvastatin in patients with hypercholesterolemia. the
Vytorin Versus Atorvastatin (VYVA Study). Am Heart J
2005;149:464–473.
92. Catapano A, Brady WE, King TR, et al. Lipid altering-efficacy of
ezetimibe co-administered with simvastatin compared with rosu-
vastatin: a meta-analysis of pooled data from 14 clinical trials.
Curr Med Res Opin 2005;21:1123–1130.
93. Determinazione AIFA 19.6.2014, n. 617. Gazzetta Ufficiale n. 156
dell’8.7.2014: Modifica alla nota 13 di cui alla Determina del
26.3.2013. http://www.agenziafarmaco.gov. it/sites/default /
files/Nota13 _GU156_08072014.pdf (19 April 2017).
94. Donfrancesco C, Palmieri L, Vanuzzo D. Omogeneita delle carte
del rischio del Progetto CUORE per la valutazione della mortalita
cardiovascolare e le carte del Progetto SCORE. G Ital Cardiol
2010;11:148–153.
95. Downs JR, O’Malley PG. Management of Dyslipidemia for
Cardiovascular Disease Risk Reduction: Synopsis of the 2014US
Department of Veterans Affairs and US Department of Defense
Clinical Practice Guideline. Ann Intern Med 2015;163:291–297.
96. Filippi A, Medea G, Catapano A. La diagnosi delle principali dislipi-
demie familiari in Medicina Generale. Sintesi per la Medicina
Generale italiana—Aggiornamento 2010. Pisa: Rivista della Societa
Italiana di Medicina Generale; 2010. p41–8.
97. Il Progetto CUORE. Calcolo del punteggio individuale. http://
www.cuore.iss.it/ sopra/calc- rischio.asp (19 April 2017).
98. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low
density lipoprotein cholesterol, ischaemic heart disease, and stroke:
systematic review and meta-analysis. BMJ 2003;326:1423–1427.
99. Heart Score. The Interactive Tool for Predicting and Managing the
Risk of Heart Attack and Stroke. http://www.heartscore. org/
Pages/ welcome.aspx (19 April 2017).
100. Stone NJ, Blum CB. Primary risk prevention in the elderly: use
clinician-patient discussions, not automatic statin prescribing. Am
J Med 2015;128:804–806.
101. Nota 13: tra ombre e luci . . . poche. http://www.informazionisuifar
maci.it/nota-13-tra-ombre-e-lucipoche (19 April 2016).
102. Bianchi A, Casula M, Linee guida e nota 13 AIFA. http://www.sisa.
it/index.php?class¼ Comp&className¼Content&op¼ Show& par
am¼ cid,393,preview,0 (19 April 2017).
103. La nuova nota 13 AIFA. https://www.simg.it/documenti/aree_
cliniche/Cardiovascolare /supporti/nota13/commento _nota_13_
marzo_2013.pdf (19 April 2017).
104. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial
hypercholesterolaemia is underdiagnosed and undertreated in the
general population: guidance for clinicians to prevent coronary
heart disease. Consensus Statement of the European
Atherosclerosis Society. Eur Heart J 2013;34:3478–3490.
105. Goldstein JK, Hobbs HH, Brown MS, Familial hypercholesterolemia.
In: CR Scriver, AL Beaudet, WS Sly, D Valle, eds. The Metabolic and
Molecular Bases of Inherited Disease. 8th ed. New York, NY:
McGraw-Hill; 2001. p2863–913.
D50 M.M. Gulizia et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article-abstract/19/suppl_D
/D
3/3792742 by guest on 22 January 2020
106. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes
of monogenic heterozygous familial hypercholesterolemia: a HuGE
prevalence review. Am J Epidemiol 2004;160:407–420.
107. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of sta-
tins in familial hypercholesterolaemia: a long term cohort study.
BMJ 2008;337:a2423.
108. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the di-
agnosis, natural history, and treatment of familial hypercholestero-
laemia. Atherosclerosis 2003;168:1–14.
109. World Health Organization. World Health Statistics 2012. http://
www.who.int/gho/publications /world_health_ statistics/2012 /
en/ (19 April 2017).
110. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial
hypercholesterolaemia is underdiagnosed and undertreated in the
general population: guidance for clinicians to prevent coronary
heart disease. Consensus statement of the European
Atherosclerosis Society. Eur Heart J 2013;34:1–14.
111. Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal domi-
nant hypercholesterolemia in the Netherlands: prevalence,
genotype-phenotype relationship and clinical outcome. Eur Heart J
2015;36:560–565.
112. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial
hypercholesterolaemia: new insights and guidance for clinicians to
improve detection and clinical management. A position paper from
the consensus panel on familial hypercholesterolaemia of the
European Atherosclerosis Society. Eur Heart J 2014;35:2146–2157.
113. British Heart Foundation. UCL LDLR Database. http://www.ucl.ac.
uk/ldlr/LOVDv. 1.1.0/index.php?select _db¼LDLR (19 April 2017).
114. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein
cholesterol gene score to distinguish patients with polygenic and
monogenic familial hypercholesterolemia: a case-control study.
Lancet 2013;381:1293–1301.
115. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterol-
emia: screening, diagnosis and management of pediatric and adult
patients: clinical guidance from the National Lipid Association
Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol
2011;5:133–140.
116. Olesen H. Properties and units in the clinical laboratory sciences.
I. Syntax and semantic rules (recommendation 1995). International
Union of Pure and Applied Chemistry (IUPAC) and International
Federation of Clinical Chemistry (IFCC). Eur J Clin Chem Clin
Biochem 1995;33:627–636.
117. Spandrio L, Pagani F, Panteghini M. Criteri interpretativi per l’uti-
lizzo ottimale degli esami di laboratorio. In M Panteghini, ed.
Interpretazione degli esami di laboratorio. Padova: Piccin Nuova
Libraria; 2008. p25–46.
118. Clinical and Laboratory Standards Institute. Defining, Establishing
and Verifying Reference Intervals in the Clinical Laboratory.
Approved Guideline—Third Edition CLSI Document EP28-A3c.
Wayne, PA: Clinical and Laboratory Standards Institute; 2010.
119. Stamler J, Wentworth D, Neaton JD. Is relationship between serum
cholesterol and risk of premature death from coronary heart dis-
ease continuous and graded? Findings in 356,222 primary screenees
of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA
1986;256:2823–2828.
120. Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults. Executive summary of the Third Report
on the National Cholesterol Education Program (NCEP) Expert Panel
on Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
121. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guide-
lines on the assessment of cardiovascular risk: a report of the
American College of cardiology/American heart association task
force on practice guidelines. J Am Coll Cardiol 2014;63:2935–2959.
122. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely
required for determination of a lipid profile: clinical and laboratory
implications including flagging at desirable concentration cut-points -
a joint consensus statement from the European Atherosclerosis
Society and European Federation of Clinical Chemistry and
Laboratory Medicine. Eur Heart J 2016;37:1944–1958.
123. National Heart, Lung, and Blood Institute. Expert Panel on
Integrated Guidelines for Cardiovascular Health and Risk Reduction
in Children and Adolescents. https://www.nhlbi.nih.gov/files /
docs/peds_ guidelines_sum.pdf (19 April 2017).
124. Westgard QC. Quality Requirements. Desirable Biological Variation
Database Specifications. https://www.westgard.com/ biodata
base1.htm (19 April 2017).
125. Sole´tormos G, Duffy MJ, Hayes DF, et al. Design of tumor
biomarker-monitoring trials: a proposal by the European Group on
Tumor Markers. Clin Chem 2013;59:52–59.
126. Lippi G, Caputo M, Banfi G, Buttarello M, et al. Raccomandazioni
per l’identificazione e la gestione dei valori critici nei laboratori
clinici. Biochim Clin 2008;32:209–216.
127. Averna M, Brignoli O, Bucci M, et al; per ANMCO, SIMG e SISA. Linee
guida cliniche per la prevenzione della cardiopatia ischemica nella
ipercolesterolemia familiare. G Ital Arterioscler 2013;4(Suppl 1):
35–63.
128. Hovingh GK, Gandra SR, McKendrick J, et al. Identification and
management of patients with statin-associated symptoms in clinical
practice: a clinician survey. Atherosclerosis 2016;245:111–117.
129. Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of
statin therapy and clinical outcome after ischemic stroke. Stroke
2007;38:2652–2657.
130. Daskalopoulou SS, Delaney JA, Filion KB, Brophy JM, Mayo NE,
Suissa S. Discontinuation of statin therapy following an acute myo-
cardial infarction: a population-based study. Eur Heart J
2008;29:2083–2091.
131. Kim MC, Cho JY, Jeong HC, et al. Impact of postdischarge statin
withdrawal on long-term outcomes in patients with acute myocar-
dial infarction. Am J Cardiol 2015;115:1–7.
132. Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and
management of statin adverse effects and intolerance: Canadian
Working Group Consensus update. Can. J Cardiol 2013;29:1553–1568.
133. Guyton JR, Bays HE, Grundy SM, Jacobson TA. The National Lipid
Association Statin Intolerance Panel An assessment by the Statin
Intolerance Panel: 2014 update. J Clin Lipidol 2014;8(3
Suppl):S72–S81.
134. Stroes ES, Thompson PD, Corsini A, et al; European Atherosclerosis
Society Consensus Panel. Statin-associated muscle symptoms: im-
pact on statin therapy—European Atherosclerosis Society Consensus
Panel Statement on Assessment, aetiology and management. Eur
Heart J 2015;36:1012–1022.
135. Santos RD, Waters DD, Tarasenko L, et al. A comparison of non-HDL
and LDL cholesterol goal attainment in a large, multinational pa-
tient population: the Lipid Treatment Assessment Project 2.
Atherosclerosis 2012;224:150–153.
136. Urbinati S, Olivari Z, Gonzini L, et al; BLITZ-4 Investigators.
Secondary prevention after acute myocardial infarction: drug ad-
herence, treatment goals, and predictors of health lifestyle habits.
The BLITZ-4 Registry. Eur J Prev Cardiol 2015;22:1548–1556.
137. Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholestero-
laemia: dual inhibition of cholesterol synthesis and absorption
with simvastatin plus ezetimibe. Curr Med Res Opin 2006;
22:511–528.
138. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe
coadministered with atorvastatin in 628 patients with primary hy-
percholesterolemia: a prospective, randomized, double-blind trial.
Circulation 2003;107:2409–2415.
139. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert
consensus decision pathway on the role of non-statin therapies for
LDL-cholesterol lowering in the management of atherosclerotic car-
diovascular disease risk: a report of the American College of
Cardiology Task Force on Clinical Expert Consensus Documents.
J Am Coll Cardiol 2016;68:92–125.
140. Kotseva K, Jennings CS, Turner EL, et al; ASPIRE-2-PREVENT Study
Group. ASPIRE-2-PREVENT: a survey of lifestyle, risk factor manage-
ment and cardioprotective medication in patients with coronary
heart disease and people at high risk of developing cardiovascular
disease in the UK. Heart 2012;98:865–871.
141. Vedin O, Hagstrom E, Stewart R, et al. Secondary prevention and
risk factor target achievement in a global, high-risk population
with established coronary heart disease: baseline results from the
STABILITY study. Eur J Prev Cardiol 2013;20:678–685.
142. EUROASPIRE Investigators. Patients with coronary artery disease
and diabetes need improved management: a report from the
EUROASPIRE IV survey: a registry from the EuroObservational
Research Programme of the European Society of Cardiology.
Cardiovasc Diabetol 2015;14:133.
Consensus document on cholesterol and cardiovascular risk D51
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article-abstract/19/suppl_D
/D
3/3792742 by guest on 22 January 2020
143. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern
Med 2001;135:825–834.
144. Colivicchi F, Abrignani MG, Santini M. Aderenza terapeutica: il fat-
tore di rischio occulto. G Ital Cardiol 2010;11(5 Suppl
3):124S–127S.
145. Patel MX, David AS. Medication adherence: predictive factors and
enhancement strategies. Psychiatry 2004;10:41–45.
146. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its impor-
tance in cardiovascular outcomes. Circulation 2009;119:
3028–3035.
147. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adher-
ence on cardiovascular disease and mortality outcomes: a system-
atic review. Br J Clin Pharmacol 2014;78:684–698.
148. Penning-van Best FJ, Termorshuizen F, Goettsch WG, Klungel OH,
Kastelein JJP, Herings RM. Adherence to evidence-based statin
guidelines reduces the risk of hospitalizations for acute myocardial
infarction by 40%: a cohort study. Eur Heart J 2007;28:154–159.
149. Colivicchi F, Uguccioni M, Ragonese M, et al. Cardiovascular risk
factor control among diabetic patients attending community-based
diabetics care clinics in Italy. Diabetes Res Clin Prac
2007;75:176–183.
150. Morisky DE, Green LW, Levine DM. Concurrent and predictive valid-
ity of a self-reported measure of medication adherence. Med Care
1986;24:67–74.
151. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a
molehill, an iceberg, or neither? Hepatology 2008;48:662–669.
152. Anfossi G, Massucco P, Bonomo K, Trovati M. Prescription of statins
to dyslipidemic patients affected by liver diseases: a subtle balance
between risks and benefits. Nutr Metab Cardiovasc Dis
2004;14:215–224.
153. Hovingh GK, Davidson MH, Kastelein JJ, O’Connor AM. Diagnosis
and treatment of familial hypercholesterolaemia. Eur Heart J
2013;34:962–971.
154. Ahn CH, Choi SH. New drugs for treating dyslipidemia: beyond sta-
tins. Diabetes Metab J 2015;39:87–94.
155. Rodriguez F, Knowles JW. PCSK9 inhibition: current concepts
and lessons from human genetics. Curr Atheroscler Rep
2015;17:487.
156. Wetterau JR, Gregg RE, Harrity TW, et al. An MTP inhibitor that
normalizes atherogenic lipoprotein levels in WHHL rabbits. Science
1998;282:751–754.
157. Dhote V, Joharapurkar A, Kshirsagar S, et al. Inhibition of micro-
somal triglyceride transfer protein improves insulin sensitivity and
reduces atherogenic risk in Zucker fatty rats. Clin Exp Pharmacol
Physiol 2011;38:338–344.
158. Cuchel M, Meagher EA, Du Toit Theron H, et al; Phase 3 HoFH
Lomitapide Study Investigators. Efficacy and safety of a microsomal
triglyceride transfer protein inhibitor in patients with homozygous
familial hypercholesterolaemia: a single-arm, open-label, phase 3
study. Lancet 2013;381:40–46.
159. Sahebkar A, Watts GF. New therapies targeting apoB metabolism
for high-risk patients with inherited dyslipidaemias: what can the
clinician expect? Cardiovasc Drugs Ther 2013;27:559–567.
160. Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-
class drugs for reducing low-density lipoprotein cholesterol in pa-
tients with homozygous familial hypercholesterolemia. Circulation
2014;129:1022–1032.
161. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apoli-
poprotein B and low-density lipoprotein cholesterol by short-term
administration of an antisense inhibitor of apolipoprotein B.
Circulation 2006;114:1729–1735.
162. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apo-
lipoprotein B synthesis inhibitor, on low-density lipoprotein choles-
terol in patients with familial hypercholesterolemia. Am J Cardiol
2010;105:1413–1419.
163. Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic
peptides: a potential new therapy for the prevention of atheroscle-
rosis. Cardiol Rev 2010;18:141–147.
164. Smith JD. Apolipoprotein A-I and its mimetics for the treatment of
atherosclerosis. Curr Opin Investig Drugs 2010;11:989–996.
165. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I
Milano on coronary atherosclerosis in patients with acute coronary
syndromes: a randomized controlled trial. JAMA 2003;290:
2292–2300.
166. Tardif JC, Gregoire J, L’Allier PL, et al. Effect of rHDL on
Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of
reconstituted high-density lipoprotein infusions on coronary athero-
sclerosis: a randomized controlled trial. JAMA
2007;297:1675–1682.
167. Sjouke B, Langslet G, Ceska R, et al. Eprotirome in patients with fa-
milial hypercholesterolaemia (the AKKA trial): a randomised,
double-blind, placebo-controlled phase 3 study. Lancet Diabetes
Endocrinol 2014;2:455–463.
168. Lagrost L, Gambert P, Dangremont V, et al. Role of cholesteryl ester
transfer protein (CETP) in the HDL conversion process as evidenced
by using anti-CETP monoclonal antibodies. J Lipid Res
1990;31:1569–1575.
169. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester trans-
fer protein inhibitor attenuates atherosclerosis in rabbits. Nature
2000;406:203–207.
170. Mohammadpour AH, Akhlaghi F. Future of cholesteryl ester transfer
protein (CETP) inhibitors: a pharmacological perspective. Clin
Pharmacokinet 2013;52:615–626.
171. Randomized EValuation of the Effects of Anacetrapib Through
Lipid-modification (REVEAL). https://clinicaltrials. gov/ct2/show/
record/ NCT01252953 (16 May 2016).
172. Langslet G, Emery M, Wasserman SM. Evolocumab (AMG 145) for
primary hypercholesterolemia. Expert Rev Cardiovasc Ther
2015;13:477–488.
173. Do RQ, Vogel RA, Schwartz GG. PCSK9 inhibitors: potential in car-
diovascular therapeutics. Curr Cardiol Rep 2013;15:345.
174. Perrone FP, Paolillo S, Trimarco B. Controllo lipidico in pazienti ad
elevato rischio cardiovascolare: focus sull’inibizione di PCSK9. G
Ital Cardiol 2015;16:44–51.
175. Cainzos-Achirica M, Martin SS, Cornell JE, Mulrow CD, Guallar E.
PCSK9 inhibitors: a new era in lipid-lowering treatment? Ann Intern
Med 2015;163:64–65.
176. European Medicines Agency. Assessment report Praluent
International non-proprietary name: alirocumab Procedure No.
EMEA/H/C/003882/0000. 23 July 2015. EMA/CHMP/392430/2015
Committee for Medicinal Products for Human Use (CHMP). http://
www.ema.europa. eu/docs/en_GB/ document_library/EPAR_- _
Public_assessment_report/ human/003882 /WC500194524.pdf (19
April 2017).
177. European Medicines Agency. Assessment report Repatha
International non-proprietary name: evolocumab. Procedure No.
EMEA/H/C/003766/0000. 21 May 2015. EMA/CHMP/222019/2015.
Committee for Medicinal Products for Human Use (CHMP). http://
www.ema.europa.eu/docs/en_ GB/document_library/EPAR_ -_
Public_ assessment_report/ human/003766/ WC500191400.pdf (19
April 2017).
178. European Medicines Agency. Product Information Repatha
International non-proprietary name: evolocumab. ANNEX I
Summary of product characteristics. EMEA/H/C/003766 03. 2015.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_
-_Product_Information/human/003766/WC500191398.pdf (19 April
2017).
179. The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing
the Occurrence of Major Cardiovascular Events in High Risk
Subjects (SPIRE-1). https://clinicaltrials.gov/ct2/show/record/
NCT01975376 (19 April 2017).
180. The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing
the Occurrence of Major Cardiovascular Events in High Risk
Subjects (SPIRE-2). https://clinical trials.gov/ct2/show /
NCT01975389 (19 April 2017).
181. Repatha: EPAR-product information. http://www.ema.europa.eu/
ema/ index.jsp?curl¼pages /medicines/human/ medicines/
003766/human_med_ 001890.jsp&mid ¼WC0b01ac058001d124 (19
April 2017).
182. Praluent: EPAR-product information. http://www.ema.europa.eu/
ema/index.jsp?curl¼pages/ medicines/human/medicines/ 003882/
human_med_001915. jsp&mid¼ WC0b01ac 058001d124 (19 April
2017).
183. Repatha prescibing information. http://www.accessdata.fda.gov/
drugsatfda_docs/label /2015/1255 22s000lbl.pdf (19 April 2017).
184. Praluent prescribing information. http://www.accessdata.fda.
gov/drugsatfda_docs/ label/2015/125559 Orig1s000 lbledt.pdf (19
April 2017).
D52 M.M. Gulizia et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article-abstract/19/suppl_D
/D
3/3792742 by guest on 22 January 2020
185. Institute for Clinical and Economic Review. PCSK9 Inhibitors for
Treatment of High Cholesterol: Effectiveness, Value, and Value-
Based Price Benchmarks Draft Report. Boston: Institute for Clinical
and Economic Review; 2015.
186. O’Riordan M. PCSK9 Inhibitors Not Cost-Effective at Current Price:
ICER Review. Medscape; 2015. http://www.medscape.com/ viewar
ticle/850715 (19 April 2017).
187. Joszt L. PCSK9 Inhibitors Should Cost 85% Less, ICER Reports. 2015.
http://www.ajmc.com /newsroom/ pcsk9-inhibitors- should-cost-
85- less-icer-reports (19 April 2017).
188. Nardi R, Scanelli G, Borioni D, et al. The assessment of complexity
in internal medicine patients. The FADOI Medicomplex Study. Eur J
Intern Med 2007;18:283–287.
189. Nardi R, Scanelli G. Multimorbidity and complexity: a current re-
search priority not only in the uK and in primary care, but all over
the world and in every care setting. bmj 2007;334:1016.
190. Nardi R, Scanelli G, Corrao S, et al. Co-morbidity does not reflect
complexity in internal medicine patients. Eur J Intern Med
2007;18:359–368.
191. Nardi R, Corbetta L, Muratori M, et al. Metodologia clinica, stru-
menti di valutazione e gestione dei pazienti anziani affetti da BPCO
e comorbilita croniche. Ital J Med 2011;5:S171–S178.
192. Leipzig RM, Hall WJ, Fried LP. Treating our societal scotoma: the
case for investing in geriatrics, our nation’s future, and our pa-
tients. Ann Intern Med 2012;156:657–658.
193. Stange KC. Assessing and acting on complexity. Ann Fam Med
2012;10:98–99.
194. Akker M, van den Buntinx F, Knottnerus JA. Comorbidity or multi-
morbidity: what’s in a name? A review of literature. Eur J Gen
Pract 1996;2:65–70.
195. Fried LP, Ferrucci L, Darer J, et al. Untangling the concepts of
disability, frailty, and comorbidity: implications for improved
targeting and care. J Gerontol A Biol Sci Med Sci 2004;59:
255–263.
196. Guralnik JM. Assessing the impact of comorbidity in the older popu-
lation. Ann Epidemiol 1996;6:376–380.
197. Canadian Institute for Health Information Partnership for Health
Information Standards. WHIC Chronic Disease Management
Infostructure. Toronto: CDM data standards; Fall; 2005.
198. Huntley AL, Johnson R, Purdy S, et al. Measures of multimorbidity
and morbidity burden for use in primary care and community set-
tings: a systematic review and guide. Ann Fam Med 2012;10:
134–141.
199. Fortin M, Stewart M, Poitras M, et al. A systematic review of preva-
lence studies on multimorbidity: toward a more uniform methodol-
ogy. Ann Fam Med 2012;10:142–151.
200. Bayliss EA, Ellis JL, Shoup JA, et al. Association of patient-centered
outcomes with patient-reported and ICD-9-based morbidity mea-
sures. Ann Fam Med 2012;10:126–133.
201. Nobili A, Licata G, Salerno F, et al. Polypharmacy, length of hospital
stay, and in-hospital mortality among elderly patients in internal
medicine wards. The REPOSI study. Eur J Clin Pharmacol
2011;67:507–519.
202. Newman AB, Comorbidity and multimorbidity. In: AB Newman, JA
Cauley, eds. The Epidemiology of Aging. Dordrecht: Springer-
Verlag; 2012. p119–33.
203. Marengoni A, Angleman S, Fratiglioni L. Prevalence of disability ac-
cording to multimorbidity and disease clustering: a population-
based study. J Comorbidity 2011;1:11–18.
204. World Health Organization. The International Classification of
Impairments, Disabilities, and Handicaps (ICIDH) Defined a
Taxonomy of Disease Impacts by the World Health Organization.
Geneva: World Health Organization; 1980.
205. Nagi SZ, Disability concepts revised: implications for prevention.
In: AM Pope, AR Tarlov, eds. Disability in America: Toward a
National Agenda for Prevention. Washington, DC: National
Academy Press; 1991. p309–27.
206. Cerimele JM, Peccoralo LA. Defining patient complexity. Ann Intern
Med 2012;156:606–607.
207. Olde Rikker MG, Schers HJ, Melis RJ. Defining patient complexity.
Ann Intern Med 2012;156:607.
208. Rockwood K, Stadnyk K, Carver D, et al. A clinimetric evaluation of
specialized geriatric care for rural dwelling, frail older people. J
Am Geriatr Soc 2000;48:1080–1085.
209. Nardi R, L’anziano fragile. In: M Mongardi, ed. L’assistenza
all’anziano—ospedale, territorio, domicilio. Cap. 21. Milano:
McGraw-Hill; 2010. p351–67.
210. Rockwood K, Song X, MacKnight C, et al. A global clinical measure
of fitness and frailty in elderly people. CMAJ 2005;173:489–495.
211. Turner BJ, Cuttler L. The complexity of measuring clinical complex-
ity. Ann Intern Med 2011;155:851–852.
212. Grant RW, Ashburner JM, Hong CS, et al. Defining patient complex-
ity from the primary care physician’s perspective: a cohort study.
Ann Intern Med 2011;155:797–804.
213. Cavicchi I. Medicina interna, paziente complesso: verso una clinica
relazionale e ragionevole. Ital J Med 2012;6:259–264.
214. Evans T, Michael W, Marciniak J. Software Quality Assurance and
Management. New York, NY: John Wiley & Sons Inc; 1987.
215. Morin E. Introduzione al pensiero complesso. Milano: Sperling &
Kupfer, 1993.
216. Wilson T, Holt T, Greenlagh T. Complexity and clinical care. BMJ
2001;323:685–688.
217. Plsek PE, Wilson T. Complexity, leadership, and management in
healthcare organisations. BMJ 2001;323:746–749.
218. Agency for Healthcare Research and Quality (AHRQ). Definition:
Complex Patient, Funding Opportunity Announcement (FOA)—
Technical Assistance Teleconference Call. https://archive.ahrq.
gov/fund/tac101507txt.htm (19 April 2017).
219. Safford MM, Allison JJ, Kiefe CI. Complexity: more than comorbid-
ity. The vector model of complexity. J Gen Intern Med
2007;22:382–390.
220. Whittle J, Bosworth H. Studying complexity is complex. J Gen
Intern Med 2007;22:379–381.
221. Reich J. A critical appraisal of overdiagnosis: estimates of its mag-
nitude and implications for lung cancer screening. Thorax
2008;63:377–383.
222. Welch G, Schwartz L, Woloshin S. Overdiagnosed: Making People
Sick in Pursuit of Health. Boston, MA: Beacon Press; 2011.
223. Moynihan R, Cassels A. Selling Sickness: How the World’s Biggest
Pharmaceutical Companies Are Turning us All into Patients. New
York, NY: Nation Books; 2005.
224. Hoffman JR, Cooper RJ. Overdiagnosis of disease: a modern epi-
demic. Arch Intern Med 2012;172:1123–1124.
225. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical
industry and disease mongering. BMJ 2002;324:886–891.
226. Upshur REG. Chronicity and complexity, Is what’s good for the dis-
eases always good for the patients? Can Fam Physician
2008;54:1655–1658.
227. Sturmberg JP, Martin CM. Complexity and health-yesterday’s tradi-
tions, tomorrow’s future. J Eval Clin Pract 2009;15:543–548.
228. Singh H, Petersen LH, Thomas EJ. Understanding diagnostic errors
in medicine: a lesson from aviation. Qual Health Saf Care
2006;15:159–164.
229. Gensini GF, Fabbri LM, Fini M, Nozzoli C. La Medicina della com-
plessita: BPCO e comorbidita. Firenze: Firenze University Press;
2010.
230. Carmel M, Martin CM, Sturmberg JP. General practice—chaos, com-
plexity and innovation. MJA 2005;183:106–109.
231. Simoons ML, Deckers JW, Intensive LDL. lowering therapy for pre-
vention of recurrent cardiovascular events: a word of caution. Eur
Heart J 2016;37:520–523.
232. Candrilli SD, Kuznik A, Mendys PM, Wilson DJ. Prevalence and coex-
istence of cardiovascular comorbidities among the US dyslipidemic
population aged  65 years by lipid-lowering medication use status.
Postgrad Med 2010;122:142–149.
233. Rodriguez F, Olufade T, Heithoff K, Friedman HS, Navaratnam P,
Foody JM. Frequency of high-risk patients not receiving high-
potency statin (from a large managed care database). Am J Cardiol
2015;115:190–195.
234. Halcox JP, Tubach F, Lopez-Garcia E, et al. Low rates of both lipid-
lowering therapy use and achievement of low-density lipoprotein
cholesterol targets in individuals at high-risk for cardiovascular dis-
ease across Europe. PLoS One 2015;10:e0115270.
235. Stone NJ, Lloyd-Jones DM, Lowering LDL. cholesterol is good, but
how and in whom? N Engl J Med 2015;372:1564–1565.
236. Aguiar C, Alegria E, Bonadonna RC, et al. A review of the evidence
on reducing macrovascular risk in patients with atherogenic dyslipi-
daemia: a report from an expert consensus meeting on the role of
Consensus document on cholesterol and cardiovascular risk D53
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article-abstract/19/suppl_D
/D
3/3792742 by guest on 22 January 2020
fenofibrate-statin combination therapy. Atheroscler Suppl
2015;19:1–12.
237. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein choles-
terol and mortality. The Framingham Heart Study. Arteriosclerosis
1988;8:737–741.
238. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density li-
poprotein cholesterol as a predictor of coronary heart disease risk.
The PROCAM experience and pathophysiological implications for re-
verse cholesterol transport. Atherosclerosis 1996;124(Suppl):
S11–S20.
239. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor
for cardiovascular disease independent of high-density lipoprotein
cholesterol level: a meta-analysis of population-based prospective
studies. J Cardiovasc Risk 1996;3:213–219.
240. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA; American
Heart Association; National Heart, Lung, and Blood Institute;
American Diabetes Association. Clinical management of metabolic
syndrome: report of the American Heart Association/National
Heart, Lung, and Blood Institute/American Diabetes Association
conference on scientific issues related to management. Circulation
2004;109:551–556.
241. Scott R, O’Brien R, Fulcher G, et al. Effects of fenofibrate treat-
ment on cardiovascular disease risk in 9,795 individuals with type 2
diabetes and various components of the metabolic syndrome: the
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD)
study. Diabetes Care 2009;32:493–498.
242. Swiger KJ, Martin SS. PCSK9 inhibitors and neurocognitive adverse
events: exploring the FDA directive and a proposal for N-of-1 trials.
Drug Saf 2015;38:519–526.
243. Lipinski MJ, Benedetto U, Escarcega RO, et al. The impact of pro-
protein convertase subtilisin-kexin type 9 serine protease inhibitors
on lipid levels and outcomes in patients with primary hypercholes-
terolaemia: a network meta-analysis. Eur Heart J 2016;37:536–545.
244. Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab,
a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on
lipoprotein(a) concentrations (a pooled analysis of 150mg every
two weeks dosing from phase 2 trials). Am J Cardiol
2014;114:711–715.
245. Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipopro-
tein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a
pooled analysis of more than 1,300 patients in 4 phase II trials. J
Am Coll Cardiol 2014;63:1278–1288.
246. Roger VL, Go AS, Lloyd-Jones DM, et al. American Heart Association
Statistics Committee and Stroke Statistics Subcommittee. Heart
disease and stroke statistics - 2012 update: a report from the
American Heart Association. Circulation 2012;125:e2–220.
247. Shepherd J, Blauw GJ, Murphy MB, et al; PROspective Study of
Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals
at risk of vascular disease (PROSPER): a randomised controlled
trial. Lancet 2002;360:1623–1630.
248. Savarese G, Gotto AM Jr, Paolillo S, et al. Benefits of statins in el-
derly subjects without established cardiovascular disease: a meta-
analysis. J Am Coll Cardiol 2013;62:2090–2099.
249. Scandinavian Simvastatin Survival Study Group. Randomised trial of
cholesterol lowering in 4444 patients with coronary heart disease:
the Scandinavian Simvastatin Survival Study (4S). Lancet
1994;344:1383–1389.
250. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardio-
vascular events in older patients with myocardial infarction and
cholesterol levels in the average range. Results of the Cholesterol
and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:
681–689.
251. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention
in elderly patients: a hierarchical Bayesian meta-analysis. J Am
Coll Cardiol 2008;51:37–45.
252. Gulizia MM, Colivicchi F, Arca M, et al. Position paper ANMCO:
Percorso diagnostico-terapeutico nel paziente con ipercolesterole-
mia e intolleranza alla terapia con statine. G Ital Cardiol
2016;17:447–455.
253. Anderson GF, Chu E. Expanding priorities - confronting chronic dis-
ease in countries with low income. N Engl J Med 2007;356:209–211.
254. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines
on the management of stable coronary artery disease: the Task
Force on the management of stable coronary artery disease of the
European Society of Cardiology. Eur Heart J 2013;34:2949–3003.
255. Giannakouris K. Ageing characterises the demographic perspectives
of the European societies. Eurostat Statistics in Focus 72; 2008
http://www.apapr.ro/images/BIBLIOTECA/demografie/eurostat%
20focus%202008.pdf (19 April 2017).
256. Kotseva K, Wood D, De Backer G, et al; EUROASPIRE Study Group.
EUROASPIRE III: a survey on the lifestyle, risk factors and use of car-
dioprotective drug therapies in coronary patients from twenty-two
European countries. Eur J Cardiovasc Prev Rehabil 2009;16:
121–137.
257. Maggioni AP, Cinconze E, Rossi E, et al. Outcomes, health costs and
use of statins in 6226 patients admitted in 2011 for an acute coro-
nary syndrome (ACS) occurring in a large community setting of
2,989,512 subjects. Presented at ISPOR 18th Annual European
Congress, Milan, Italy, 7–11 November 2015.
258. Maggioni AP, Cinconze E, Rossi E, et al. Costs and outcomes of pa-
tients admitted for a cardiovascular ischemic disease in a large
community setting of 2,989,512 subjects of the Italian National
Health Service (NHS). Presented at ISPOR 18th Annual European
Congress, Milan, Italy, 7–11 November 2015.
259. Il Sole-24 Ore. Info Data Blog, 8/4/2015. Sanita, la spesa pubblica
pro capite scende a 1816 euro. E nelle regioni? http://www.info
data.ilsole24ore. com/2015/04/08/sanita- spesa-pubblica-pro- cap
ite-scende-a-1816- euro-e-nelle-regioni/ (16 May 2016).
260. Lazar LD, Pletcher MJ, Coxon PG, et al. Effectiveness of statin ther-
apy for primary prevention in a low-cost statin era. Circulation
2011;124:146–153.
261. Comparative effectiveness Public Advisory Council (CEPAC) and
Institute for Clinical and Economic Review (ICER) Review. PCSK9 in-
hibitors for treatment of high cholesterol: effectiveness, value,
and value-based price benchmarks draft report. Final Report.
November 24, 2015.
262. Navarese EP, Kolodzejczac M, Shulze V, et al. Effects of proprotein
convertase subtilisin/kexin type 9 antibodies in adults with hyper-
cholesterolemia. A systematic review and meta-analysis. Ann
Intern Med 2015;163:40–51.
263. Degli EL, Sangiorgi D, Arca M. Il raggiungimento dei livelli di coles-
terole LDL nella pratica clinica. Risultati dello studio STAR (Statins
Target Assessment in Real Practice). Monaldi Arch Chest
2011;76:160–167.
264. Griffo R, Ambrosetti M, Tramarin R, et al. Effective secondary pre-
vention through cardiac rehabilitation and predictors of poor ad-
herence to lifestyle modification and medication. Results of the
ICAROS survey. Int J Cardiol 2013;167:1390–1395.
D54 M.M. Gulizia et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article-abstract/19/suppl_D
/D
3/3792742 by guest on 22 January 2020
